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CHAPTER I 
 
MULTIDIMENSIONAL SEPARATIONS BY ION-MOBILITY- 
MASS SPECTROMETRY 
 
1.1. Ion Mobility-Mass Spectrometry: Multidimensional Gas Phase Separations 
Mass spectrometry (MS) is an increasingly powerful analytical technique with 
applications in fields ranging from the life sciences to nanotechnology. MS analyses are 
extraordinarily rapid and well-suited for large-scale studies requiring high-throughput. As 
a highly sensitive technique MS requires only pico to femtomole quantities of sample, 
making it a preferred method in situations where a limited amount of sample is available. 
Combined with the availability of MS databases and informatics, unknown species are 
often readily identified even from complex matrices. For the life sciences in particular, 
MS holds significant advantages in the analysis of complex samples, but is limited due to 
complications arising from isobaric (i.e. same mass) species resulting in endogenous or 
exogenous sources of noise. Such complications can be surmounted by combining MS 
with additional dimensions of analyte selectivity. 
The pairing of pre-ionization separations with MS is widely used to increase the 
dimensionality of data, thereby increasing the information obtained. Most commonly 
these include condensed-phase separations (e.g. high performance liquid chromatography 
(HPLC)) or gas-phase separations (e.g. gas chromatography (GC)), respectively. The 
fields of metabolomics and proteomics have advanced greatly in the recent decades 
through the interfacing of mass spectrometry with GC and LC separations, as well as by 
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the improved capabilities in data analysis that such multidimensional separations 
demanded. GC-MS is a widely-used tool in the quantitation of metabolite levels for 
metabolic flux analyses of microorganisms and cells.
1,2
 Identification of metabolites or 
proteins from complex biological samples, such as serum or plasma, is now routinely 
performed by LC-MS or LC-MS/MS.
3-6
 In contrast to separations based on bi-phasic 
partitioning, i.e. chromatography, gas phase electrophoretic separations by ion mobility 
(IM) are significantly more rapid, occurring within µs-ms versus the min-hrs required for 
GC and LC separations. The nature of IM separations offers additional information as 
direct structural information on analytes can be obtained nearly regardless of the 
complexity of the sample. As a post-ionization technique, IM-MS is also amenable to the 
addition of pre-ionization separations for even greater data dimensionality. 
The aim of this chapter is to provide a survey of the key aspects of IM-MS for 
those seeking an introductory discussion and is not intended to be a comprehensive 
review. The merits and motivations of coupling IM and MS and the transformation of 
IM-MS measurements to structural information are discussed in Section 1.1. A survey of 
the arrangements of modern IM-MS instruments and the practical aspects of coupling IM 
and MS are presented in Section 1.2. Section 1.3 highlights the diverse range of 
applications of IM-MS, with particular emphasis on applications to the life sciences and 
nanotechnology. Lastly, Section 1.4 provides a summary and the objectives of the 
dissertation research. 
 
1.1.1. The Evolution of Ion Mobility Technology 
 Although the fundamentals of both MS and ion mobility spectrometry (IMS) are 
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rooted in the late 1  0s, with the discovery of  -rays by   ntgen and the first gas-phase 
IMS experiments (Figure 1.1), progress in the development of these technologies did not 
occur in parellel.
7,8,9
 Since the construction of the first mass spectrometer in the early 
1900s, MS has experienced consistent growth in the development of new techniques for 
mass analysis. For example, the precursor of obitrap technology, the Kingdon trap, was 
described in a 1923 publication and has since become a powerful tool for high-resolution 
mass analysis.
10,11
 Conceptualization of the time-of-flight (TOF) mass analyzer, a staple 
instrument in modern mass spectrometry labs, is attributed to Stephens in 1946 and 
further developments by Mamyrin led to the reflectron TOF- MS  for  high  resolution  
measurements  twenty  years  later.
12,13-15
  The late 1980s marked a time of significant 
advances in MS for applications to the life sciences. With the development of soft 
ionization techniques such as matrix-assisted laser desorption/ionization (MALDI) and 
electrospray ionization (ESI), MS analyses of proteins up to 100 kDa by MALDI-MS and 
130 kDa proteins by ESI-MS were reported for the first time.
16,17,18
 By the mid-1990s, the 
advantages of ESI- and MALDI-MS for fields such as proteomics were evident and it has 
since become the primary tool for such work. 
 In the development of IMS, the late 1890s to mid-1920s marked a period of 
interest in fundamental physics studies of the movement of ions in the gas phase and 
these works would later be regarded as the foundations of modern day IMS. Construction 
of the first IM spectrometer is attributed to Zeleny, who in 1898 developed an apparatus 
for the purpose of measuring the ratio of the velocities of positive and negative ions in an 
electrical field through several gases.
9
 Nearly 30 years later, precise measurements of the 
mobilities   of   ions   in  air   were   performed  by   Tyndall.
19-23
    Despite  these  early  
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Figure 1.1.  Timeline highlighting some of the significant advances in mass spectrometry 
(left) and ion mobility (right) from the 1890s to 2010. 
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developments, little progress was made in the field of IMS over the next three decades. 
Renewed interest in IM separations did not occur until the early 1960s, when the 
first reports of IMS and MS analyses performed in tandem were published by McDaniel, 
Edelson, and colleagues.
24,25
 It was nearly a decade later that the first commercially 
produced IM spectrometer was released in 1970.
26
  eferred to as “plasma 
chromatography” at the time, IMS developed as an analytical tool for gas phase 
separations of organic molecules in the 1960s-70s with applications in the detection of 
drugs and explosives.
27-29
  
 Similar to mass spectrometry, the applications of IMS to the biological sciences 
began to appear in the mid-1980s with the utility of ESI-IMS for the separation of 
multiply charged proteins demonstrated by Dole.
30
 IM-MS separations of peptides were 
first reported in the mid-1990s by Bowers and colleagues.
31,32
 At the same time, studies 
of the gas-phase conformations of intact proteins were performed by Jarrold, Clemmer 
and colleagues.
33,34
 These works and others mark a significant milestone in the 
development of IM-MS as a multidimensional separations tool for biologically-relevant 
applications such as complex biological sample analysis and structural studies of 
biomolecules in the gas phase. 
 Over the past 50 years, the fields of IMS and IM-MS research have experienced 
an extraordinarily rapid growth. With applications spanning biological and physical 
sciences, the number of IM-related publications per year (Figure 1.2, top) has increased at 
a nearly exponential rate since the 1960s and technological innovations for IM-MS have 
experienced   similar   growth  (Figure 1.2, bottom).   With   the   recent  availability   of  
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Figure 1.2.  Trends in the numbers of IM-MS publications (top) and patents (bottom) 
from 1970-2010. The data displayed above was obtained by searching the phrase “ion 
mobility with mass spectrometry” in SciFinder. 
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commercial instruments and demonstration of its utility for imaging
35
 and 
macromolecular  complex  analysis,
36
  the  field  of  IM-MS  is  expected  to  continue its 
exponential expansion in applications and innovations for the foreseeable future. 
 
1.1.2. The Correlation of Ion Mobility and Mass Spectrometry Dimensions 
 The pairing of IM and MS separations provides structural information derived 
from the ion-neutral collision cross section in the IM dimension as well as accurate mass 
information in the form of the ion’s mass-to-charge (m/z) in the MS dimension, thereby 
providing an increased dimensionality in the data. Figure 1.3 shows a typical 
representation of 2D IM-MS data, which is demonstrated with the ESI-IM-MS analysis 
of a cytochrome c tryptic digest. Panel (a) contains the plot of drift time (ms) versus m/z, 
referred to as conformation space. The intensity of signals is represented by a color scale, 
where signal intensity increases from white (no signal) to grey (low intensity) to black 
(high intensity). The full m/z profile (b) for the data can be produced by integrating the 
IM-MS plot (a) over all drift time space. Alternatively, integrating the IM-MS plot (a) 
over all m/z space yields the full IM drift time profile, as shown in panel (c). For a given 
signal in the IM-MS plot (a), such as the singly charged signal corresponding to the 
peptide “GITWK”, integrating over a defined region of drift time-m/z space about the 
signal (indicated by the black rectangle in (a)) yields both the m/z and drift time profiles 
for the individual signal, as shown in panels (d) a (e), respectively. 
For the analysis of biomolecules, which are mainly comprised of the atoms C, H, 
O, N, P and S, the mass of such species scales as length cubed, or volume, while  in  the  
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Figure 1.3.  (a) A 2D ESI-IM-MS plot of conformation space obtained for the tryptic 
digest of cytochrome c. (b) The full m/z profile produced by integrating (a) over all drift 
time space. (c) Integrating (a) over all m/z space yields the full IM drift time profile. For 
the singly charged signal corresponding to the peptide GITWK, integrating about a define 
region of drift time-m/z conformation space (black rectangle in (a)) produces both the m/z 
(d) and drift time (e) profiles for the individual signal. 
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IM dimension the collision cross section, or surface area, scales as length squared. As 
both scale by length, the IM-MS separation dimensions are highly correlated due to the 
limited range of densities in which biomolecules exist. This high degree of correlation 
can present a significant advantage and some challenges when compared to 
multidimensional separations with more orthogonality.
37
 As discussed in the section 
below (1.1.2.2), the classes of biomolecules, such as peptides and carbohydrates, each 
display different average densities or gas-phase packing efficiencies which can be a great 
advantage in complex sample analysis. In contrast, the high correlation of IM and MS 
dimensions observed for a particular class of biomolecule results in a decreased peak 
capacity (approx. 10
3 
- 10
4
) in comparison to highly orthogonal multidimensional 
separations such as LC-FT-MS (approx.10
7 – 108), however IM-MS benefits from an 
extraordinarily high peak capacity production rate (10
6 
s
-1
) due to the rapid nature of the 
gas-phase separation.
38-41
 
 
1.1.2.1. Tailoring the Configuration of Multidimensional Separations 
 Unlike multidimensional separations with a high degree of orthogonality, the 
correlation between IM and MS allows versatility in the configurations of 
multidimensional separations, which may be tailored to fit the experimental goals. The 
most common configuration, as depicted in Figure 1.4(a), consists of an ion source, 
usually ESI or MALDI, from which ions are injected directly into the IM drift region. 
Mobility separated ions exiting the IM region are transferred to the mass analyzer. 
Depending on the goals of the experiment, full mass analysis of the mobility separated 
analyte ions can be  performed with an orthogonal TOFMS  (oTOFMS) or a  quadrupole  
10 
 
 
 
Figure 1.4. Arrangements of IM-MS instruments (left) and examples of the data obtained 
from each (right). The simplest arrangement (a) consists of an ionization source, typically 
MALDI or ESI, coupled to an IM drift cell, followed by a mass analyzer and detector. 
Placement of the collision cell prior the IM drift cell (b) provides mobility separated 
fragment and precursor ions. Fragmentation after IM separation (c) yields fragment ions 
which with the drift time of the precursor ion. IM-MS is compatible with pre-ionization 
separations (HPLC or GC) for additional data dimensionality (d). 
 
 
11 
 
MS may be used for the selection of a single m/z. Due to the complementary time scales 
of   IM and TOFMS separations  (ms vs. µs, respectively),  an  oTOFMS  is  typically 
preferred for IM-MS of biomolecules to achieve multiple sampling across the analyte IM 
profile.  
 Additional structural information can be obtained from the MS dimension by 
performing IM-MS/MS, in which a collision cell is placed prior to the IM drift cell 
(Figure 1.4b). The IM region then behaves similarly to the MS
1
 dimension in a tandem 
MS experiment, but disperses ions by ion-neutral collision cross section in time as 
opposed to dispersal by m/z. Pre-fragmentation mass selection, typically required for 
scanning MS/MS methods, is not required in this arrangement. Placement of the collision 
cell after the IM region (Figure 1.4c) produces mobility organized precursor and 
fragment ions, such that the fragment ions occur with the drift time as the precursor ion 
from which they were formed and both are determined in the MS region. This correlation 
of precursor and fragment ions allows fragmentation to be performed on nearly all ions, 
providing a multiplexed MS/MS experiment.
42
 Further tailoring of the instrumental 
arrangement may include additional regions of MS, MS/MS, IM or IM/IM to suit the 
goals of the experiment. For example, the addition of a mass filter (e.g. a quadrupole MS) 
for precursor ion selection and placement of the ion activation region prior to the IM drift 
cell enables IM structural information to be obtained for the fragment ions. IM-MS is 
also amendable to the addition of pre-ionization separation techniques (Figure 1.4d) such 
as GC, HPLC, capillary electrophoresis (CE), etc. for enhanced peak capacity and data 
dimensionality in the analysis of complex samples.
38-40,43
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1.1.2.2. Advantages for Complex Biological Sample Analysis 
Biologically derived complex samples natively contain multiple classes of 
biomolecules, such as proteins, lipids, carbohydrates, etc. The analysis of such samples 
by MS requires steps to enrich for the species of interest (i.e. peptides and proteins for 
proteomic experiments) by depleting the other components from the sample. This is 
necessary to prevent complications arising from ion suppression effects and interference 
from chemical noise, and to obtain mass spectra from which identifications or 
quantifications can be determined with high confidence. While condensed-phase pre-
ionization separations are commonly used for these purposes, gas-phase separations on 
the basis of analyte structure by post-ionization IM-MS achieve the same goals of 
improved sensitivity and limit of detection but require separation times nearly 4 to 5 
orders of magnitude faster.  
The separation of complex samples in the IM dimension is based in the 
differences in gas-phase packing efficiencies amongst the classes of biomolecules, which 
decrease in the order:  oligonucleotides > carbohydrates > peptides/proteins > lipids.
44-48
  
Ultimately, the gas phase packing efficiency of a biomolecule dictates its conformation 
and is therefore inherent to its collision cross section as well. The result is the observation 
of unique regions of collision cross section-m/z correlation, as depicted in Figure 1.5, for 
each of the classes of biomolecules in the 2D IM-MS conformation space, the general 
order of which is conserved despite the separation parameters. This consistency in the 
order of separation simplifies the general assignment of signals in a complex sample to 
their respective biomolecular classes and provides increased confidence in the validity of  
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Figure 1.5.  A hypothetical depiction of the correlation lines observed in IM-MS 
conformation space for each of the classes of biomolecular species. Adapted from L.S. 
Fenn and J.A. McLean, Analytical and Bioanalytical Chemistry 2008, 391, 905-909, Fig. 
2(a), with permission from Springer Science+Business Media. 
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signal identifications. Fine-grained structural details within a biomolecular class can be 
visualized upon closer inspection of its correlation region (discussed in Section 1.3.1). 
The structural separation of molecular classes by IM has practical advantages for 
many analyses typically performed by MS methods. In proteomics experiments 
performed by IM-MS, non-peptide interferences can be removed by extracting the 2D 
region of conformation space in which the peptide signals reside, providing higher 
confidence in the identifications provided by proteomics databases and an improved 
dynamic range.
38
 Isobaric peptides with conformational isomers or amino acid sequence 
permutations can be resolved with IM on the basis of their unique preferred structures but 
would be challenging to observe by MS alone.
47,49-52
 
 
1.1.3. Structural Information from Two-Dimensional Conformation Space 
 In the analysis of biological samples, ion mobility separations are generally 
utilized in two distinct, but complementary ways: (i) as a structural separations technique 
on the basis of collision cross section, and (ii) to derive low resolution structural data that 
is interpreted by complementary molecular simulation strategies. There exist a number of 
means to perform ion mobility using electrostatic and electrodynamic drift fields. 
However, these two approaches differ in that absolute structural information can be 
obtained from first principles of gas kinetic theory using electrostatic fields, and relative 
structural can be obtained by comparison with structural standards using electrodynamic 
fields, respectively. The present discussion focuses deriving structural information 
exclusively using electrostatic, or uniform-field, separation devices. 
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1.1.3.1. Relating Mobility Drift Time to Collision Cross Section 
 The ion-neutral collision cross section (CCS) is effectively the rotationally-
averaged surface area (in Å
2
) presented by the ion during the collision with a neutral drift 
gas molecule, and is directly related to analyte structure. If these collisions are considered 
to be brief and elastic, an equation can be derived from the kinetic model of gases for the 
calculation of collision cross sections from ion mobility separation parameters.  
Under the influence of a weak electrostatic field (E), the partitioning of ions in a 
drift cell of fixed length (L) is given by the ion drift velocity (vd) and is related to E by the 
ion’s mobility constant, K, in the neutral gas: 
   
 
  
         [1] 
The velocity of a packet of ions is derived from the time required for the ions to traverse 
the IM drift cell, or drift time (td), which is empirically measured and used to evaluate the 
CCS. Under “low-field”, or weak electrostatic field, conditions, the velocity of ions in the 
neutral drift gas will be attributed mainly to the random motion of ions at the temperature 
of the drift gas. This requires the assumption that molecular or ion velocities in 
thermodynamic equilibrium can be described by a Maxwellian distribution function, 
where the mean thermal velocity of the gas is: 
      (
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     [2] 
where T (Kelvin) is the temperature of the gas, kB is the Boltzmann constant, and M is the 
molar mass of the gas. In addition to the mean thermal velocity, a small component of 
velocity is added in the direction of the electrostatic field. As the ion packet’s drift 
velocity depends on the temperature of the separation, as well as the pressure (p, Torr), K 
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is conventionally normalized to standard conditions of 0 °C and 760 Torr (STP) and 
reported as the reduced mobility, K0: 
    
 
   
   
 
      [3] 
Alternatively, at high field conditions the distribution of ion velocities is less strongly 
dependent on the separation temperature and K is no longer constant, but depends on the 
ratio of the electrostatic field to the gas number density (E/N).  
 Under low field conditions, in which K is constant, the mobility of an ion is 
inversely related to the ion-neutral collision cross section, effectively, the surface area, Ω:  
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where K0 is also dependent upon the charge of the ion (ze), the drift gas number density at 
STP (N0), and the masses of the ion (mi) and neutral gas (mn) in the form of the reduced 
mass of the ion-neutral collision pair. To solve for the collision cross section, Eqn. [1] 
can be substituted for K0 and Eqn. [4] can be rearranged to yield the form commonly used 
to calculate collision cross sections from IM separations: 
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   [5] 
The dimensionality of units used in Eqns. [4] and [5] should be closely monitored and the 
units of E in particular must be expressed the cgs Gaussian units statvolts cm
-1
.  
 As previously discussed, collisions which occur during the IM separation are 
approximated to be brief and elastic, i.e. the total translational kinetic energy of the ion 
and the molecule are conserved during the collision. However, it has been shown by the 
comparison of experimental and theoretical collision cross sections that the elastic, or 
“hard sphere,” approximation hold best for analytes 1000 Da or larger.53 These 
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approximations are also challenged by analytes which are similar in size to the neutral 
separation gas, resulting in long-range interactions between the collision pair.
54-56
 To 
obtain accurate collision cross sections for such analytes, the long-range interaction 
potential should be accounted for. For biological IM studies, the analytes of interest 
typically do not fall under these limitations and accurate collision cross sections can be 
obtained using Eqn. [5]. 
 
1.1.3.2. Correlating Empirical and Computational Collision Cross Sections 
 Collision cross sections derived from experimental IM-MS data provide a very 
general view of analyte ion structure in the form of rotationally averaged surface area. To 
gain insight into the analyte structure, empirically derived collision cross sections are 
often paired with computationally determined results. Structures arrived at by this process 
are useful in identifying the dominant structural motifs as well as eliminating those which 
are in disagreement with empirical data, but results should not be over interpreted as 
providing fine-course details such as atomic coordinates. 
In general, the work flow for comparing empirically and computationally-derived 
structures consists of five procedures. As the first step, in silico model structures of the 
analyte ion are generated by molecular modeling software. The conformational landscape 
of the model structure is then sampled with methods such as simulated annealing, 
molecular mechanics/molecular dynamics (MM/MD), or distance geometry. Of the 
conformational sampling approaches, MM/MD methods are most commonly used for the 
structural study of large biomolecules. However, MM/MD approaches experience 
difficulties in the sampling of compact conformations and MM/MD force fields must 
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exist that are properly parameterized for the analyte.
57-59
 Collision cross sections are then 
calculated for each of the conformations obtained by the sampling technique. This 
procedure is widely performed with the MOBCAL software developed by Jarrold and 
coworkers.
53,54,60
 The relative energies of the conformations are plotted against their 
computationally derived collision cross sections. The structures of most interest are the 
lowest energy conformations with collision cross sections consistent with the 
experimental results. A web-based tutorial on the procedures and considerations for 
comparing empirical and computation collision cross sections, with an emphasis on 
simulated annealing methods, is also available from Bowers and colleagues.
61
 The 
specific IM-MS arrangement used does have implications for the calculation of collision 
cross sections, and several IM-MS arrangements used for determining CCSs are detailed 
in the following section. 
 
1.2. Instrumental Configurations of Modern Ion Mobility-Mass Spectrometers 
 The flexibility available in pairing IM and MS has led to a number of unique 
instrumental arrangements designed around the needs of specific experiments or a 
preferred type of drift cell and/or mass analyzer. Early IM-MS instruments were 
comprised of drift tube ion mobility (DTIM) spectrometers combined with quadrupoles
24
 
or TOFMS
25
 and such arrangements have remained popular throughout the years.
62-67
 
Additionally, IM spectrometers have been interfaced with mass analyzers such as double-
focusing sector fields,
68
 quadrupole ion traps,
69,70
 and Fourier transform ion cyclotron 
resonance.
71
 IM spectrometers are also available in a variety of designs and IM-MS 
instruments have incorporated segmented quadrupoles,
72-74
 field asymmetric ion mobility 
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spectrometers (FAIMS),
75,76
 and traveling-wave ion mobility (TWIM).
36,77,78
 This section 
highlights a few fundamental considerations necessary in choosing an appropriate IM-MS 
arrangement and the configurations of several modern IM-MS instruments. 
 
1.2.1. Impact of Ion Source Selection on Ion Mobility Arrangement 
 The development of MALDI
16,17
 and ESI
18
 greatly expanded the applicability of 
both MS and IM-MS to biologically-relevant analyses. IM-MS instruments have been 
successfully interfaced with both ESI
65,66,69,78-83
 and MALDI
67,68,84
 ion sources, although 
ESI remains the more widely used ionization method. The fundamental differences in the 
ionization processes of MALDI and ESI dictate the selection of ion source for certain 
experiments, and therefore the particular design of the IM-MS instrument. MALDI 
typically produces singly charged ions, while ESI produces a series of ions at multiple 
charge states depending on the analyte’s size and the number of basic sites available. For 
IM-MS, the ion’s charge state and the number of charges per ion are key considerations 
as the mobility of the ion is directly proportional to its charge state. In the analysis of 
complex samples, the multiplicity of signals produced for an ion existing in multiple 
charge states may lead to overly congested spectra while also reducing the sensitivity as 
the analyte signals are partitioned into several channels. For structural analyses in which 
collision cross sections CCS are experimentally calculated, charge repulsion due to the 
low dielectric of the IM cell results in CCS larger than predicted solution phase structure. 
Despite these factors, the multiple charges incurred during ESI may sometimes be 
necessary to produce ions within the appropriate m/z range for the mass analyzer (e.g. 
quadrupoles, which are typically limited to a lower m/z range). The detection scheme 
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may also dictate the use of ESI, as the higher charge state ions provide higher sensitivity 
for micro-channel plate or image current detectors. Fragmentation studies performed by 
IM-MS/MS also benefit from multiply charged ions as they provide higher fragmentation 
efficiencies. 
 In regards to structural IM-MS studies, it should be noted that the equivalency of 
structures generated by MALDI and ESI, as well as the equivalency of gas-phase versus 
solution-phase structures, remains to be determined on a case-by-case basis. The presence 
of acids or organic modifiers for ESI and the co-crystallization with small organic matrix 
molecules for MALDI both to some extent produce denaturing conditions during sample 
preparation. For both MALDI and ESI, evaporative cooling from matrix cluster 
evaporation and solution evaporation, respectively, can alleviate the additional internal 
energy transferred to the analyte during the ionization process. In the absence of 
intermolecular solvation, the anhydrous ions generated by both ionization methods 
should adopt the minimum energy conformation available via intramolecular folding 
forces. An instrumental approach to this issue is the development of a dual source 
instrument in which the IM-MS operates independent of the source in use, allowing for 
direct comparison of collision cross sections of ion produced by MALDI and ESI. Using 
this arrangement, it has been shown that the collision cross sections of +1 MALDI and 
ESI ions are in good agreement, while the +2 ions generated by ESI tend to be larger than 
+1 MALDI ions.
85
 The combination of IM-MS with structural analyses such as X-ray 
crystallography and NMR has provided some insight into the correlation of gas and 
solution phase structures.
34,86-88
 Such work has typically been limited to relatively small 
model systems but recently advances have been made towards much larger systems.
89
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Further research into the structural differences between MALDI and ESI-generated ions, 
as well as between gas and solution phase structures, would be of great benefit to MS-
based studies of protein structure and protein complexes.
90,91
 
 
1.2.2. Ion Mobility-Time-of-Flight Mass Spectrometers 
 Similar to IM separations, time-of-flight mass analyzers disperse ions in time 
which allows the interfacing of IM and TOFMS to be relatively straightforward. This 
arrangement further benefited from the complementary timescales of analyte elution from 
the IM drift cell (100s µs-ms) and mass analysis in the TOFMS (10s µs), ensuring the 
nearly simultaneous mass analysis of the analytes as they elute from the IM drift cell. For 
these reasons, TOFMS and orthogonal TOFMS (oTOFMS) are widely used in IM-MS 
arrangements. Several arrangements of TOFMS-based IM-MS instruments based on ESI 
and MALDI ionization sources and drift tube and traveling wave IM are discussed, as 
well as an arrangement for imaging MALDI-IM-MS. 
 
1.2.2.1. MALDI-IM-TOFMS 
 Ions produced by MALDI are both spatially and temporally focused, which 
allows for the rapid separations and high sensitivity necessary for high throughput studies 
such as proteomic analyses. As the MALDI event itself is a pulsed process, it is 
unnecessary to temporally gate the ions prior to injection into the drift cell, a limiting 
factor for resolution.
92-95
 Additionally, the pulsed nature of MALDI provides an inherent 
t0  for  the  IM  drift  time  measurement.   A schematic  diagram of  a  moderate  pressure  
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Figure 1.6.  Schematic diagrams of an IM-MS instrument with a drift tube ion mobility 
cell, MALDI ionization source and TOF mass analyzer (a), and a traveling wave-based 
IM-MS instrument with an ESI source and TOF mass analyzer (b). Panel (a) is adapted 
with permission from John Wiley & Sons, Inc., J.A. McLean, J.A. Schultz, A.S. Woods, 
Ion Mobility-Mass Spectrometry for Biological and Structural Mass Spectrometry, in 
Electrospray and MALDI Mass Spectrometry: Fundamentals, Instrumentation, Practices 
and Biological Applications, Richard B. Cole (Ed.), John Wiley & Sons, Inc., New York, 
2010, pp. 411-439. 
 
23 
 
MALDI-DTIM-TOFMS is presented in Figure 1.6(a). Ions are produced at the same 
pressure (3-10 Torr) as the IM drift cell with high repetition rate MALDI (approx. 5000  
Hz). The moderate pressure MALDI source allows for a simplification in the design of 
the instrument, which would otherwise require a pressure transition from high vacuum to 
moderate pressure to accommodate a high vacuum MALDI  source.
67
  Under moderate 
pressure, successive pulses of the laser will experience higher ionization efficiencies due 
to neutral plume stagnation. High repetition rate MALDI is advantageous under such 
conditions as it provides higher throughput and improved limits of detection (fmol-
amol).
96
 The ions then enter a dc-only ion guide drift cell. This design radially refocuses 
the ions to the center of the drift cell to prevent losses due to radial diffusion of the ions 
as they migrate through the cell, thereby improving the sensitivity.
97
 As ions elute from 
the drift cell, they are focused through a region of differential pumping and skimming 
and transferred to the entrance of an oTOFMS (approx. 10
-8
 Torr). Overall, this 
arrangement yields ATDs of 100s µs for peptides and approximately 1-2 ms for proteins. 
   While interfacing two time-dispersive measurements may seem straightforward 
at first glance, matching the time resolution of each dimension may be complicated. For 
an oTOFMS operating at a 10 kHz pulse frequency, an MS spectrum would be collected 
ever 100 µs. The resulting IM profile would be 1 ms long and composed of 10 points at 
100 µs time resolution. The peak profile widths (FWHM) would be approximately 10-20 
µs for an IM operating at a resolution of 30-50. Consequently, the ion packets exiting the 
drift cell during the 100 µs MS cycle will not be recorded by the oTOFMS. The solution 
to this challenge is a specialized data acquisition scheme in which the time resolutions of 
both dimensions are independent and interleaved post-acquisition.
38,98
 Sequential MS 
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spectra are acquired at the rate of the TOFMS, but after each subsequent MALDI event 
the TOFMS acquisition is offset by a desired amount. These offset MS spectra are 
interleaved, or stitched together, after a sufficient number of ion injections into the drift 
cell. This provides a two-dimensional IM-MS plot with independent resolution (i.e. 
number of time points) in the IM and MS dimensions. 
 
1.2.2.2. ESI-IM-TOFMS 
 ESI ion sources provide a continuous source of ions in contrast to the pulsed 
generation of ions provided by a MALDI ion source. For injection into the IM region, a 
continuous ion source such as ESI requires modulation of the ion beam by storing ions 
and gating the injection. Ion funnels
80,99,100
 and pulse ion traps
69,77,82
 are typically used for 
these functions. The performance characteristics of modern devices provide very little ion 
loss between the source and injection into the drift region, and ESI-IM-MS instruments 
can achieve sensitivities comparable to commercial ESI-MS instruments.
99
 The inclusion 
of an ESI source is advantageous as it enables the interfacing of pre-ionization liquid-
phase separations with IM-MS with relative ease. The development and utility of LC-
ESI-IM-MS has been widely explored for proteomics applications by Clemmer and 
colleagues.
43,101-105
 A detailed discussion of an ESI-IM-TOFMS instrument utilizing 
traveling wave IM is provided in the following section. 
 
1.2.2.3. Traveling Wave IM-TOFMS 
 The first commercially available IM-MS instrument based on traveling wave ion 
mobility was released in the late 2000s (Waters Corporation) and has since become 
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widely used. The basic principles of TWIM are similar to those of DTIM in that ions 
travel through the drift region under the influence of an electric field and their motion is 
impeded to some extent by collisions with a neutral drift gas. A key difference is the 
nature of the electric field used to propel ions through the drift cell. In contrast to uniform 
field DTIM instruments, TWIM drift cells utilize a dynamic electric field. The TWIM 
drift cell is comprised of a series of planar ring electrodes and the opposite phases of an 
RF voltage are applied to adjacent ring electrodes to radially confine ion motion to the 
center of the ring electrodes.
77
 In addition to the RF voltages, a dc voltage is briefly 
applied to a pair of neighboring electrodes in a repeating pattern across the length of the 
drift cell (typically comprised of 61 electrode pairs).
78
 The dc pulse generates a potential 
hill and, when applied in the repeating sequence, results in a series of traveling waves 
which propel ions away.
77, 78
 Ions of different mobilities are then separated based on their 
abilities to travel with, or “surf,” a traveling wave pulse, which is dependent upon the 
traveling wave height and velocity and the neutral drift gas pressure.
77
 High mobility ions 
tend to surf the front of the traveling wave and exit the drift cell quickly. In contrast, low 
mobility ions cannot keep up with the traveling wave and will roll over the top of the 
wave. The low mobility ions, on average, will be propelled through the drift cell and exit 
at a time dependent upon the number of roll over events.
77
  
 A schematic diagram of an ESI-TWIM-TOFMS instrument is shown in Figure 
1.6(b). Following ionization, ions are directed by a traveling wave ion guide into the 
quadrupole, which typically operates in RF-only mode for full mass analysis. Ions then 
enter the IM region of the instrument, which is comprised of three stacked ring electrode 
ion guides capable of traveling wave separations. The trap region stores ions during ion 
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mobility separation, as necessary to modulate the continuous ion beam from the ESI 
source. This region typically operates without the traveling wave and the gating and 
release of stored ions into the IMS cell is performed by the last ring electrode, which is 
operated as dc-only. As discussed above, the IMS cell utilizes the traveling wave and 
separation is typically performed in nitrogen gas (N2). The transfer ion guide operates 
with a small traveling wave to maintain the mobility separation of the ions. Ions eluting 
from the IM region travel through a series of focusing lenses prior to entering the source 
of the oTOFMS. The TOFMS pusher is synchronized to the release of ions from the trap 
and up to 200 mass spectra are recorded per cycle of the TOF pusher. Note that in present 
instrumentation there is no interleaving of data, so time resolution in both the IM and MS 
dimensions are not independent. 
 The ESI-TWIM-MS arrangement shown in Figure 1.6(b) offers an important 
advantage in that several types of fragmentation studies can be performed. The 
quadrupole, when operated as a mass filter, enables the mass selection of precursor ions. 
Both the trap and transfer regions are capable of fragmentation via collision induced 
dissociation (CID). Fragmentation within the trap occurs prior to IM analysis (termed 
pre-mobility fragmentation) and product, as well as precursor, ions undergo mobility 
separation. Thus, structural information for both the precursor and fragment ions is 
obtained simultaneously. Alternatively, fragmentation in the transfer region occurs post-
mobility and product ions are aligned in drift time with their precursor ion. This scheme 
is particularly useful where isobaric, but structurally distinct species are present, as it 
would be straightforward to distinguish which product ions correspond to a given 
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precursor ion. It is also possible perform multiplexed fragmentation by operating the 
quadrupole in full-MS mode and utilizing post-mobility CID in the transfer region.  
 As discussed above (Section 1.1.1.3) the electrodynamic nature of separations in 
TWIM do not provide a convenient means for calculation of absolute collision cross 
sections by Eqn. [5]. Nevertheless, relative collision cross sections can be determined but 
the TWIM drift times must be calibrated against absolute collision cross sections 
determined by DTIM. Several detailed protocols are available for performing the 
calibration of TWIM drift times to collision cross sections.
106, 107
 
 
1.3. Applications of IM-MS 
 As the availability and popularity of IM-MS technologies has grown, so too has 
the number and diversity of its applications. IM-MS has become a key research tool in 
fields ranging from the life sciences to nanotechnology. In addition to emerging IM 
applications, IM-MS has also been demonstrated as an advantageous technique in 
established fields, such as proteomics and systems biology. This section serves as an 
introduction to a few of the many applications of IM-MS technologies, with focuses on 
conformation space analysis, “omics” analyses, and macromolecular protein complexes. 
 
1.3.1. Conformation Space Analysis 
 The area formed by the 2D plot of IM drift time versus m/z, a typical data output 
from IM-MS experiments, is commonly referred to as conformation space. As previously 
discussed (Section 1.1.2.), the correlation of m/z and drift time (or mass and size, 
respectively) results in a low peak capacity for IM-MS and signals do not occupy every 
28 
 
region of the conformation space. Instead, signals form into regions of correlation, or 
trend lines, based on their chemical composition. The comprehensive mapping of the 
regions of conformation space typically occupied by biomolecules also revealed 
generalized strategies for ion mobility labeling approaches to utilize those regions 
typically void of signals and increase information content. 
 
1.3.1.1. Mapping the Conformation Space of Biomolecules 
 For biological analytes, it is well known that the gas-phase packing efficiencies 
differ significantly amongst the different classes of biomolecules due to their differing 
degrees of freedom. The relative packing efficiencies of the biomolecular classes follow 
the trend in order of decreasing packing efficiency or density: oligonucleotides > 
carbohydrates > peptides/proteins > lipids.
44-48
 This ordering is observed in the IM-MS 
conformation space in the form of trend lines unique to each biomolecular class, as 
illustrated in Figure 1.5 in Section 1.1.2.2. The ordered separation of biomolecular 
species in IM-MS conformation space can be utilized as a predictive tool for identifying 
the biomolecular class to which unknown species belongs. A map of IM-MS 
conformation space developed from a large dataset of singly-charged lipids (n = 53), 
peptides (n = 610), carbohydrates (n = 192), and oligonucleotides (n = 96) is presented in 
Figure 1.7a. In contrast to typical plots of IM-MS conformation space, the drift times 
have been transformed to collision cross sections and then plotted against m/z. The 
primary purpose for the transformation from drift time to collision cross section is to 
normalize for experimental conditions, but the nonlinear nature of the transformation has 
the added benefit of enhancing the separation of the biomolecular trend lines.
48
 The data  
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Figure 1.7.  (a) A plot of collision cross section versus m/z for the different classes of 
biomolecular species:  lipids (n = 52), peptides (n = 610), carbohydrates (n = 192), and 
oligonucleotides (n = 96). All species are singly charged ions generated by MALDI, and 
the data point generally contains error ±1σ. (b) For each biomolecular class, the average 
collision cross section and m/z data in (a) has been fitted to a logarithmic regression. 
Adapted from L.S. Fenn, M. Kliman, A. Mahshutt, S.R. Zhao, and J.A. McLean, 
Analytical and Bioanalytical Chemistry 2009, 394, 235-244, Fig. 1(a,b), with permission 
from Springer Science+Business Media. 
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in Figure 1.7a has been fitted to a logarithmic function and the average logarithmic 
correlation for each biomolecular class is presented in Figure 1.7b. The approximation of 
collision cross section as a logarithmic function of m/z is appropriate as the increase in 
collision cross section with increased mass would be expected to approach a limit at high 
mass depending on the average packing density of a molecular class.
47
 Inspection of the 
distribution of collision cross section values about the average correlations for each class  
reveals that the breadth of conformation space occupied increases in the order: lipids < 
oligonucleotides < peptides < carbohydrates.
47
 This ordering can be explained by 
examination of the structural components from which each biomolecular class is 
composed as well as their prevailing intramolecular forces (e.g. hydrogen bonding, π-π 
interactions, van der Waals interactions, etc.). Oligonucleotides are linear biopolymers 
comprised of only four monomeric units, and therefore the narrowness of their 
distribution can be explained by the limited arrangements available and the strong π-π 
base pair stacking intramolecular forces. Alternatively, peptides and carbohydrates have 
greater numbers of monomeric units and greater potential for structural diversity due to 
branching. The small distribution of the lipids can be rationalized by the highly conserved 
structure of the class, in which most species are comprised of a small head group and two 
large fatty acid tails; however, it should also be noted that the small deviation may be due 
to under sampling.
47
 
In addition to course-grained structural information, closer inspection of the 
correlations observed in conformational space can reveal fine structural details. The 
different sub-classes or structural motifs within a biomolecular class can be visualized in 
the form of deviations from the average correlation for the class, as  depicted  in  Figure  
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Figure 1.8.  A plot demonstrating the deviations about the average correlations of 
oligonucleotides, carbohydrates, natural products, peptides and lipids resulting from the 
structural motifs or sub-classes present within the biomolecular classes. The length of the 
arrows indicated the relative magnitude of the deviation and the direction up or down 
indicates their location above or below the average correlation line of the class. Reprinted 
from J. Am. Soc. Mass Spectrom., 20, J.A. McLean, The mass-mobility-correlation redux: 
the conformational landscape of anhydrous biomolecules, 1775-1781, 2009, with 
permission from Elsevier. 
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1.8. For example, the dominant tertiary structural motif of a peptide results in a deviation  
above or below the average peptide correlation, where elongated α-helical peptides have 
a larger deviation than more compact β-hairpin peptides.38,47,48  Similarly, post- 
translational modifications (PTMs) of peptide sequence such as phosphorylation and 
glycosylation result in a deviation below the average peptide correlation.
38,48,108
 The sub-
classes  of  lipid  species  display  a  clear  bimodal  distribution  about  the  average  lipid 
correlation, as shown in Figure 1.8. These sub-classes can be further grouped into the 
sphingolipid and glycerophospholipid families, which differ in the linkage (sphingosine 
and glycerol, respectively) of the phosphate and head group to the fatty acyl tails. The 
sphingomyelin and cerebroside lipids, belonging to the sphingolipid family, have much 
more extended structures than the more compact glycerophospholipid family (e.g. 
phosphatidylcholines, phosphatidylserines, etc.). This is clearly indicated in Figure 1.8, as 
the sphingolipids tend to have large relative deviations above the average lipid correlation 
while glycerophospholipids have smaller relative deviations below the average 
correlation.
47, 48, 109
 
 
1.3.1.2. Utilizing Conformation Space with Ion Mobility Shift Reagents 
 The correlation of the mobility and mass dimensions leads to only a portion of the 
total conformation space being occupied by signals. For highly complex samples such as 
plasma or cell lysates, this area can become congested and detection of low abundance 
species can be challenging due to overlap. With knowledge of the regions of IM-MS 
conformation space which are expected to be occupied by biomolecules, it becomes 
possible to utilize those regions predicted to be unoccupied. With the assistance of ion 
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mobility shift reagents, analytes containing specific chemical functionalities (i.e. cysteine 
residues, phosphorylations, etc.) can be shifted from the correlation region for their 
biomolecular class to an unoccupied area of conformation space. These empty regions of 
conformation space occur both above and below the correlation region, giving rise to two 
possibilities for shifting the analyte. To shift analytes to an area above the correlation 
region for their biomolecular class, the IM shift reagent must have a lower density than 
that biomolecular class, as depicted by the parachutes in Figure 1.9. In contrast, higher 
density IM shift reagents, which behave like anchors (Figure 1.9), must be used to shift 
analytes below their correlation region.  
 One approach to the development of IM shift reagent labeling has been focused 
on the formation of noncovalent ion-molecule complexes in the gas phase, in which 
chemical complexation occurs at a specific functional group in the ion. Crown ethers, in 
particular, have been widely studied due to their ability to form ion-crown complexes in 
the gas-phase.
110-117
 The utility of crown ethers to form complexes with primary amines 
and amino acids was described by Creaser and colleagues.
116, 117
 In a series of IM-MS 
experiments, they demonstrated the ability to separate isomeric amines and peptides 
based on the increase in collision cross section which occurred upon complexation with 
the crown ethers.
116, 117
 The utility of crown ethers as low density IM shift reagents for 
peptides was further developed by Clemmer and colleagues, who demonstrated the 
sequence selectivity of crown ether-peptide complexation, as the crown ethers 
preferentially formed complexes with the basic sites in the peptides (i.e. arginine and 
lysine).
118
 It was also demonstrated that the peptide-crown ether complexes could be 
dissociated by collisional activation to reveal the free peptide, enabling mass analysis of  
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Figure 1.9.  A graphical depiction of the peptide mobility-mass correlation in IM-MS 
conformation space based on the collision cross sections of ca. 600 singly-charged 
peptides. The effects of low density and high density shift reagents are illustrated as 
parachutes and anchors, respectively. Reprinted from Int. J. Mass Spectrom., 307, T.J. 
Kerr, R.L. Gant-Branum, J.A. McLean, Multiplexed analysis of peptide functionality 
using lanthanide-based structural shift reagents, 28-32, 2011, with permission from 
Elsevier. 
 
 
 
 
 
 
35 
 
the free peptide ions rather than the peptide-crown ether complexes. Although there are 
benefits to the use of noncovalent complexes as IM shift reagents, the complexity arising 
from the presence of both complezed and free target species is not ideal as the approach 
cannot be used quantitatively.  
 Labeling via covalent chemical modification is an alternative approach to ion 
mobility  shift  reagents  which allows relative  quantitation  information  to  be  obtained.  
Originally described for MS-based relative quantitation of peptides and proteins
119,120,121
, 
lanthanide-based labeling strategies have recently been demonstrated as high-density IM 
shift reagents.
122,123
 The tags function as high density IM shift labels as the chelated 
lanthanide metal contributes a large mass increase without significantly increasing the 
collision cross section of the labeled peptide.
122, 123
 Subsequently, the labeled peptide is 
shifted below the predicted peptide correlation line to a region of IM-MS conformation 
space where such signals are not predicted to occur. The label generally consists of a 
lanthanide metal chelating moiety, a linker region and a chemically selective moiety 
which covalently modifies a specific functional group in the peptide or protein. A variety 
of chemical selective moieties have been developed for the selective modification of 
peptide functional groups such as primary amines, cysteine residues, and phosphorylated 
residues.
123
 Incorporation of two different lanthanide metals in a known ratio allows for 
relative quantitation in a manner analogous to stable isotope labeling strategies such as 
isotope-coded affinity tagging (ICAT).   
 The use of lanthanide-based labeling for relative protein quantitation is illustrated 
in Figure 1.10(a). The cysteine residue of the peptide CLRRASLG was selectively 
labeled with  a 1:2  mixture  of  the lanthanide  metals Tb and Ho, respectively.  Relative  
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Figure 1.10.  (a) The mass spectrum from a MALDI-TOFMS relative quantitation 
experiment in which the peptide CLRRASLG was selectively labeled at the cysteine 
residue with a 1:2 Tb:Ho mixture of lanthantide-based tags. Relative quantitation 
information is obtained by calculating the ratio of the isotopic envelopes for the Ho and 
Tb species. (b) The utility of lanthanide-based tags as ion mobility shift reagents is 
demonstrated. The model phosphoprotein β-casein (bovine) was digested with trypsin 
and labeled with a phosphopeptide selective lanthanide-based labeling reagent 
incorporating Tb. The peptide correlation line (white dashed line) is formed by the 
unlabeled tryptic peptides. The labeled phosphorylated peptide is shifted to a region of 
IM-MS conformation space which is not predicted to contain peptide signals. The peaks 
marked with an asterisk “*” correspond to excess reagents remaining from the labeling 
process. R.L. Gant-Branum, T.J. Kerr, J.A. McLean, Labeling Strategies in mass 
spectrometry-based protein quantitation, Analyst, 2009, 134, 1525-1530. – Reproduced 
by permission of The Royal Society of Chemistry. 
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quantitation was performed by calculating the ratio of the isotopic envelopes for the Tb 
and Ho-labeled species, whereby the measured Tb:Ho ratio for the data presented in 
Figure 1.10(a) was determined to be 1:2.04.
122
 Figure 1.10(b) demonstrates the utility of  
phosphopeptide selective lanthanide-based tags as IM shift reagents. The model 
phosphoprotein β-casein was proteolytically digested with trypsin and the resulting 
phosphopeptide,   FQpSEEQQQTEDELQDK,  was  selectively  labeled   with  a   tag 
incorporating Tb. The unlabeled tryptic peptides were then used to establish the peptide 
correlation line, as indicated by the white dashed line in Figure 1.10(b). The lanthanide-
labeled phosphopeptide is shifted to a region significantly below the peptide correlation 
line, providing a rapid means to locate phosphorylated peptides and improve accuracy in 
peak area analysis for relative quantitation experiments.
122, 123
 
 
1.3.2. Integrating Omic Analyses by IM-MS 
 An important feature of the different conformation space regions in which classes 
of molecules reside is the ability to integrate various omics measurements into the same 
measurement. Contemporary MS-based strategies in proteomics, glycomics, lipidomics, 
etc. involve extensive sample purification and preparation prior to the analysis to limit the 
identifications that are made to the molecular class of interest. In this manner, all other 
types of molecules are considered undesirable chemical noise. Conformation space 
analysis allows the simultaneous separation and identification of these various classes 
without these time consuming and potentially sample altering protocols. In the sections 
that follow, protomics, glycomics, and lipidomics are treated separately, but it should be 
noted that conformational analysis provides a well suited tool for the comprehensive 
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characterization of these different molecular classes in the same analysis as necessary in 
nascent fields such as systems biology. 
 
1.3.2.1. Proteomics 
 Mass spectrometry-based approaches such as of top-down
124
 and bottom-up
125
 
proteomics have become standard practices in the pursuit of protein identifications from 
biological systems.
126,127
 Due to the broad range of protein concentrations in the 
biological samples (e.g. 10
-3
 to 10
-24
 M for human plasma
128
) typically submitted for 
proteomic analysis, an additional dimension of separation is often implemented prior to 
detection by mass spectrometry to decrease the complexity of the sample and improve the 
dynamic range.
129-131
 Among the commonly used separation techniques are two-
dimensional polyacrylamide gel electrophoresis (2D-PAGE) and LC. Utilizing multiple 
dimensions of LC separation, techniques such as multidimensional protein identification 
technology (MudPIT) have been developed to further resolve sample complexity prior to 
MS in an online manner.
132, 133
 However, liquid-phase chromatography typically requires 
minutes to hours to achieve good separation, limiting the throughput for proteomic 
analyses. 
 Two dimensional gas-phase IM-MS separations are an alternative technique for 
reducing the complexity of samples for protein analysis and offer unique advantages for 
proteomic applications. In contrast to liquid-phase separations, gas-phase IM separations 
are significantly more rapid (µs-ms) and more closely match the timescale of the MS 
separation.
38
 Although the peak capacity (Φ) of IM-MS (5.5 x 103 for MALDI-IM-MS40) 
is limited relative to more orthogonal two-dimensional separation techniques (6 x 10
7
 for 
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LC-FTICR-MS
41
), IM-MS benefits from an exceptionally high peak capacity production 
rate (2.8 x 10
6
 Φ s-1 for MALDI-IM-MS40 vs. 1.25 x 104 Φ s-1 for LC-FTICR-MS41). As 
discussed in Section 1.3.1.1., separation on the basis of structure in IM results in the 
formation of trendlines for each class of biomolecular species (see Figure 1.7). The 
presence of a peptide trendline in proteomic IM-MS analyses improves the confidence in 
identification while also increasing signal-to-noise of peptide species. Signals due to 
chemical noise (i.e. those corresponding to surfactants, MALDI matrices, or internal 
calibrants) occur in a different region of conformation space than the peptide signals and 
can be removed by extracting only the defined 2D region of correlation space containing 
the peptide trendline.
38
 The location of a peptide signal about the average peptide 
correlation line in conformation space can provide insight into its secondary structure (i.e. 
α-helix, β-sheet, etc.) or the presence of PTMs, as discussed in Section 1.3.1.1. (see 
Figure 1.8).
38,47,48,108,134,135
 Additionally, it has been demonstrated that peptides with 
structural or sequence isomers can be resolved in the IM dimension due to differences in 
their adopted gas-phase structures.
33, 136
 
 Much work has been done to further enhance the utility of IM-MS techniques for 
proteomic applications. One such goal has been the development of peptide drift time and 
collision cross section prediction algorithms based on intrinsic factors such as amino acid 
sequence and amino acid size.
137-144
 From the analysis of 113 lysine-terminated tryptic 
peptides, Clemmer and colleagues determined that collision cross section correlated with 
the amount of nonpolar or polar residues in the peptides, where nonpolar residues 
contributed more to the collision cross section that polar residues.
138
 They demonstrated 
highly accurate calculations of collision cross sections from intrinsic amino acid size 
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parameters, with greater than 90% of calculated CCS values falling with 2% of the 
experiment CCS measurements.
138
 An improvement on this approach was later developed 
by Clemmer and colleagues in which the position of the amino acid within the peptide 
sequence is taken into account by the size parameters, referred to as sequence-specific 
intrinsic size parameters (SSISPs).
139
 Most recently, a method based on intrinsic amino 
acid size parameters has been proposed in which the ion mobility predictions can be 
utilized as a ranking tool to improve candidate peptide ion assignment.
143
 
 From an instrumental perspective, the incorporation of a means by which peptide 
sequencing can be performed has been a key advance for IM-MS as a tool for proteomic 
analyses as primary sequence information is highly desirable for accurate protein 
identifications. IM-MS platforms have been developed around dissociation methods such 
as surface-induced dissociation (SID)
145
 and collision-induced, or activated, dissociation 
(CID or CAD, respectively).
42,84,103,146-149
 As discussed in Section 1.1.2.1, placement of 
the collision cell between the IM and MS enables multiplexed fragmentation to be 
performed without precursor mass selection, as the fragment ions are essentially labeled 
with the drift time of the precursor ion.
42
 For greater separation of complex protein 
mixtures, a number of three dimensional LC-IM-MS and LC-IM-MS/MS platforms have 
been described.
43,101,103,104,136,150-152
 Relative to LC-MS techniques, incorporation of a 
dimension of IM separation enhances component resolution by more than one order of 
magnitude without increasing analysis times.
152
 
 The viability and merits of IM-MS for proteomic applications are best 
demonstrated by its application proteome profiling experiments comparable to those 
typically performed by LC-MS- based platforms. One of the earliest examples was the 
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analysis of the human urinary proteome by LC-IM-MS and LC-IM-MS/MS techniques. 
Precursor and fragmentation data were collected separately and combined post-
acquisition by alignment of retention and drift times (tR and td, respectively). This data set 
of precursor and fragment ions was searched against a protein database and 13 proteins 
were identified from 27 peptides.
103
 Importantly, this study demonstrated the benefit of 
IM separations in that peptide signals unresolved in the LC dimension were successfully 
resolved in the mobility dimension.  
Several proteomic LC-IM-MS studies have focused on the model organism 
Drosophila melanogaster.
104,105,150,153
 In one such study, the use of SCX-LC-IM-MS 
analyses was described as a means to build proteome maps, in which peptides 
corresponding to a specific protein are reproducibly located within a multidimensional 
space.
150
 This approach was applied in a study of the developmental phases of D. 
melanogaster, the whole embryo and the adult head, to identify the proteins present in 
both stages. Comparison of the proteome maps, containing the values of td, tR, tSCX, m/z 
and intensity for each feature, for the two development stages revealed that 307 of the 
1133 proteins identified were observed in both samples.
150
  
Most impressively, mapping of the human plasma proteome has also been 
attempted with LC-IM-MS and SCX-LC-IM-MS techniques.
102, 152, 154
 For studies of such 
highly complex samples, the rapid nature of IM-MS techniques is greatly beneficial for 
sample throughput as multiple experiments are likely required to obtain maximal 
proteome coverage. For example, a 50 hr (10 runs, cumulative) LC-MS analysis of 
human plasma resulted in the identification of 300 proteins.
155
 In contrast, 438 protein 
identifications were reported by Clemmer and colleagues from a single 3.3 hr LC-IM-
42 
 
CID-MS analysis of human plasma.
152
 Proteomic profiling of plasma is particularly 
challenging as protein concentration range is approximately 10 
21,128
 Frequently the most 
abundant proteins must be depleted to improve the experimental dynamic range for the 
detection of low abundance species.
156
 With the use of 2D-LC-IM-MS techniques such as 
SCX-LC-IM-MS depletion of the most abundant plasma proteins is not typically 
necessary, as the mobility dimension can resolve the lower abundance species from 
coeluting high abundance species.
151, 152
  
 
1.3.2.2. Glycomics 
 The carbohydrates which form glycoconjugates such as glycoproteins and 
glycolipids derive their functions from the monosaccharide units from which they are 
composed and the structures those monomers collectively form.
157
 The role of 
glycosylation in biological processes such as cell signaling and communication and its 
implication in certain types of cancer and in Alzheimer’s disease have underscored the 
need of analytical techniques for rapid determination of the compositions and structures 
of the carbohydrates forming glycoprotein and glycolipid glycoconjugates.
157-160
 A 
number of MS-based approaches to glycoconjugate and carbohydrate characterization 
have been described.
161-166
 This approach, however, can be challenging due to the 
complex branching patterns of glycans and the potential for numerous isobaric positional 
and/or structural isomers.
161, 167, 168
 
 IM-MS techniques have been evaluated as an approach to the characterization of 
carbohydrates, as isobaric and isomeric carbohydrates can be resolved in the IM 
dimension due to differences in gas-phase conformation.
158, 169-178
 Early works focused on 
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small linear and cyclic (e.g. cyclodextrins) oligosaccharides, for which experimental 
collision cross sections of free or metal-coordinated oligosaccharides were 
determined.
169-172,174
 Comparison of these experimental collision cross sections with 
computationally derived values provided insight into the preferred conformations of 
metal-coordinated oligosaccharides, notably with alkali metals.
170,172
 Gas-phase structural 
separations (FAIMS and IM-MS) have also been demonstrated with mono and 
disaccharides as means to resolve carbohydrate anomeric configurations and 
stereoisomers.
173, 179
 
   IM-MS has also been demonstrated for the separation of larger branched 
carbohydrates and their isobaric positional or structural isomers.
158,175-177
 Positional 
isomers, which differ only in the specific glycosidic linkage arrangement (e.g. 1→3 vs. 
1→4), and structural isomers, which differ in branching patterns, have both been resolved 
by IM-MS.
158, 177
 The differences in the structures of the isomers results in differences in 
their gas-phase mobilities, and therefore drift times. This is depicted in Figure 1.11, 
which shows the arrival time distributions for three sets of isomeric carbohydrates. 
Overall, it is clear from panels (a) – (c) that smaller and more compact carbohydrates 
eluted from the drift cell more rapidly than the larger structures. Structures (1) – (4), 
shown on the left, are positional isomers, where carbohydrates (1) and (2) differ by the 
shift of both 1→3 glycosidic linkages to 1→4 linkages and carbohydrates (3) and (4) 
differ by the shift of one 1→3 linkage to a 1→4 linkage. As indicated in Figure 1.11a, the 
positional isomer (1) displayed a shorter drift time than that of positional isomer (2). For  
positional isomers (3) and (4), carbohydrate (3) showed a shorted drift time (Figure 
1.11b).   The  shorter  drift times of carbohydrates  (1) and (3) relative to their respective  
44 
 
 
 
 
 
 
Figure 1.11. (Left) Three sets of isobaric positional or structural isomers. Positional 
isomers (1) and (2) differ by the change of both 1→3 glycosidic linkages in glycan (1) to 
1→4 linkages in (2). Only one of the 1→3 linkage in (3) has been varied to a 1→4 
linkage to form structure (4). Structures (5) and (6) represent structural isomers, in which 
a fucose monomer has been transferred from the galactose in (5) to the N-
acetylglucosamine to form (6). (Right) The drift time profiles for the pairs of isomers. (a) 
Structure (1) (dotted line) has a shorter drift time than structure (2) (solid line) as the 
1→4 linkages result in a more elongated structure. (b) The presence of only one 1→4 
linkage increases the drift time of glycan (4) (solid line) relative to glycan (3) (dashed 
line), which has only 1→3 linkages. (c) The increased branching of glycan (6) (dashed 
line) results in a shorter drift time than the linear glycan (5) (solid line). L.S. Fenn and 
J.A. McLean, Structural resolution of carbohydrate positional and structural isomers 
based on gas-phase ion mobility-mass spectrometry, Phys. Chem. Chem. Phys. 2011, 13, 
2196-2205. – Reproduced by permission of the PCCP Owner Societies. 
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positional isomers is indicative of a general trend in which carbohydrates with 
predominantly 1→3 glycosidic linkages have more compact structures than those with 
1→4 linkages.158 
Carbohydrates (5) and (6), as shown in the bottom left of Figure 1.11, are isobaric 
structural isomers which are comprised of the same five monomers and have  identical 
glycosidic linkages but differ in the placement of a fucose monomer. The shift of the 
fucose monomer from the non-reducing end of the linear carbohydrate (5) to the 
secondary N-acetylglucoseamine creates a branched carbohydrate (6) with two non-
reducing ends. The drift time profiles of carbohydrates (5) and (6) (Figure 1.11(c)) reveal 
that the branched carbohydrate (6) shows a shorter drift time than its linear structural 
isomer (5), indicating that (6) can adopt a more compact structure than (5) due to the site 
of branching.
158
 
 For complex mixtures of glycans, such as those derived from glycoconjugates in 
biological samples, the ability to resolve isobaric isomeric species in the IM dimension 
significantly reduces spectral complexity and improves de novo sequencing 
capabilities.
158,175,176
 An IM-MS analysis of the N-linked glycans enzymatically released 
from model glycoprotein ovalbumin identified a total of 42 distinct isomers and/or 
conformers from 19 m/z values corresponding different glycan structures.
180
 Large scale 
studies of complex glycan mixtures from biological samples such as serum and urine 
have been performed by LC-IM-MS to demonstrate its potential for revealing disease-
related differences in glycan expression.
175, 176
  
An IM-MS approach for the simultaneous analysis of glycoproteins has also been 
described.
178
 Typical MS-based techniques for glycoprotein analysis require that the 
46 
 
carbohydrates and peptides be separated and analyzed individually, requiring extensive 
and time consuming sample preparation.
161,166
 Based on the separation of different classes 
of biomolecules in IM-MS conformation space,
46,47
 it is possible to simultaneously 
characterize both the deglycosylated peptides and their associated glycans.
178
 The 
glycoprotein is proteolytically digested and the N-linked glycans are released from the 
resulting glycopeptides by addition of PNGase F.
178
 The mixture of glycans and peptides 
is then analyzed by IM-MS. A plot of conformation space from the MALDI-IM-MS 
simultaneous glycomic analysis of bovine ribonuclease B (RNAse B) is presented in 
Figure 1.12(a). The tryptic peptides adopt more elongated structures than the glycans and 
are structurally separated into their respective mobility-mass correlations,
46,47
 as indicated 
by the white and black dashed lines, respectively. The mass spectra corresponding to the 
two mobility-mass correlations (Figure 1.12b,c) can be isolated from each other, allowing 
for simultaneous analysis of both the peptides and the glycans without interference from 
overlapping isobaric species.
178
 
 
1.3.2.3. Lipidomics 
 Lipids are integral components of cells which function in roles such as cell 
structure, energy storage, and cell signaling.
181,182
 The recent realizations of their 
involvement in diabetes,
183
 atherosclerosis,
184
 and neurological disorders such as 
Alzheimer’s disease185 have propelled the development of MS-based lipidomics for lipid 
profiling in biological systems.
186,187
 Howver, the analysis of lipids by MS-based 
approaches poses several analytical challenges. Naturally occurring lipids occupy a 
narrow range of m/z space and interference from isobaric lipid species is common.
109
 For  
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Figure 1.12.  (a) A 2D plot of IM-MS conformation space from the MALDI-IM-MS 
analysis of digested and deglycosylated RNAse B. The mobility-mass correlations for the 
singly charged peptides and glycans are indicated by the white and black dashed lines, 
respectively. (b) The mass spectrum corresponding to the tryptic peptides is obtained by 
extracting along the peptide correlation line (white dashed line in (a)). (c) The extracted 
mass spectrum corresponding to the glycans, obtained by extracting along the glycan 
correlation line (black dashed line in (b)). The open circles correspond to mannose and 
filled boxes correspond to N-acetylglucosamine. L.S. Fenn and J.A. McLean, 
Simultaneous glycoproteomics on the basis of structure using ion mobility-mass 
spectrometry, Mol. BioSyst. 2009, 5, 1298-1302. – Reproduced by permission of The 
Royal Society of Chemistry. 
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the direct analysis of lipids from complex samples, the presence of exogenous and 
endogenous chemical noise, including some highly-abundant lipid species,
188
 limits the  
detection and identification of low abundance lipid signals.
109,189
 Furthermore, the 
ionization preference for different classes of lipids are highly dependent on the chemical  
composition of the polar headgroup, making a single optimum of broad lipid ionization 
elucsive 
 IM-MS-based approaches for lipidomics are highly amenable due to the diverse 
structures of the different sub-classes of lipids. A detailed study of the separation of 
phospholipids in IM-MS conformation space has been performed by Woods and 
colleagues.
190
 Standard extracts of phosphatidic acid (PA), phosphatidylcholine (PC), -
ethanolamine (PE), -glycerol (PG), -serine (PS), –inositol (PI) and sphingomyelin  (SM)   
were  analyzed   by  MALDI-IM-MS  to  obtain   their   mobility-mass   correlations. 
Although both phosphatidylcholines and sphingomyelins contain choline head groups, 
these two species were consistently separated, with SM species generally having longer 
drift times, due to the differences in backbone structure. The effect of cationization was 
also investigated for its utility as lipid IM-MS shift reagents. The addition of an alkali ion 
was demonstrated to significantly reduce IM drift times, with the exception of cesium 
adduct formation which greatly shifted both the m/z and drift time. In general, the 
different phospholipid species occupy different regions of IM-MS conformation space 
due to the differences in head group, acyl chain degree of unsaturation and length, and 
adduct formation.
47,48,109,190
 
 The effects of phosphatidylcholine acyl chain degree of unsaturation was further 
investigated by Kim and coworkers with ESI-IM-MS.
191
 The addition of a single double 
49 
 
bond in the acyl chain resulted in a 5% decrease in drift time, with a further reduction by 
1% per each additional double bond. To understand the structural source of the observed 
reductions in drift time, molecular dynamics simulations were performed for several 
saturated and unsaturated PCs. Evaluation of the computationally generated structures 
indicated an increase in the structural rigidity of the unsaturated acyl chain due to the 
presence of the cis double bond, resulting in a decrease of the collision cross section of 
the unsaturated PCs relative to the saturated PCs.
191
 
 A number of studies have utilized the IM-MS approach for the direct analysis of 
lipids from tissues and, in particular, brain tissues.
35,189,192,193
 Lipid changes in a 
Drosophila model of epilepsy were measured directly from microdissected Drosophila 
brains with MALDI-IM-MS by Kliman et al.
192
 Signals corresponding to lipids were 
extracted from IM-MS conformation space, reducing the chemical noise due to MALDI 
matrix signals. Spectral alignment and statistical analysis of the lipid MS data revealed 
significant changes in multiple biosynthetically related lipid species between the mutant 
and wild type control.
192
 MALDI-IM-MS imaging of lipids from directly tissues has also 
been demonstrated.
35, 193
  
 
1.3.3. Structural Biology by IM-MS 
 Noncovalent assemblies of multiple proteins, or protein complexes, act as 
machines to collectively perform of an array of cellular functions and the particular 
function a protein complex performs is highly correlated to its overall structure.
194, 195
 
Electrospray ionization-mass spectrometry (ESI-MS) has proven to be an informative 
tool for the characterization of the structures of protein complexes, in that soft ionization 
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by ESI can leave the noncovalent assemblies intact and generally can conserve their 
condensed-phase quaternary structure.
91,196-198
 With molecular mass and charge state 
distribution information available from ESI-MS, insight into the stoichiometries and 
conformations of protein complexes can be derived.
91, 196
 Over the past decade, IM-MS 
has emerged as a complementary technique for studying the shape and conformations of 
protein complexes due to the direct structural information available from the IM 
dimension. Critical works in the development of IM-MS for protein complex 
characterization set out to determine the stability of noncovalent complexes in the gas-
phase and were often paired with complementary data from classical methods of 
structural biology (e.g. X-ray crystallography, nuclear magnetic resonance, electron 
microscopy) to evaluate if condensed-phase structure was conserved in the absence of 
bulk solvent (Figure 1.13).
36,89,106,199-202
 In general, it has been shown that protein 
complexes do maintain their solution-phase structure under the condition of minimal 
collisional heating, or low activation voltages;
198
 however, the application of higher 
activation voltages is often necessary for desolvation of the protein complex and optimal 
mass accuracy.
203, 204
 These competing parameters for optimal accuracy in both IM and 
MS data requires special considerations in the experimental approach to studying protein 
complexes. A detailed protocol addressing such issues is available from Robinson and 
colleagues.
106
  
 At high activation voltages, IM-MS can be utilized to study the conformational 
transitions protein complexes undergo as they dissociate. To determine if dissociation of  
the tetrameric transthyretin complex occurs via unfolded intermediates, Ruotolo et al. 
measured the arrival time distribution of the tetramer at increasing activation energies.
205
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Figure 1.13. A flow diagram depicting three approaches for generating model structures 
of protein complexes, which can then be used to compare experimental and 
computational collision cross section measurements. The information available on the 
protein complex in the form of X-ray crystallography or NMR structures, as well as the 
computation resources available, dictates the detail of the model. Atomic and hybrid 
modeling require X-ray or NMR data for the entire complex or part of the complex, 
respectively, but are also highly demanding of computation resources. In contrast, course-
grained modeling is appropriate when no such data is available. B.T. Ruotolo, J.L.P. 
Benesch, A.M. Sandercock, S.J. Hyung, and C.V. Robinson, Ion mobility-mass 
spectrometry analysis of large protein complexes, Nature Protocols, 2008, 3, 1139-1152. 
– Reproduced by permission of Nature Publishing Group. 
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It was observed that the activated protein complex had a significantly broadened arrival 
time distribution relative to the ATD observed without activation, suggesting the 
presence of extended intermediate structures resulting from activation. For the 15+ 
charge state, three populations of structures with collision cross sections (CCSs) greater 
than that of the unactivated species were observed at medium activation energy. Higher 
activation energy resulted in a single population of even larger CCS. These results were 
compared with CCSs calculated for a series of increasingly unfolded structures generated 
by molecular modeling simulations. Experimental CCSs for the 15+ charge state of the 
activated tetramer were found to closely match model structures in which one monomer 
was up to 80% unfolded and model structures in which multiple monomers had partially 
unfolded. These results indicated that dissociation of activated protein complexes occurs 
through a mechanism which generates partially unfolded intermediate structures.
205
  
Additionally works have focused on the dependence of complex dissociation upon 
factors such as charge state and subunit packing.
206-210
 Collision induced dissociation 
(CID) of the dodecameric and toroidially-shaped heat shock protein 16.9 (HSP16.9) and 
stable protein 1 (SP-1) protein complexes demonstrated that they dissociated through 
different pathways.
207
 While HSP16.9 dissociates by ejected unfolded monomers, SP-1 
dissociates ejects monomers as well as dimers and multimers of the dimers. Investigation 
of these alternate dissociation pathways of similarly shaped protein complexes by IM-
MS/MS revealed a charge state dependence in the dissociation of multiple dimers from 
SP-1, where the occurrence of multimer loss increased with higher charge states. The 
unfolding and dissociation of HSP16.9 and SP-1 were monitored as a function of 
collision energy. For HSP16.9, dissociation followed the pattern most typically observed 
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for multiprotein, in which unfolding begins to occur at low energies and is followed by 
dissociation at higher energies. In contrast, the behavior of SP-1 was more atypical in that 
it simultaneously undergoes unfolding and dissociation at the same energy. From 
inspection of the SP-1 crystal structure, it was concluded that the resistance to unfolding 
prior to dissociation observed in SP-1 is due to the inability of terminal residues to 
initiate unfolding because they are not exposed on the surface of the complex.
207
 Such 
studies have demonstrated the critical influence of quaternary structure and charge 
density on the dissociation pathways of macromolecular protein assemblies, and initiated 
further studies into the effects of charge state manipulation (e.g. charge reduction and 
supercharging) on dissociation pathways.
206-208, 211
  
 
1.4. Conclusions 
The historical evolution of IM and IM-MS is characterized by periods of rapid 
and explosive growth in specific application areas interspersed with periods of slow 
maturation in these areas. The record is clear that IM-MS is experiencing a renaissance of 
this type as a multidimensional separations strategy in life sciences research, both for the 
analysis of complex biological samples and as a new tool for structural biology studies. 
The rapid separations afforded by IM-MS and the reduction of chemical noise in omic 
applications provide compelling reasons for adopting its utilization in systems biology 
research. Higher confidence assignments in allied omic areas like proteomics and 
lipidomics can be obtained by incorporating retention time, drift time, and accurate mass 
measurements. Similar to the advances in MS-based approaches to these endeavors, 
considerable research in smoothly integrating bioinformatics and biostatistics with these 
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multidimensional workflows are ongoing research goals. Our proclivity for generating 
vast amounts of data for biological systems is nearly unsurpassed, but translation of that 
data to desired biological information remains the rate limiting step. 
 Technological advances will certainly continue in this vibrant research area and 
wider adoption of these techniques in shotgun omics, spatial imaging IM-MS, and 
temporal studies of biological phenomena will presumably be forthcoming. In part this is 
facilitated by broader commercial offerings of these techniques to a wider biological 
community. Nevertheless, it is important to be vigilant of the past and the unique physical 
aspects of ion mobility in contrast with its bigger, but younger, sibling mass 
spectrometry. 
 
1.5. Summary and Objectives of Dissertation Research 
The identification of biomolecular signatures of disease from complex biological 
samples holds great promise for the discovery of potential diagnostic or prognostic 
markers as well as new avenues of therapeutics and preventative treatments.
212
 While the 
variety and complexity of diseases has led to a multitude of analytical methodologies for 
the study of complex biological samples, the scope of research has often been reduced to 
a singular class of biomolecules, resulting in the specialized fields of glycomics, 
lipidomics, metabolomics, and proteomics. Such reductionist approaches to complex 
biological sample analysis require rigorous and time-consuming sample preparation 
procedures to isolate the desired molecular species and significantly alter the original 
state of the biological sample in the process. While these approaches have greatly 
increased the knowledge of disease processes, the reduction of biological problems such 
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as disease to a single class of biomolecular species provides only a narrowed view of a 
naturally broad and intricate system.
213-215
   
 As described in sections 1.1.2.2 Advantages for Complex Biological Sample 
Analysis and 1.3.1 Mapping the Conformation Space of Biomolecules, ion mobility-mass 
spectrometry is well-suited for the analysis of complex biological samples given its 
ability to structurally resolve molecules arising from different biomolecular classes. My 
dissertation research in the McLean laboratory has focused on developing workflows for 
applying ion mobility and mass spectrometry-based techniques to the untargeted 
identification of biomolecular signatures of disease. Ion mobility-mass spectrometry 
approaches for revealing such biomolecular signatures from complex samples offer 
advantages including: (i) reduced sample preparation and purification, and preservation 
of the native sample complexity; (ii) improved throughput by combining multiple 
“omics” experiments into one analysis; and (iii) direct observation of the 
interdependencies between different types of biomolecules, i.e. proteins and their 
metabolites. Methodologies which combine IM-MS, chromatographic separations, 
specialized sample preparation, bioinformatics strategies, and statistically-directed 
transitions from untargeted to targeted analyses have been developed to reveal the 
biomolecular signatures most significantly distinguishing disease from non-disease states. 
Chapter II describes the initial effort toward these goals using an animal model of wound 
healing in diabetes, in which biomolecular species ranging from proteins to lipids were 
distinguished diabetic from non-diabetic wound fluids over a two-point time course 
experiment. Chapter III expands upon the strategies developed in Chapter II to 
distinguishing cancerous, benign and healthy breast tissues based on the differential 
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expression of biomolecular species, including a number of which are well known to be 
aberrantly overexpressed in cancer. Chapter IV demonstrates a more established 
approach to biomolecular signatures of disease by extensively mapping the 
phosphorylation of guanine nucleotide exchange factor Asef2 using multiple proteolysis 
strategies, and characterizing the effects of phosphorylation at S106 on adhesion turnover 
and cell migration. Finally, Chapter V closes with perspectives on future directions for 
both the works described here and, more broadly, for the development of IM-MS as a 
platform for biomolecular signature identification. 
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CHAPTER II 
 
BIOMOLECULAR SIGNATURES OF DIABETIC WOUND HEALING BY 
STRUCTURAL MASS SPECTROMETRY 
 
2.1. Introduction  
Diabetes is a metabolic disease characterized by abnormally high blood glucose 
levels resulting from the body’s inability to produce or use insulin. The Centers for 
Disease Control and Prevention (CDC) has reported that diabetes affects 8.3% of the U.S. 
population.
1
 Patients with diabetes are at significantly greater risk of complications such 
as blindness, kidney failure, and heart disease, making it the seventh leading cause of 
death in the U.S.
1
 Additional complications of diabetes occur in the extremities and 
include the loss or reduction of nerve sensation and decreased blood flow.
2,3
 The lack of 
nerve sensation is experienced by nearly 70% of diabetics and is particularly serious 
when it occurs in the lower extremities.
1
 Due to decreased blood flow and 
microcirculation in the lower limbs, signaling defects in the cytokine response, and the 
potential for infection, injuries incurred on the feet or lower leg can suffer from a delayed 
healing process, resulting in the formation of a chronic ulcer at the wound site.
2,3
 These 
chronic diabetic ulcers contribute significantly to the high number of lower-limb 
amputations performed per year on diabetics in the U.S. (65,700 in 2010).
1
  
The increased risk of chronic ulcer formation stems from disruption of the 
complex process of wound healing by the pathophysiological abnormalities associated 
with diabetes.
3,4
 Analysis of human diabetic ulcers has revealed the differential 
77 
 
expression of growth factors, chemokines, cytokines and their receptors, which are 
crucial to several phases of the normal wound healing process.
5,6
 Matrix 
metalloproteinases (MMPs), a family of endoproteinases involved in tissue remodeling, 
are also differentially expressed in chronic wounds, causing the dysfunctional breakdown 
of the extracellular matrix.
7,8
 Macrophages isolated from the wounds of diabetic mice 
have exhibited decreased ability to remove dead cells, resulting in a prolonged 
inflammatory response.
9
 Although it is evident that diabetes and hyperglycemia cause 
widespread disruption of the wound healing process, studies of diabetic wound healing 
continue to provide only a narrow view of a large and complex process.  
The protein detection methods of immunoblotting, microbead (Luminex), and 
enzyme immunoassays commonly utilized in wound healing studies rely on costly 
antibodies that are protein specific, requiring multiple antibodies for the analysis of 
multiple proteins. Proteomic analyses of wound healing have emerged recently with the 
broader focus of developing prognostic and diagnostic tools and potential therapies for 
chronic wounds.
8,10,11
 However, both proteomic and antibody-based analyses require 
rigorous and time-consuming sample preparation procedures to isolate the desired 
proteins that can alter the original state of the biological sample. To capture the full 
complexity of diabetic wound healing, it is desirable to utilize a more inclusive analysis 
requiring minimal sample manipulation. 
Ion mobility-mass spectrometry (IM-MS) is a rapid method of analysis which 
requires minimal sample preparation and offers the flexibility to include pre-ionization 
separations, making it well suited for holistic studies of complex biological systems. IM-
MS is a two-dimensional separation combining gas-phase ion mobility (IM) structural 
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separations with the mass-to-charge (m/z) separations of mass spectrometry (MS). In gas-
phase IM separations, ions travel under the influence of an electric field through a drift 
cell filled with neutral background gas. The number of collisions that occur between the 
ion and the neutral gas molecules results in a characteristic drift time, measured in micro- 
to milliseconds, which is dependent on the collision cross section (effective ion surface 
area). Within a class of biomolecules, such as lipids, proteins, or carbohydrates, a strong 
correlation between collision cross sections and m/z ratios is observed, resulting in the 
separation of each biomolecular class along unique mobility-mass correlation lines 
according to gas-phase packing efficiencies.
12, 13,14
   
Integrating ion mobility with MS measurements  provides four primary 
advantages over MS-only techniques in the analysis of complex biological samples  for 
the fields of imaging,
15,16
 proteomics,
17,18
 glycomics,
19,20
 lipidomics,
21,22
 
metabolomics,
23,24
 and systems biology.
25
  Firstly, the IM-MS integration provides rapid 
separations, increased peak capacity, and enhanced peak capacity production rate as a 2D 
separation over 1D separation dimensions. Secondly, IM-MS is inherently gas-phase and 
the timescales of separation are well suited for further integration with separations such 
as liquid chromatography (LC) to further increase peak capacity.
17, 18, 26-28
 Thirdly, 
different classes of biomolecules are readily distinguished from one another on the basis 
of their gas-phase structure. This provides higher signal-to-noise for low abundant 
species of one class (e.g. metabolites) that are separated from a species of a different 
class (e.g. peptides) having nearly, or the same, mass, which are unresolvable in the MS 
alone. Finally, ion activation following the IM separation, but prior to the MS separation 
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provides the ability to obtain fragment ion spectra for all of the molecules nearly 
simultaneously. 
This study demonstrates the use of IM-MS in identifying biomolecular signatures 
of diabetic wound healing. Wound exudate, a non-invasive sampling approach for human 
diabetic wounds, was collected from the wounds of diabetic and non-diabetic rats. The 
wound fluid was analyzed by IM-MS using electrospray ionization (ESI) after minimal 
sample preparation. Biomolecular signatures distinguishing diabetic and non-diabetic 
wound fluid and between wound fluids collected at two time points were revealed by 
direct comparison of IM-MS spectra and with the assistance of statistical analyses. Ultra-
performance liquid chromatography (UPLC), tandem MS, and database searching were 
used in a targeted manner to identify and validate the biomolecular signatures of diabetic 
wound healing. 
 
2.2. Experimental 
Rat Model 
Sixteen Sprague Dawley rats (300 g, male, Harlan Laboratories) were divided into 
treatment (n=10) and control (n=6) groups. The treatment group was dosed twice with 
streptozotocin (55 mg/kg), which induces diabetes by selective destruction of the insulin-
producing pancreatic β-islet cells. A blood glucose concentration greater than 300 mg/dL 
confirmed the diabetic state in the treatment group, and all ten treated rats converted to 
the diabetic phenotype. Four sterilized 10 mm polyvinyl alcohol (PVA) sponges 
(Merocel, Medtronic, Mystic, CT) were inserted subcutaneously on the dorsal side of 
each animal. The PVA sponges were used to elicit a geometrically defined granulation 
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tissue response as a model of wound healing and to retain wound fluid. Sponges were 
harvested two days post-implantation from five diabetic and three control rats. Sponges 
were removed from the remaining diabetic (n=5) and control (n=3) rats five days post-
implantation. Approximately 40-50 µL of wound fluid was extracted from each PVA 
sponge by centrifugation through spin columns (Pierce Spin Cups, cellulose acetate filter, 
Thermo Fisher Scientific, Waltham, MA). Protein concentrations in the wound fluids 
ranged from 36 – 114 µg/mL. The remaining wound fluid was flash frozen and stored at -
80°C. 
 
Sample Preparation for ESI-IM-MS Direct Infusion Experiments 
Scheme 2.1 illustrates a general workflow for the preparation and IM-MS analysis 
of wound fluid. The 64 different sponge wound fluid samples to be analyzed by ESI-IM-
MS were prepared by diluting 20 µL of wound fluid to 1 mL with 4% formic acid 
(Thermo Fisher Scientific, Waltham, MA) prepared in distilled deionized (DDI) water 
(1  MΩ cm; Millipore, Billerica, MA). The diluted wound fluid was desalted with 1 
cc/30 mg Oasis HLB desalting cartridges (Waters, Milford, MA), using CHROMASOLV 
methanol (Sigma-Aldrich, St. Louis, MO) with 0.1% formic acid as the elution solvent. 
After desalting, samples were dried and reconstituted with 1 mL of 50% methanol 
containing 0.1% formic acid. Each of the 64 different samples were run in duplicate for 
technical replicates, resulting in 128 independent datasets. 
 
Sample Preparation for UPLC-ESI-IM-MS Experiments 
 50 µL each from two of the previously prepared diabetic day 2 wound fluid
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Scheme 2.1. Workflow for the preparation and IM-MS analysis of wound fluid for 
biomolecular signatures of diabetic wound healing. Briefly, wound fluid collected from 
PVA sponges was desalted and analyzed by ESI-IM-MS. An orthogonal partial least-
squares discriminant analysis (OPLS-DA) statistical analysis of the ESI-IM-MS data 
revealed biomolecular signatures of diabetic wound healing. UPLC-IM-MS/MS was 
performed in a targeted fashion to obtain accurate mass and fragmentation data for select 
biomolecular signatures. These data were then used for database searching, from which 
tentative identifications of the biomolecular signatures were determined. 
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samples were combined and diluted with 100 µL H2O (CHROMASOLV-grade; Sigma-
Aldrich, St. Louis, MO) for a total volume of 200 µL. The sample was centrifuged for 10 
minutes at 14,500 rpm and transferred to an auto-sampler vial for UPLC separation. 
 
Sample Preparation for UPLC-ESI-IM-MS Experiments 
50 µL each from two of the previously prepared diabetic day 2 wound fluid 
samples were combined and diluted with 100 µL H2O (CHROMASOLV-grade; Sigma-
Aldrich, St. Louis, MO) for a total volume of 200 µL. The sample was centrifuged for 10 
minutes at 14,500 rpm and transferred to an auto-sampler vial for UPLC separation. 
 
Instrumentation  
IM-MS was performed on a Synapt G2 (Waters, Milford, MA), which utilizes a 
traveling wave ion mobility cell and an orthogonal time-of-flight (TOF) mass 
spectrometer. The instrument was operated with electrospray ionization (ESI) and the 
TOFMS was operated in the single-stage reflectron, or “V,” configuration.29, 30   
 
ESI-IM-MS 
An external syringe pump (Harvard Apparatus, Holliston, MA) was used for 
direct infusion of the samples into the ESI source at a flow rate of 6 µL/min. The ESI 
source was operated in positive (+) mode. The electrospray voltage was 4.14 kV with 
sampling and extraction cone voltages of 20 V and 8 V, respectively. The desolvation 
temperature and gas flow were 150°C and 10 L min
-1
, respectively. Ion mobility 
separation was performed through nitrogen gas with a traveling wave velocity of 550 m s
-
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1
 and an amplitude of 40 V. Mass calibration was performed with sodium iodide (2 µg/µL 
in 50% 2-propanol) in the range of m/z 100 - 3000. Data were acquired over two minutes 
at a rate of 1 scan s
-1
. The transfer region was used to perform post-mobility MS/MS 
experiments. 
 
UPLC-ESI-IM-MS 
An ACQUITY (Waters, Milford, MA) UPLC system with an ACQUITY HSS 
C18 column (1.8 µm, 1.0 X 100 mm; Waters, Milford, MA) was used for the 
chromatographic separations prior to IM-MS. The column was coupled to the Synapt G2 
by the ESI source. The autosampler and column temperatures were maintained at 4°C and 
45°C, respectively. Chromatographic separation was performed with a binary solvent 
system of 95% water/5% acetonitrile (CHROMOSOLV-grade; Sigma-Aldrich, St. Louis, 
MO) with 10 mM ammonium acetate (Solvent A) and 5% water/95% acetonitrile with 10 
mM ammonium acetate (Solvent B). The mobile phase flow rate was set to 70 µL min
-1
 
and the injection volume was 5 µL. The initial gradient conditions were 99% A: 1% B for 
1 min, followed by a linear gradient to 1% A: 99% B over the next 7 min. The solvent 
gradient was held at 1% A: 99% B for 2 min, and then linearly increased to 99% A: 1% B 
over the next 0.5 min. The positive mode (+) ESI conditions were as follows: capillary 
+3.5 kV; sampling cone: 35 V; extraction cone: 2 V; source temperature: 130 °C; 
desolvation temperature: 150 °C. The negative mode (-) ESI conditions were as follows: 
capillary -2.5 kV; sampling cone: -25 V; extraction cone: -2 V; source temperature: 100 
°C; desolvation temperature: 150 °C. Desolvation and cone gas flow were 600 and 20 
L/hr, respectively. A traveling wave with a velocity of 550 m s
-1
 and height of 40 V was 
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used for IM separation. Leucine-enkephalin (m/z 556.2771) was used for lock mass 
correction. MS
E
 was performed in the transfer region with ramping collision energy from 
10 – 30 eV. 
 
Biostatistics 
The MarkerLynx XS (Waters, Manchester, U.K.) software package was used to 
perform mass spectral peak detection, alignment and normalization. Mass spectral peak 
alignment was performed by the combined scan method, where peaks within a 0.1 Da 
mass window were combined, and all 120 scans in the 2 min ESI-IM-MS acquisitions 
were combined. The spectral peak detection threshold was set at 1000 counts. 
Normalization was performed by the constant sum method, where the intensities are 
normalized such that the sum of intensities of all peaks in a sample sums to 10,000. The 
aligned data were then exported to the Extended Statistics component of MarkerLynx XS 
for partial least-squares discriminant analysis (PLS-DA) to show group differences and 
orthogonal partial least-squares discriminant analysis (OPLS-DA) S-plots to show the 
molecular species responsible for the group differences. Model parameters (R2Y,Q2) for 
PLS-DA and OPLS-DA can be found in the supporting information documentation. Two 
sample t-tests (assuming unequal variance) were selectively performed to calculate 
significance p-values for the species revealed to contribute the most to the group 
differences in the OPLS-DA S-plot analysis of the ESI-IM-MS data. Peak areas from 
mobility-extracted mass spectra were used for the calculation of p-values, fold-changes 
and to prepare box-and-whisker plots. 
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Bioinformatics 
Online database searching was performed by accurate mass through the 
MarkerLynx XS software package. The metabolite databases utilized included 
ChemSpider, the Human Metabolite Database (http://www.hmdb.ca), KEGG 
(http://www.kegg.com), LipidMAPS (http://www.lipidmaps.org), and METLIN 
(http://metlin.scripps.edu/). Searches were performed with a mass tolerance of 0.05 Da. 
Protein sequence similarity searches were performed with the UniProt BLAST program 
(http://www.uniprot.org/?tab=blast) and the UniProtKB protein database. 
 
Validation 
The tentative identifications from the bioinformatics were validated by MS/MS 
fragmentation experiments. When available, chemical standards of the tentatively 
identified species were purchased from Sigma Aldrich (St. Louis, MO). To be considered 
a positive identification, all MS and MS/MS peaks of the standard were required to match 
those of the analyte. 
 
2.3. Results and Discussion 
Two-dimensional projections of IM-MS data representative of control day 2 and 
diabetic day 2 wound fluid are illustrated in Figure 2.1(a),(b). The mass-to-charge (m/z) 
ratio is displayed along the x-axis, and drift time, measured in milliseconds (ms), is 
displayed along the y-axis. Intensity (counts), displayed on the z-axis in three-
dimensional IM-MS spectra, is represented by false coloring in the two-dimensional 
projection. Integrating the drift time dimension of IM-MS data yields a mass spectrum, 
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where intensity is displayed on the y-axis and m/z on the x-axis (Figure 2.1c). Mass 
spectra may also be extracted from a user-defined region of mobility-mass space and are 
referred to as mobility-extracted mass spectra (Figure 2.1d).   
Several mobility-mass correlation lines were apparent in the IM-MS spectra of the 
control day 2 and diabetic day 2 wound fluid (Figure 2.1a,b). These lines were predicted 
to represent biomolecular species such as lipids, proteins, or carbohydrates. While most 
of these correlation lines were consistently present in all samples, a line of strong signals 
was observed between m/z 700-950 and 4.2-5.6 ms in the diabetic day 2 mobility-mass 
spectra (e.g., white dashed box in Figure 2.1b) that was not distinguishable in control day 
2 samples or day 5 samples (day 2 control vs. diabetic: fold-change = 5.0; p = 9.56 x10
-5
; 
see Figure B.1a). Mass spectra extracted from the area outlined by the white rectangle in 
Figure 2.1(b) revealed several highly charged signals (Figure 2.1d). From the isotopic 
distributions, the signals were identified as the +11 to +14 charge states of an 
approximately 10.15 kDa species. The number of charges carried by this species and its 
corresponding molecular weight suggested it was a small protein.   
While these signals were strongly apparent in the ion mobility-mass spectra, 
identifying these unique features of the diabetic day 2 wound fluid from conventional 
mass spectra would be more challenging. The region between m/z 600-1200 in the 
mobility-mass spectrum of diabetic day 2 wound fluid (Figure 2.1b) contained another 
correlation line of highly charged signals which was separated in drift time from the 
series of nearly isobaric signals corresponding to the 10.15 kDa protein. Without 
separation in the drift time dimension, these signals were collapsed onto one another in  
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Figure 2.1. Three-dimensional ion mobility-mass spectra (a and b), two-dimensional 
mass spectra (c and d) representative of the ESI-IM-MS analysis of the 64 wound fluid 
samples. (a) IM-MS spectrum representative of control day 2 wound fluid. The red circle 
corresponds to m/z 544.4 as discussed in the text. (b) IM-MS spectrum representative of 
diabetic day 2 wound fluid. The region outlined by the white dotted rectangle contains 
the +11 to +14 charge states of protein S100-A8. (c) MS-only spectrum of the region m/z 
700-950 (as indicated by the grey dotted lines) of diabetic day 2 wound fluid (b), 
obtained by collapsing the IM dimension. (d) Mobility-selected mass spectrum of the 
region outlined by white-dashed lines in (b). A 2.7-fold increase in the chemical signal-
to-noise ratio (S/N) of the +13 charge state signal of S100-A8, m/z 781, was observed 
between the two-dimensional mass spectrum (c) and mobility-extracted mass spectrum 
(d) of the same m/z region. 
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the corresponding mass spectrum (Figure 2.1c). A mass spectrum extracted from the 
region of the mobility-mass spectrum containing the 10.15 kDa species (outlined in 
Figure 2.1b) showed a significant reduction in the chemical noise baseline (Figure 2.1d). 
For the +13 peak, m/z 781.7, a 2.7-fold improvement in the signal-to-noise ratio (S/N) 
was observed between the extracted mass spectrum and the full mass spectrum.  
Tandem MS (MS/MS) experiments are another approach widely used in attempts 
to identify unknown species, but the low S/N due to the overlapping isotopic distributions 
of several species would provide fragmentation spectra from which it would be 
challenging to make confident identifications. Two-dimensional IM-MS analysis allows 
ready discrimination of the chemical noise in a typical MS measurement from isobaric 
chemical species and overlapping isotopic distributions that are not resolved in one-
dimensional separations (for examples, see Figures B.2 and B.3 in Appendix B).
12,24,30
 
The challenges presented to MS/MS experiments by isobaric signals and 
overlapping isotopic distributions can be overcome with the addition of ion mobility.
31
 
The present instrumentation enables MS/MS experiments to be performed before or after 
IM separation, termed pre-mobility or post-mobility MS/MS, respectively, or both in 
series. While pre-mobility MS/MS (also known as ion activation) provides the unique 
drift times of precursor and fragment ions, post-mobility MS/MS yields fragment ions 
with the same drift time as the precursor ion. Fragmentation spectra are then mobility-
organized, separating the precursor of interest and its corresponding fragment ions from 
isobaric signals in drift time. In contrast to conventional MS/MS, the current IM-MS/MS 
instrumentation does not require preselecting particular ion species for fragmentation 
 89 
 
analysis, since the current IM-MS/MS instrument supports multiplexed MS/MS 
measurements during the initial sample run, with a wealth of fragmentation data readily 
available for subsequent analysis without rerunning the sample for targeted MS/MS 
based upon an initial analysis.  
Post-mobility MS/MS experiments were performed to identify the differentially 
expressed protein observed in the diabetic day 2 wound fluid. The MS/MS spectra taken 
for several charge states of this species yielded the amino acid sequence NFEEFLVLV 
from a series of triply charged y-ions (Figure 2.2). A UniProt BLAST sequence search of  
 “NFEEFLVLV” yielded a match with 100% identity, a score of 70, and an E-value of 
0.29 to residues 67-75 of protein S100-A8 (89 residues), also known as Calgranulin-A. 
The experimental monoisotopic molecular weight was calculated from the raw data to be 
10,144.35 ± 0.04 Da, which corresponds to the calculated monoisotopic molecular weight 
of S100-A8 with 26 ppm mass accuracy. Protein S100-A8 is a member of the S100 
family of proteins, characterized by the presence of two calcium binding domains which 
regulate cell functions such as cell stress, signal transduction, chemotaxis and 
inflammation.
32,33
 The heterodimer S100-A8/9 has been found at increased levels in the  
serum of type I diabetics.
34
 S100-A8 and S100-A9 were also found to be differentially 
expressed in wounds caused by scalpel incisions, and the role of S100-A8 in wound 
healing is suspected to be the differentiation of fibroblasts and accumulation of 
monocytes in areas of inflammation.
35, 36
  
To identify additional signatures of diabetic wound healing, statistical analysis 
was performed using MarkerLynx XS software.   Data  were  aligned  by  mass-to-charge 
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Figure 2.2. Mobility-extracted fragmentation spectrum for collision-induced dissociation 
(CID) of m/z 677.4, present only in diabetic day 2 wound fluid. The series of triply 
charged ions were identified as y-ions 14-23 (residues 67-75) of the protein S100-A8, 
corresponding to the partial sequence “NFEEFLVLV.” The hit to the UniProt protein 
database had an identity score of 100% and an E-value of 0.29. The experimental 
monoisotopic molecular weight from the raw data corresponded to the theoretical 
monoisotopic molecular weight for S100-A8 with 26 ppm mass accuracy. 
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only, as MarkerLynx XS did not have the capability of aligning by drift time. Partial 
least-squares discriminant analysis (PLS-DA) and orthogonal partial least-squares 
discriminant analysis (OPLS-DA) were used to identify signals which contributed most 
significantly to the differences between control and diabetic samples. The results of these 
statistical tests were visualized in score plots and S-Plots (Figure 2.3). PLS-DA scores 
depict the separation of control and diabetic wound fluid by group (Figure 2.3a,c,e), 
while OPLS-DA S-Plots (Figure 2.3b,d,f) depict which molecular signals are contributing 
to the group separation. As shown by the arrows in Figure 2.3(b), movement of a variable 
away from the origin in the x-direction correlates to its contribution to, or abundance in, a 
specific condition. Movement away from the origin in the y-direction is correlated with 
increased confidence in that variable’s uniqueness to a specific condition, i.e., the 
variable displays a substantial change between the diabetic and control groups. Features 
in the lower left quadrant of the S-Plots (Figure 2.3b, d,f) relate to the respective control 
samples, while features in the upper right quadrant relate to the respective diabetic 
samples.  
Three signals strongly contributed to the differences between the diabetic and 
control groups: m/z 544.4, 373.3, and 355.3. The maximum group separation was 
observed in the PLS-DA score plot for control day 2 and diabetic day 2 wound fluids 
(Figure 2.3a). In the corresponding S-Plot (Figure 2.3b), this separation was attributed to 
the signals m/z 544.4, 355.3 and 373.3, which were at their maximal separations from the 
other molecular signals. The signal m/z 544.4 contributed to the separation of control day 
5 and diabetic day 5 (Figure 2.3c,d) as well as control day 2 and diabetic day 5 (Figure 
2.3 e, f)  wound  fluid;  however, overall  group  separation  decreased  due  to  the  lower  
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Figure 2.3. Partial least-squares discriminant analysis (PLS-DA) scores (a,c,e) and 
orthogonal partial least-squares discriminant analysis (OPLS-DA) S-Plots (b,d,f) for ESI-
IM-MS data of control day 2 and diabetic day 2 wound fluids (a,b), control day 5 and 
diabetic day 5 wound fluids (c,d), and control day 2 and diabetic day 5 wound fluids (e,f). 
Model parameters (R2Y, Q2) can be found in Appendix B. 
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contribution of m/z 355.3 and 373.3 to the diabetic groups. This result inferred that the 
diabetic day 5 wounds became more similar to the control wounds. The absence of S100-
A8 in the control day 2, control day 5, and diabetic day 5 wound fluids (Figure 2.1a,b) 
supported this inference. 
A four-fold increase in the intensity (p = 3.66x10
-11
, Figure B.1b) of m/z 544.4 
occurred in the control day 2 group relative to the diabetic day 2 group, and a 2.7-fold 
increase was observed in the control day 5 group relative to the diabetic day 5 group (p = 
8.37x10
-6
, Figure B.1b). In the IM-MS spectra of control day 2 wound fluid, this species 
was located above the region of the mobility-mass spectra containing the protein S100-
A8, with a drift time of 5.03 ms (red circle in Figure 2.1a). The area of mobility-mass 
spectra above the protein region (i.e., with longer drift times) has been demonstrated 
previously as the region which lipids occupy, and localization of m/z 544.4 in this general 
region indicated it was a lipid species.
13,14
  
Extracted post-mobility MS/MS spectra of m/z 544.4 yielded fragments m/z 104 
and m/z 184 (Figure 2.4). This fragmentation pattern is diagnostic of a 
glycerophosphocholine (GPCho) lipid species, as the fragment m/z 184 is indicative of 
the loss of the lipid’s phosphocholine head group. A mass-based database search in 
MarkerLynx XS suggested that m/z 544.4 was lysophosphatidylcholine (20:4) (LysoPC 
20:4, LPC 20:4). Interrogation of the mobility-mass spectra had previously revealed this 
species to be a lipid due to its location above the protein mobility-mass correlation 
region, and the fragmentation and database results provided additional confirmation. 
Lipidomic analyses of human plasma have revealed decreased levels of 
lysophosphatidylcholines (LPCs), in general, for individuals with pre-diabetic conditions,  
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Figure 2.4. Post-mobility MS/MS of m/z 544.4 revealed a base peak fragment at m/z 
184.1. This fragmentation pattern is indicative of the loss of the phosphocholine head 
group from a glycerophosphocholine lipid species. 
 
 
 
 
 
 
 95 
 
such as insulin resistance and glucose intolerance.
37-40
 LPCs have also been studied in 
regards to their  involvement in inflammation,
41
 and recent work has indicated potential 
anti-inflammatory properties of polyunsaturated LPCs such as LPC (20:4).
42, 43
 
Nine- (p = 2.3x10
-10
; Figure B.1d) and 2.6-fold (p = 2.5x10
-8
; Figure B.1c) 
increases in intensity were observed for m/z 373.3 and 355.3, respectively, in the diabetic 
day 2 group relative to the control day 2 group. Furthermore, m/z 355.3 and m/z 373.3 
presented similar trends in intensity across the four sample groups, in which intensity was 
most abundant in the diabetic day 2 group, but also had increased intensity in the diabetic 
day 5 group relative to its control (Figure B.1c,d). The species m/z 355.3 and 373.3 were 
located within the same mobility-mass correlation line in the IM-MS spectra of diabetic 
day 2 wound fluids, with respective drift times of 3.28 and 3.50 ms (Figure 2.5), and 
generally located between the lipid and protein regions of the mobility-mass spectra. The 
proximity of these two signals in drift time and in m/z, as well as the similarity in 
expression across the sample groups, indicated that these signals shared a common 
structure and perhaps a similar function. The structural similarities of these species, as 
indicated by their adjacent drift times, strongly guided further analysis to identify the 
nature of these signals.  
The mass difference of 18 Da between m/z 355.3 and 373.3 was suspected to 
correspond to a neutral water loss and to occur via in-source fragmentation. A pre-
ionization separation by UPLC was paired with IM-MS in a targeted analysis to 
determine a common precursor from which these species were generated in the ionization 
process. In the postive-mode targeted UPLC-IM-MS analysis of diabetic day 2 wound 
fluid, m/z  355.26 and 373.27 were observed to co-elute from the column with a signal  at  
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Figure 2.5. Three-dimensional ion mobility-mass spectrum of control day 2 (a) and 
diabetic day 2 (b) wound fluid. The signals m/z 355.3 and m/z 373.3, encircled in white, 
are located at 3.28 and 3.50 ms, respectively. These signals are present at decreased 
intensities in the control day 2 (a) wound fluids relative to the diabetic day 2 (b) wound 
fluids.  
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426.32 at 5.31 min (Figure 2.6a,b), confirming the two signals were chemically, as well 
as structurally, similar. Mobility-extracted fragmentation spectra from post-mobility 
MS/MS of m/z 373.27 were dominated by a fragment at m/z 355.26. The loss of 18 Da 
from m/z 373.26 to form the fragment at m/z 355.26 was consistent with a neutral water 
loss. Both the chromatographic and fragmentation data supported the hypothesis 
generated from the mobility data that m/z 355.26 and 373.27 are homologous species. 
The targeted UPLC-IM-MS analysis was repeated in negative ionization mode 
and a peak at 5.31 min was observed in the chromatogram (Figure 2.6c), similar to that 
observed in the positive mode UPLC chromatogram (Figure 2.6a). The mass spectra at 
5.31 min contained a signal at m/z 407.2809 (Figure 2.6d), on which post-mobility 
fragmentation was performed (Figure 2.7a). An accurate mass-based search of the 
METLIN metabolomics database (http://www.metlin.scripps.edu) for m/z 407.2809 
suggested that this species was the [M-H]
-
 signal of cholic acid, with an experimental 
mass accuracy of 1.47 ppm. 
Tandem MS data provided by METLIN and Lipid Maps 
(http://www.lipidmaps.org) matched that obtained from the analysis of diabetic day 2 
wound fluids (Figure 2.7a), strongly suggesting that m/z 407.2809 was cholic acid. 
Fragmentation of a cholic acid standard (Figure 2.7b) was performed to validate the 
assignment of m/z 407.2809 as cholic acid.  
Database searches of the signals present in the ESI+ chromatographic peak at 5.31 
min were also performed (Figure 2.6a,b). A mass-based search for m/z 426.3216 strongly 
suggested that this species was the [M+NH4]
+
 adduct of cholic acid, with an experimental  
mass  accuracy of  0.47  ppm.  The signals m/z  355.2627  and  373.2735 corresponded to  
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Figure 2.6. Chromatograms (a and c) and mass spectra (b and d) from the positive (a and 
b) and negative (c and d) mode UPLC-ESI-IM-MS analyses of diabetic day 2 wound 
fluid. The species m/z 355.26 and 373.27 (b) were observed at 5.31 min in the ESI+ 
chromatogram (a), with an additional signal at m/z 426.32. A peak at 5.31 min was also 
observed in the ESI- chromatogram (c), resulting from the species m/z 407.28 (d). 
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Figure 2.7. (a) Post-mobility MS/MS of m/z 407 (ESI-) in diabetic day 2 wound fluid 
revealed fragments characteristic of cholic acid. (b) Fragmentation of a standard 
reference of cholic acid (1 µg/mL) was performed to validate the assignment of m/z 407 
as cholic acid. (c) The primary species observed from the positive ionization (ESI+) MS 
analysis of the cholic acid standard were m/z 355 and 373. These signals corresponded to 
three and two neutral waters losses from cholic acid, respectively. 
 
 100 
 
corresponded to three and two neutral water losses from cholic acid, indicating that these 
species may be the result of in-source fragmentation of cholic acid in positive ionization 
mode. An ESI+ analysis of the cholic acid standard confirmed that fragments 
corresponding to two and three neutral water losses are the primary species observed 
from cholic acid in positive ionization mode (Figure 2.7c), while the [M-H]
- 
of cholic 
acid is the primary species generated by ESI-. Bile acids, such as cholic acid and its 
derivatives, and their receptors are emerging as important factors in the regulation of 
glucose homeostasis and diabetes.
44-46
 
 
2.4. Conclusions 
We have illustrated the utility of IM-MS in the analysis of complex biological 
samples for the study of diabetic wound healing. After minimal sample preparation, IM-
MS spectra were rapidly collected for 64 samples of diabetic and non-diabetic wound 
fluid and four biomolecules distinguishing diabetic and control wound fluid were 
identifed. IM-MS spectra revealed a 10.15 kDa protein, in the form of a unique mobility-
mass correlation line, was highly enriched in diabetic day 2 wound fluid. Post-mobility 
MS/MS aided in the identification of this protein as S100-A8. The separation of S100-A8 
in ion mobility drift time from another highly charged, high mass protein provided a 2.7-
fold increase in S/N over the MS-only spectrum of the +13 charge state of S100-A8. An 
OPLS-DA statistical analysis revealed three additional species distinguishing diabetic 
from control wound fluid, and subsequent UPLC separations and post-mobility MS/MS 
were performed in a targeted manner to identify and validate these species. The locations 
of these species in mobility-mass space greatly aided in their identification, as the drift 
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times indicated that m/z 544.4 was a lipid and the proximity of m/z 355.3 and 373.3 in 
drift time revealed they were structurally homologous species. A combination of 
fragmentation experiments and accurate mass database searching led to the identifications 
of lysophosphatidylcholine (20:4) and cholic acid, which were found at increased 
intensities in control and diabetic wound fluid, respectively.  
The methodology demonstrated in this study can be applied to the analysis of a 
variety of complex biological systems to rapidly identify biomolecular signatures of 
diseases and biological processes with IM-MS. In a disease such as the diabetic model 
examined herein, there can be both increased and decreased (or absent) abundance of 
chemical species relative to the control. After an intervention, such as the wounding of 
the tissue, the kinetics of the intervention-induced changes may also differ between the 
disease model and control. In this study, we focused on the three most abundant and most 
significantly different species in the first and third quadrants of the S-plot, but with a 
sufficient investment in effort, an IM-MS/MS workflow as outlined in this paper could be 
applied to every species in Figure 2.3(b),(d),(f). We expect that such an examination of 
just the subsets of species that lie within the three we have studied provides, in an 
efficient manner, an even deeper physiological investigation of the processes that differ 
between normal and diabetic wound healing. We believe that such an analysis lies 
midway between narrowly targeted and totally untargeted searches for important 
contributors to the wound healing process in health and disease.  
The growing reliance on structural mass spectrometry stems in part from the 
flexibility of IM-MS systems, which span smoothly the range between fully targeted and 
totally untargeted analyses. The workflow that we present demonstrates that a single 
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instrument can both identify and validate chemical species whose concentrations differ 
statistically between two experimental conditions. One of the contemporary challenges in 
metabolomic measurements on complex samples is to transition from untargeted to 
targeted analysis, not because of instrumentation limitations, but because of the need for 
both standard samples for target validation and new bioinformatic and biostatistical tools 
optimized for identification of the salient features in differential and time-series 
experiments. 
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CHAPTER III 
 
STRUCTURAL MASS SPECTROMETRY OF TISSUE EXTRACTS TO 
DISTINGUISH CANCEROUS AND NON-CANCEROUS BREAST DISEASES 
 
3.1. Introduction 
 Among women in the United States, breast cancer is the most prevalent type of 
invasive cancer, affecting 118.7 women per 100,000 in 2010, the most recent year for 
which statistics are available.
1
 Although it is currently the second leading cause of cancer 
deaths, the mortality due to breast cancer has steadily decreased from 26 women per 
100,000 in 2001 to 21.9 in 2010.
1
 The general decrease in breast cancer-related 
mortalities is in part due to the discovery of novel diagnostic and prognostic markers, and 
the subsequent development of targeted cancer therapies born of extensive genomic and 
proteomic profiling endeavors.
2, 3
 Despite these advances, there still remain breast cancer 
subtypes, such as triple negative breast cancer (named so due to the absence of genetic 
markers HER2, PR, and ER), which do not respond to the currently available targeted 
therapies.
4,5
 
 Metabolomics approaches have also been applied in the efforts to discover 
molecular differences between tumor and healthy cells. As the downstream endpoint of 
changes in the genome or proteome, metabolites best represent the cellular phenotype 
while also reflecting environmental influences.
6,7
 Cellular metabolism is significantly 
altered in the transformation of healthy cells into malignant cells, likely due to the rapid 
cellular proliferation in cancer.
6
 Affected pathways include glycolysis, oxidative 
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phosphorylation, choline metabolism, and protection against reactive oxygen species, 
giving rise to a metabolic phenotype common to cancers in general.
6,8,9
 Among the most 
notable hypotheses of aberrant metabolism in cancer is the Warburg effect, which 
describes cancer cells’ preferential use of glycolysis, typically an anaerobic process, to 
generate energy despite aerobic conditions amenable to oxidative phosphorylation.
6,8-10
 
Thus, interrogation of the metabolic phenotype of cancer may provide targets for 
therapeutics designed to decrease tumor viability by disrupting the metabolic drivers 
specific to tumors.
6
 
 Among the tools typically used to perform cancer metabolomics studies are 
nuclear magnetic resonance (NMR) and mass spectrometry (MS).
7-9
 The former offers a 
number of tailored approaches, from proton (
1
H) and carbon (
13
C) NMR to phosphate 
(
31
P) NMR which may be used to monitor pathway-specific high-energy phosphate 
metabolites.
11,12
 Analysis of solid tissues is feasible with magnetic resonance 
spectroscopy (MRS) approaches such as high resolution magic angle spinning (HR-
MAS).
13,14
 These techniques are nondestructive, which is an advantage when working 
with limited volumes of sample or tissue; however, they are generally less sensitive than 
MS-based approaches.
14,15
 Chromatographic separations, such as gas chromatography 
(GC) and ultra-performance liquid chromatography (UPLC), are frequently combined 
with MS to increase peak capacity, reduce ionization suppression effects, and reduce 
mass spectral complexity. However, the derivatization necessitated for GC-MS analyses 
can be undesirable. MS-based cancer metabolomics are amenable to a variety of sample 
types including serum, plasma, urine and tissues.
15
 These studies may be targeted or 
untargeted, where targeted approaches aim to measure a predefined subset of molecules 
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based on their class or pathway and untargeted approaches aim to observe as many 
metabolites as possible without bias.
16
  
 Ion mobility-mass spectrometry (IM-MS) is a hybrid two-dimensional technique 
which combines the gas phase structural separation of IM with mass-to-charge (m/z) 
separation of mass spectrometry. Briefly, IM separation occurs as ions travel through a 
drift cell containing a neutral buffer gas, such as helium or nitrogen, under the influence 
of a static or dynamic electric field. As the ions traverse the drift cell, they experience a 
number of collisions with the neutral buffer gas dependent on the collision cross section 
(CCS; effective ion surface area) of the ion. This process results in a characteristic drift 
time in the range of micro- to milliseconds, which can be used to calculate CCSs and 
determine coarse structural information.
17
  
IM-MS-based analyses have been demonstrated for fields ranging from 
proteomics
18, 19
 to systems biology.
20, 21
 For metabolomics analyses of complex biological 
samples,
22-25
 IM-MS offers unique advantages relative to MS-only approaches. IM-MS 
platforms are highly flexible, allowing a range of pre-ionization separations, such as 
UPLC, to be combined in tandem with the IM-MS experiment. Relative to UPLC-MS 
approaches, UPLC-IM-MS provides even greater peak capacity without increasing the 
time of analysis due to the complementary time scales of minutes, milliseconds and 
microseconds for the UPLC, IM, and MS dimensions, respectively.
18,19,26-28
 For classes of 
biomolecules, such as lipids, proteins, and carbohydrates, a correlation is observed 
between mass and size, or m/z and CCS, based on their gas phase packing efficiencies. In 
an IM-MS experiment, this correlation results in the separation of each biomolecular 
class into unique regions, or trendlines, in IM-MS conformation space.
29-31
 The 
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separation of biomolecular classes in IM-MS conformation space enables a more holistic 
approach with minimal sample preparation for the analysis of complex biological 
samples, where multiple species of biomolecules may be present.
32
 Rather than 
performing sample purification strategies to isolate a particular class of biomolecules, the 
molecules of interest (e.g. metabolites) can be separated from other biomolecular classes 
in the IM dimension, effectively increasing the signal-to-noise (S/N). For metabolomics, 
this is particularly advantageous as isobaric species may be resolved in the IM dimension 
based on the differences in their gas phase structures. Lastly, data independent acquisition 
of MS/MS spectra post-ion mobility enables multiplexed fragmentation experiments to be 
performed nearly simultaneously, and minimizing the need to perform additional 
experiments to obtain fragmentation data. 
Here, we describe an UPLC-IM-MS/MS approach to the characterization of the 
metabolites differentially expressed in breast cancer. Based on a previously demonstrated 
workflow for the analysis of complex biological samples,
32
 disease (n=3) and control 
(n=3) breast tissues were homogenized, polar metabolites were extracted and 
characterized by UPLC-IM-MS/MS.
33
 Although it was known which tissues represented 
healthy and disease, researchers were blind to the exact pathologies of the tissues. 
Principal components analysis (PCA) revealed an unexpected grouping of the breast 
tissues. Features giving rise to this separation in the PCA were interrogated to determine 
tentative molecular identifications based on chromatographic retention time, accurate 
mass, drift time, and fragmentation analysis. The merits of IM-MS for untargeted 
metabolomics analyses are demonstrated in the transition from a list of features to 
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validated identifications of the biomolecular species distinguishing cancerous from non-
cancerous tissues.  
 
3.2. Experimental 
 The workflow demonstrated here for the UPLC-IM-MS/MS analysis of human 
tissues, as described below, is based on a previously developed workflow to transition 
from wholly untargeted to targeted analyses of complex biological samples in the pursuit 
of identifying key biomolecular features distinguishing disease and healthy conditions.
32
 
The general workflow demonstrated here is illustrated in Scheme 3.1, where this 
methodology has been adapted to include the additional online UPLC separation, 
methods for chromatographic peak picking and alignment, post-mobility data-
independent acquisition of MS/MS spectra, and inclusion of MS/MS spectra in addition 
to accurate mass as a parameter for generating tentative identifications. 
 
Tissues 
 Six surgically resected fresh-frozen tissues were selected from the Meharry 
Medical College Translational Pathology Shared Resource Core Facility to control for 
gender, age and ethnicity. Matched controls were used when available, such that the 
control would be grossly normal peritumoral tissue from the same patient. The specific 
pathology of the disease tissues was withheld from the researchers to create a partially 
blinded experiment, however it was known which three of the six tissues represented a 
form of breast disease (C, control; D, disease; matched pairs indicated by consecutive 
numbering (i.e. 1C and 2D are a matched pair)). Tissues were stored at -80°C.  
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Scheme 3.1. Illustration of the workflow for the preparation and extraction of breast 
tissues, including the steps necessary to transition from a multidimensioanl dataset to the 
identification of statistically-prioritized molecular features. 
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Sample Preparation 
 The procedure for homogenization and extraction of the human breast tissues was 
adapted from the methods described by Want et al. for the extraction of polar metabolites 
from tissues for UPLC-MS analysis.
33,34
 Intact tissues were initially coarsely 
homogenized on ice in a dounce homogenizer, and 50 ± 4 mg (wet) of each tissue was 
transferred to an eppendorf tube. To each tissue, 1 mL of cold 1:1 methanol/water (v/v) 
(Chromasolv, Sigma-Aldrich, St. Louis, MO) was added and the samples were further 
homogenized on ice using a hand-help homogenizer with disposable plastic probes 
(Omni International, Kennesaw, GA). A fresh disposable probe was used for each 
sample. An additional 500 µL of cold 1:1 methanol/water was added to each sample for a 
total volume of 1.5 mL, and extraction was allowed to proceed overnight at -20°C.  
 Samples were centrifuged (16,500 g for 5 min at 2°C; Heraeus Fresco 21, Thermo 
Scientific) and the supernatants were transferred to fresh eppendorf tubes. For the UPLC-
IM-MS/MS analysis, 750 µL of each supernatant was dried on a speed-vac and 
reconstituted with 200 µL of H2O. Protein precipitation was performed by adding cold (-
20°C) methanol in a 3:1 ratio, or 600 µL, to the samples on ice. Samples were then 
transferred to dry ice for 5 min, after which they were vortexed and centrifuged. 
Supernatants were transferred to fresh tubes, dried on a speed-vac, and then stored at -
80°C.  
 Samples were reconstituted with 500 µL of H2O with 0.1% formic acid (HPLC-
grade, Fisher Scientific), vortexed, and centrifuged briefly. From each sample, 250 µL 
was transferred to autosampler vials. A pooled quality control (QC) sample was prepared 
with 30 µL of each sample (taken from the 250 µL), for a total volume of 180 µL. 
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UPLC-IM-MS/MS 
 A nanoACQUITY (Waters, Milford, MA.) UPLC system, modified to provide 60 
µL min
-1
 flow rates, was used to perform chromatographic separations on an ACQUITY 
HSS C18 column (1.8 µm, 1.0 x 100mm; Waters, Milford, MA.). The autosampler and 
column temperatures were maintained at 4 and 40°C, respectively, and an injection 
volume of 6 µL was used to overfill the 5 µL loop. Chromatographic separation was 
performed with a binary solvent system, where solvent A was 0.1% formic acid in water 
(Fisher Scientific) and solvent B was 0.1% formic acid in acetonitrile (Chromasolv, 
Sigma-Alrdrich). Gradient conditions for the 25 min run with 60 µL min
-1
 flow rate were 
as follows: initial, 99% A; 1 min, 99% A; 6 min, 40% A; 16 min, 1% A; 18 min, 1% A; 
19 min, 99% A; 21 min, 99% A.   
 IM-MS/MS was performed on a Synapt G2 ion mobility-mass spectrometer 
(Waters, Milford, MA.), which utilizes a traveling wave IM cell pressurized with nitrogen 
gas and an orthogonal time-of-flight mass spectrometer (TOFMS) operated in the single 
stage reflectron configuration.
35, 36
 The outflow from the chromatographic system was 
couple to the instrument through the electrospray ionization (ESI) source. Conditions for 
positive mode ESI were as follows:  capillary, 3 kV; sampling cone, 40 V; extraction 
cone, 7 V; source temperature, 80°C; desolvation temperature, 150°C; cone gas flow, 20 
L/hr; desolvation gas flow, 300 L/hr. Mass calibration was performed with sodium 
formate in the range of m/z 50-1400, and a leucine enkephalin lockmass signal was 
continuously acquired throughout the MS acquisition for external mass correction of the 
data. IM separation was achieved with a traveling wave velocity of 650 m s
-1
 and height 
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of 40 V. Data independent MS/MS by collision induced dissociation (CID) was 
performed in the transfer region with collision energies alternating between 10 and 30 V. 
 The sample queue was prepared to run one set of technical replicates (injections 
of a sample) in a randomized order, bracketed by QCs samples. This was repeated two 
more times to provide three technical replicates for each sample and four QC injections 
through the queue to monitor performance.  
 
Biostatistics 
Data was first mass corrected using the continuously acquired lockmass signal, 
and the data was centroided during this process. The corrected data were then processed 
with ProteoWizard (version 3.0.4243) MSConvert to convert the .raw files to .mzXML 
files.
37
 The .mzXML files were processed with XCMS (Scripps, La Jolla, CA.) to 
perform peak picking and peak alignment in the chromatographic domain.
38,39
 Briefly, 
the “matchedFilter” algorithm was used for peak picking and peak alignment and 
retention time correction was performed with the “obiwarp” algorithm. Details of the 
XCMS processing are provided in Appendix C. The output from XCMS was normalized 
such that the sum of all intensities within a sample equaled 10,000. This dataset was then 
imported into Extended Statistics (Umetrics) for visualization of multivariate statistical 
analyses. PCA was used to determine the quality of the dataset, in terms of the grouping 
of triplicate technical replicates and grouping of QCs injections near the origin of the 
PCA plot. Model parameters (R2Y and Q2) for the PCA are provided in Appendix C. 
Analysis of the corresponding loadings plot was used to identify the features contributing 
to the score of each sample along PC1 and PC2 of the PCA plot. To determine 
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significance, p-values were calculated with the Student’s t-test for means (two-tailed, 
equal variance, α = 0.05) using the normalized aligned dataset. Means were calculated 
from the three technical replicates of each sample, and all reported p-values were 
calculated between the matched disease and control samples. 
 
Bioinformatics 
 For the statistically prioritized molecular features, values of m/z were retrieved 
from the lockmass-corrected .raw files to ensure the best mass accuracy. In addition, the 
IM-MS spectra containing the post-mobility data-independent MS/MS acquisitions 
(saved as function 2 of the data file) were accessed and mobility-organized fragmentation 
spectra for the features were extracted. This was performed by extracting a defined 
window of retention time containing the chromatographic peak in which the feature 
eluted, followed by extracting a defined window of drift time across all m/z which 
bracketed the drift time of the feature (see Figures 3.2 and 3.4). When possible, both 
accurate mass and fragmentation information were used to make tentative identifications 
from database searches. Databases used for generating tentative identifications by 
accurate mass included the Human Metabolite Database (HMDB, http://www.hmdb.ca), 
KEGG (http://www.kegg.com), and METLIN
40-42
 (http://metlin.scripps.edu). The 
METLIN MS/MS spectrum match feature or the MetFrag
43
 (http://msbi.ipb-
halle.de/MetFrag/) in silico fragmentation tool were used to search the experimental 
fragmentation spectra peak lists, which were filtered by intensity to include only the top 
30 peaks. 
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Validation 
 Tentative identifications where validated with standards when possible. The 
experimental MS and MS/MS spectra, as well as the drift times, were compared against 
those of the standard. Standards of glutathione, oxidized glutathione, and adenosine 5’-
monophosphate were purchased from Sigma-Aldrich (St. Louis, MO.). Standards were 
prepared at concentrations from 1-3 µg/mL in 1:1 methanol/water with 0.1% formic acid. 
Each standard was directly infused into the ESI source of the Synapt G2 with an external 
syringe pump (10 µl/min flow rate) with ionization conditions identical to those 
described above. Post-mobility fragmentation was performed at collision energies 
between 10 and 30 V to approximate the conditions of the data-independent MS/MS 
acquisitions.  
 
3.3. Results and Discussion 
 Data representative of the UPLC-IM-MS analysis of sample 4D is presented in 
Figure 3.1. The IM-MS plot (Figure 3.1a), shows the dimensions of m/z on the x-axis and 
drift time (ms) on the y-axis. Intensity, measured as counts, is depicted as a color scale, 
where white indicates high intensity signals, black indicates the absence of signals, and 
blue represents low-to-medium intensity signals. A portion of the UPLC chromatogram 
from the analysis of 4D is presented in panel (b). User-defined regions of the 
multidimensional dataset may be selectively extracted to isolate species of interest and 
effectively increase the S/N by separating those species from chemical noise.
32
  Figure 
3.1 demonstrates the extraction of two acetylated polypeptides, thymosins β4 and β10, in  
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Figure 3.1. Data representative of the UPLC-IM-MS/MS characterization of breast 
tissue extract 4D. A user-defined region of conformation space, containing the 
polypeptides Thymosin β4 and Thymosin β10, is indicated on the IM-MS spectrum (a). 
Panel (b) represents a portion of the UPLC chromatogram from the same analysis, where 
the chromatographic peak in which the Thymosin polypeptides eluted is highlighted by 
the grey bar. Extraction of these signals in both the drift time and chromatographic 
dimensions provides a mass spectrum (c) with improved S/N in which the isotopic 
distributions (inset, magnification of the area highlighted by grey bar) of the 7+ species 
are resolved.  
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both the chromatographic (b) and drift time dimensions (a). The chromatographic peak 
containing thymosins β4 and β10, as indicated in Figure 3.1(b) by the grey bar, may be 
extracted to yield the IM-MS plot containing the polypeptides and any co-eluting species. 
Likewise, a user defined area (outlined in white in (a)) of m/z-drift time space, or 
conformation space, containing the polypeptides may be extracted to provide an extracted 
ion chromatogram for thymosins β4 and β10. Extraction in both the chromatographic and 
ion mobility dimensions yields a mass spectrum (c) of the polypeptides (highlighted in 
grey), in which the isotopic distributions (inset) of the multi-charged species are well-
enough resolved to determine their charge states as 7+. This strategy may be applied in 
both the analysis of IM-MS and post-mobility-MS/MS spectra, where extraction in 
chromatographic and IM dimensions effectively increases confidence in tentative 
identifications by reducing isobaric interferences.
31,32,36
 
 Although the presence or absence of molecular features may be visually observed 
from the IM-MS plots representing different disease statuses (i.e. disease vs. control), 
multivariate statistical analyses are required to detect more subtle variations in the 
expression of molecular species as a function of disease status. However, utilization of 
the drift time information in the initial peak picking and peak alignment remains a 
challenge for biostatistical tools. Therefore, peak picking and alignment of data resulting 
from the analysis of the breast tissue extracts was performed at the chromatographic level 
and the ion mobility dimension was returned to as an aid in generating or filtering 
putative identifications of statistically significant molecular features.  
 Results from the statistical analysis of the breast tissue extract dataset are 
summarized in Figure 3.2. As described previously, samples were injected in three 
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batches, where each batch contained one replicate injection for each sample a in 
randomized order bracketed by QC samples (not shown). The PCA score plot (Figure 
3.2a) provides an overview of the samples. Grouping of the technical replicates for each 
sample, as seen in the score plot, indicates good reproducibility throughout the analysis. 
Samples forming a matched pair of disease and control tissues are identified with the 
dashed ellipses on the score plot (Fig. 3.2a). Generally, the 4D and 6D separated from the 
other samples along principal component (PC) 1, but were separated from each other 
along PC2. Interestingly, 2D grouped with the control tissues. This suggested that 
although 2D represented a tissue affected by disease, this tissue was generally more 
metabolically normal than the pathologically abnormal tissues 4D and 6D. The initial 
hypothesis as to the location of 2D in the PCA score plot was that this tissue represented 
a benign breast disease, whereas 4D and 6D potentially represented more malignant 
diseases of the breast.  
 The corresponding loadings plot (Figure 3.2b) was investigated to determine the 
specific molecular features giving rise to the separations observed in the PCA score plot. 
In general, the loadings plot presents the coefficients or weights assigned to each variable 
in the process of generating the principal components. The values of the PC1 and PC2 
loadings for a particular feature are representative of the correlation between the 
respective PC and the feature. For example, feature 16 in Figure 3.2(b) has a loading of 
0.09 for PC1 and a loading near zero (0.01) for PC2. This indicates that PC1 is highly 
correlated with feature 16 and PC2 is poorly correlated with feature 16. Similar to 
interpretation of the PCA score plot, features which group together in the loadings plot 
demonstrate similar behavior.  
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Figure 3.2. Summary of the multivariate statistical analysis of the breast tissue extract 
dataset. (a) Grouping of technical replicates and separation of biological replicates is 
shown by PCA of the UPLC-IM-MS/MS data. The plot contains three technical 
replicates for each sample, and each sample is represented by a different color. Matched 
control and disease tissues are indicated with ellipses. (b) Analysis of the corresponding 
loadings plot indicates the molecular features contributing to the separation of the 
samples along PC1 and PC2. Select features (in black) showing statistical significance 
are numbered. Average normalized abundances from three technical replicates for select 
features are shown in (c). The coloring scheme is the same as (a). Error bars indicate the 
standard deviations of the means.  
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The loadings (Fig. 3.2b) and score plots (Fig. 3.2a) may be compared to 
understand the relationship between the features, shown in the loadings plot, and the 
samples, shown in the score plot. The chart shown in Figure 3.2(c) provides the average 
normalized abundances of several of the features labeled in Fig. 3.2(b) across the six 
tissues. Looking at feature 16, a clear pattern emerges where the samples to the right of 
PC1 (2D, 1C and 3C) all have high abundances of feature 16 (m/z 203.05), while samples 
to the left of PC1 (4D and 6D) have significantly lower abundances. Sample 5C, which 
has a score near zero on PC1, has an intermediate abundance of m/z 203.05. This feature 
contributes significantly to the variability extracted by PC1, which generally separates the 
disease and control samples. Likewise, features 1-4 in the lower left quadrant of the 
loadings plot are all substantially more abundant in tissue 4D than the other tissues, 
giving rise to the location of 4D in the lower left quadrant of the PCA score plot. Fold-
changes for the data shown in Figure 3.2(c) may be found in Table 3.1, along with the 
m/z and retention time associated with the feature.  
The raw data was then revisited to determine tentative identities of the 
differentially abundant molecular features. Upon investigating feature 4, m/z 308.09, the 
extracted ion chromatogram indicated this species was found in two chromatographic 
peaks (retention times 2.47 and 3.78 min). While the peak at 2.47 min contained m/z 
308.09 as the base ion, the chromatographic peak at 3.78 min contained a base ion of m/z 
613.16. Closer inspection of the mass spectrum around m/z 308.1 revealed that there were 
overlapping isotopic envelopes present (Figure 3.3b). Analysis of the IM-MS spectrum 
using the same approach described above revealed that there were in fact two species 
contributing to the spectrum in Fig. 3.3(b). In contrast to one dimensional MS analyses, 
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Table 3.1.  Tentative identifications, mass accuracy, and fold-changes of the features 
highlighted in loadings plot (Figure 3.2b). 
 
No. m/z RT Tentative ID ppm 2D 
a, b 
4D 
a, c 
6D 
a, d 
1 258.11 1.51 Glycerophosphocholine 9.7 ↓   .1 ↑  3.7 ↑  6.0 
2 348.07 2.33 Adenosine monophosphate (V) 3.2 ↓  5.7 ↑  3.2 ↑  10.5 
3 136.06 2.33 Adenine
 e
 6.6 ↓  3.9 ↑  3.4 ↑  5.2 
4 308.09 2.45 Reduced glutathione (V) 5.2 ↓  7.8 ↑  4.8 ↑  4.6 
5 613.16 3.76 Oxidized glutathione (V) 5.5 ↓  20.1 ↑ 15.6 N.S.f 
6 104.11 1.51 Choline 7.7 ↑  1.3 ↑  2.2 ↑  1.4 
7 705.94 4.56 Thymosin β10, acetylated (7+) 6.5 ↓  7.4 ↑  22.1 ↑  2.3 
8 823.44 4.56 Thymosin β10, acetylated (6+) 9.6 ↓  6.8 ↑  29.9 ↑  2.5 
9 827.76 4.56 Thymosin β4, acetylated (6+) 5.9 ↓  11.8 ↑  10.4 ↑  2.0 
10 152.06 2.26 Guanine 6.6 ↓  4.4 ↑  17.1 ↑  3.5 
11 184.07 1.51 Phosphocholine 6.0 ↓  3.5 ↑  3.7 ↑  5.8 
12 137.05 3.93 Hypoxanthine 9.5 ↑  1.3 ↑  2.0 ↑  1.5 
13 246.17 5.01 
2-Methylbutyroylcarnitine 
Pivaloylcarnitine 
3.7 ↑  1.9 N.S.f ↑  67.8 
14 137.05 2.67 Allopurinol 10.9 ↑  3.3 ↑  3.5 ↑  2.6 
15 152.06 3.93 2- or 8-Hydroxyadenine 5.9 ↑  2.1 ↑  5.7 ↑  1.7 
16 203.05 1.45 Monosaccharide [M+Na]
+
 5.9 N.S.
f ↓  7.3 ↓  3.5 
17 437.19 9.31 Unknown - N.S.
f
 ↓  3.2 ↓  1.9 
18 387.19 9.14 Unknown - N.S.
f
 ↓  7.0 ↓  2.1 
 
a
 Arrows indicate directionality of fold-change, where ↑ represents increase in tumor and ↓ represents decrease in tumor relative to 
the respective matched control. The p-values (shown in supporting information document) were calculated with the two-tailed 
student’s t-test with equal variance. p ≤ 0.05 was used to determine significance; 
b
 Fold change and p-value calculated against the 
matched control, 1C; 
c
 Fold change and p-value calculated against the matched control, 3C; 
d
 Fold change and p-value calculated 
against the matched control, 5C; 
e 
MS/MS of adenosine 5’-monophosphate standard (Appendix C) revealed presence of m/z 136.06 
with no or little collision energy applied. Feature #4 may be adenine fragment of adenosine monosphosphate (feature #3).
  f
 N.S. 
indicates no significance, as determined by p > 0.05. “V” indicates features whose identifications where validated with standards. 
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these overlapping isotopic distributions can be easily resolved in the IM dimension as the 
separation occurs on the basis of size-to-charge, where the general trend is that multiply 
(≥2+) charged species have short drift times owing to greater charge repulsion 
effects.
17,31,36
 This can be seen in Figure 3.3(a-d), where (b) represents the mass spectrum 
obtained from summing across all drift time as demonstrated with the white dashed lines 
in (a), mimicking a typical one dimensional MS analysis. Creating a user-define area of 
drift time-m/z space by combining the vertical white dashed lines and the horizontal blue 
dashed lines allows the peak inside the blue box to be extracted away from the isobaric 
inference. This yields the spectrum presented in (c), from which it is evident that this 
species, m/z 308.09 is singly charged. Performing the same steps for the region outline in 
(a) with green dashed lines provides a mass spectrum (d) of a doubly charged species, m/z 
307.09. This corresponds to a molecular weight of 612.16, or [M+H]
+
 of 613.16, which 
corresponds to feature 5 (Table 3.1). Database searches of the m/z and molecular weight 
values suggested that m/z 308.09 (feature 4) and m/z 307.09 (i.e. [M+H]
+
 613.16, feature 
5) were reduced and oxidized glutathione, respectively.  
 The post-mobility fragmentation spectra for m/z 308.09 and m/z 613.16 were 
studied to assess the plausibility of the potential identifications of reduced and oxidized 
glutathione as features 4 and 5, respectively. The chromatographic peak containing m/z 
613.16 at 3.78 min was extracted to provide the IM-MS spectrum of the data independent 
MS/MS acquired post-mobility separation, shown in Figure 3.4(a). Multiple regions of 
fragmentation were evident in the IM-MS spectrum, as outlined by the purple, green and 
blue  lines.   As fragmentation occurs after mobility separation, the fragment  ion  should 
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Figure 3.3. Demonstration of IM separation of isobaric overlapping isotopic 
distributions convoluting the mass spectrum around m/z 308.1 at retention time 3.78 min. 
(a) IM-MS plot with regions correlating to extracting the mobility separated isobaric ion. 
Extracting a defined window around m/z 308 across all drift times (outlined by the white 
dashed lines) yields the extracted mass spectrum (b). Combining the defined window 
about m/z 308 with a discrete window of drift times (blue dashed lines) allows the peak in 
the blue box to be extracted (c) away from the isobaric interference (green dashed lines, 
c). The end result is separate mobility-extracted mass spectra resolving the isotopic 
distributions to that of a singly-charged m/z 308.1 (feature 4) and doubly charged m/z 
307.1 (feature 5). 
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Figure 3.4. Interpretation of post-mobility MS/MS of m/z 613.16 at 3.78 min acquired 
by data-independent acquisition. (a) The IM-MS spectrum resulting from extraction of 
the chromatographic peak at 3.78 min reveals multiple regions of fragmentation. The 
region outlined in blue is indicative of fragmentation which occurred prior to the mobility 
separation (e.g. in-source fragmentation), while the purple region corresponds to post-
mobility fragmentation of the intact molecular ion (m/z 613.16), and the green region 
corresponds to post-mobility fragmentation of an in-source fragment ion (m/z 484) of m/z 
613.16. Extracting the purple region yields a true MS/MS spectrum of m/z 613.16 (b). 
MS/MS was performed on a standard of oxidized glutathione (c) to validate the tentative 
identification. 
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retain the drift time of the corresponding precursor ion, thus generating a horizontal line 
of precursor and fragment ions (regions outlined by purple and green lines).
44
 Effectively, 
this mobility organization of fragments circumvents complications which may arise from 
the presence isobaric species and eliminates the requirement of mass selection prior to 
MS/MS experiments. Similarly, fragmentation which occurred prior to IM can be 
discerned from the post-mobility fragmentation as each ion, regardless of whether it is a 
precursor or fragment, will have a unique drift time. This may arise in situations where 
in-source fragmentation has occurred, and such a phenomenon is indicated by the blue 
lines in Figure 3.4(a). In order to obtain a true fragmentation spectrum of the intact 
molecular ion m/z 613.16, only a discrete window of drift time centered at the drift time 
of m/z 613.16 is extracted. As shown in (a) with the purple lines, this area contains the 
mobility-organized fragments of m/z 613.16. Extracting this region provides the MS/MS 
spectrum shown in Figure 3.4(b). Database searches and in silico fragmentation analysis 
of this spectrum supported the tentative identification of m/z 613.16 as oxidized 
glutathione. To validate this identification, a standard of oxidized glutathione was 
characterized by ESI-IM-MS/MS. The resulting extracted post-mobility MS/MS 
spectrum is shown in (c), and confirms the proposed identification as there is a peak-to-
peak match between the experimental and standard spectra. A similar process was 
performed to obtain the identifications shown in Table 3.1, and standards were used to 
validate IDs where possible (noted in Table 3.1).  
 Although tissue 4D is the only sample to reside in the lower left quadrant of the 
PCA (Figure 3.2a), a number of the more significant molecular features (No. 1-11) are 
located in the corresponding quadrant of the loadings plot (Figure 3.2b). Interestingly, 
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many of these features were identified as biomolecular species previously demonstrated 
to be differentially expressed in the tumor environment. For example, thymosins β4 and 
β10 (features #7-9) are highly conserved, highly abundant polar polypeptides which are 
overexpressed in a number of tumor types, including breast cancer.
45
 A primary function 
of thymosin peptides is to bind G-actin, the primary component of the cellular 
cytoskeleton, and inhibit G-actin polymerization.
45
 As actin sequestration increases the 
motility of the cell, thymosin polypeptides have been suspected to play a key role in the 
processes of cell migration and tumor metastasis.
45-47
 Characterization of the effects of 
thymosin β4 overexpression on lung tumor metastasis revealed increases in tumor sizes, 
number of metastatic nodules, neoangiogenesis, and cell migration, strongly suggesting 
that thymosin β4 stimulates tumor metastasis.46 In the analysis described here, thymosin 
β4 and β10 were found to be increased greater than 10 and 20-fold (based on single peak 
in isotopic distribution of multiple charged species), respectively, between tissue 4D and 
its corresponding control 3C (p-values: β10 (#7), p= 7.3x10-7; β10 (# ), p = 2.9x10-7; β4 
(#9), p = 1.5x10-5). A bar chart demonstrating the differential expression of thymosins β4 
and β10 across the disease and control breast tissues using summed peak areas for the 
whole isotopic envelope of the 6+ charge states can be found in Appendix C. Using the 
peak area results, fold-changes of 38 (p-value = 7.0x10
-7
) and 75 (p-value = 1.4x10
-6
) 
were observed between samples 3C and 4D for thymosins β4 and β10, respectively 
 Three features contributing significantly to location of 4D within the PCA were 
identified as choline-containing metabolites: (#1) glycerophosphocholine, (#6) choline, 
and (#11) phosphocholine. Aberrant metabolism of choline phospholipids is a hallmark 
of cancer cells and tumors, including breast cancer, typically presenting in the form of 
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increased levels of phosphocholine (PC) and total choline-containing species (tCho; free 
choline (Cho) + PC + glycerophosphocholine (GPC)) due to increased activity and/or 
expression of choline kinase, choline transporters and phospholipases.
48-52
 Generally, the 
extent to which levels of PC and tCho are increased is reflective of the tumor 
aggressiveness or malignancy.
12, 50
 From Figure 3.2(c) and Table 3.1, it is evident that 
both 4D and 6D showed significant increases in GPC (4D: 3.7-fold, p-value = 1.4x10
-6
; 
6D: 6.0-fold, p-value = 3.0x10
-5
) and PC (4D: 3.7-fold, p-value = 3.3x10
-6
; 6D: 5.8-fold, 
p-value = 1.3x10
-7
) relative to the respective controls, suggesting both may represent 
types of breast tumors. Sample 2D, suspected to represent a non-cancerous breast disease, 
had significantly less GPC (8.1-fold decrease, p = 6.5x10
-7
) and PC (3.5-fold decrease, p 
= 6.2x10
-5
) relative to the matched control.  
 Additionally, samples 4D and 6D presented higher levels of glutathione (#4; 4D: 
4.8-fold, p-value = 1.3x10-5; 6D: 4.6-fold, p-value = 9.9x10-6) relative to the controls, 
while only 4D showed increased levels of oxidized glutathione (#5; 15.6-fold, p-value = 
1.5x10
-5
; see Table 3.1 and Figure 3.2c). Glutathione (GSH) is the primary intracellular 
thiol responsible for protection against free radicals.
53
 This detoxification may occur 
directly or in conjunction with the enzyme glutathione s-transferase, which conjugates 
electrophilic compounds to reducing sulfhydryl (-SH) group of glutathione’s cysteine 
residue. Oxidized glutathione, or glutathione disulfide, is composed to two glutathione 
units linked through a disulfide bond between the cysteine residues. The relative 
abundances of reduced and oxidized glutathione (GSSG) in tissues have been examined 
as an indicator of the redox status of the tissue given the potential to detoxify to cancer 
drugs which work via oxidative damage.
53-56
 Previous studies of glutathione levels in 
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breast tumors have found significantly elevated levels of reduced and oxidized 
glutathione in tumor tissues relative to matched peritumoral (i.e. control) tissues.
53,54,56
 
However, it was observed in the tumor tissues that reduced glutathione levels were 
significantly greater than oxidized glutathione levels, representing an increase in the 
detoxification capacity of the tumors.
56
 Our results were consistent with these findings, 
where abundances of GSH were approximately 2-fold greater than GSSG in both 4D and 
6D (Figure 3.2c and Appendix C).  
 For many of the tentatively identified features selectively highlighted in Figure 
3.2(c) and Table 3.1, a consistent pattern has been observed in which abundances are 
increased in 4D and 6D relative to their controls, while 2D demonstrates the opposite 
correlations despite also representing a tissue affected by breast disease. Our general 
hypothesis has thus been that 4D and 6D represented cancerous breast diseases, perhaps 
differing in malignancies, given the identities of the most significant molecular features 
and their known involvement in breast cancer. On the other hand, 2D has been suspected 
to represent a benign cancer or a non-cancerous breast disease. Examination of the 
pathology reports for 2D, 4D and 6D revealed our initial data-driven hypotheses to be 
generally accurate. Sample 2D was diagnosed as a fibroadenoma, a benign breast tumor 
most commonly diagnosed in patients in their early 20s.
57
 However, this sample did not 
represent a typical fibroadenoma diagnosis as the patient from whom this biopsy was 
taken was 47 years old. Sample 4D, as suspected, was diagnosed as an infiltrating duct 
carcinoma of grade 3 and pathological state IIA which was found to be ER, HER2/NEU, 
and PR negative, often referred to as triple negative cancer. This particular type of breast 
cancer is challenging to treat as it does not respond to targeted therapies and is often 
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associated with a shorter time between relapse and death.
4
 Lastly, the diagnosis of sample 
6D was a pseudoangiomatous stromal hyperplasia, a benign breast tumor.
58
 Similar to 
triple negative tumors, psuedoangiomatous stromal hyperplasias are highly metabolic and 
perhaps this was the primary director for the separation of 4D and 6D away from the 
other tissues. 
 
3.4. Conclusions 
 Metabolic profiling of breast tissues using the UPLC-IM-MS/MS-based platform 
described here was demonstrated to be a highly sensitive technique for the differentiation 
of breast tissues representing a range of benign to cancerous breast diseases. The ion 
mobility aspect of the analysis provided an additional dimension of separation orthogonal 
to that provided in the chromatographic dimension. This enabled simultaneous isolation 
of features of interest in both IM and LC dimensions, improving confidence in locating 
features of interest while also increasing their signal-to-noise ratios. In the instance of co-
eluting isobaric species, it was demonstrated that IM could effectively separate thses 
species and eliminate the overlapping isotopic peaks which may confound accurate mass 
determination and subsequent identification. Data-independent tandem MS acquired post-
mobility separation provided a means to distinguish fragmentation occurring prior to the 
mobility and collision cells from that of true collision induced dissociation, providing 
MS/MS spectra from which feature identifications could be made with high confidence. 
 The molecular features giving rise to the distinction of cancerous and benign 
tissues from peritumoral control tissues included species known to be affected by the 
aberrant metabolism observed in breast cancer. These included choline, phosphocholine, 
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glycerophosphocholine, glutathione, and oxidized glutathione. Similarly, our analysis 
revealed that the actin-sequestering polypeptides thymosin β4 and β10 were differentially 
expressed between disease and control tissues. Thus, the UPLC-IM-MS/MS platform 
provided a truly untargeted approach in which features from multiple classes of 
biomolecules could be utilized to differentiate tissues representing an array of breast 
diseases from cancerous to benign. In general, this approach would be straightforward to 
apply to both larger datasets and different biological matrices.  
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CHAPTER IV 
 
PHOSPHORYLATION OF SERINE 106 IN ASEF2 REGULATES CELL 
MIGRATION AND ADHESION TURNOVER 
 
4.1. Introduction 
 Cell migration is a complex, actin-dependent process that plays a central role in 
embryonic development and wound healing.
1
 The tightly controlled signaling pathways 
that mediate cell migration can be altered in pathological states, such as tumor metastasis 
and atherosclerosis.
2,3
 Cell migration involves several canonical steps: the extension of 
actin-rich protrusions, the assembly of nascent adhesions at the leading edge, the 
translocation of the cell body, and the retraction of the rear of the cell.
4
 The assembly of 
leading edge adhesions, which are sites of contact between cells and the extracellular 
matrix, stabilizes protrusions and provides traction to propel the forward movement of 
cells.
4-6
 Once formed, nascent adhesions can disassemble, or they can continue to grow 
into larger, more stable adhesions.
7,8
 The constant assembly and disassembly of leading 
edge adhesions, termed adhesion turnover, is crucial for efficient cell migration
7, 9
 but not 
well understood on a molecular level.   
 Small GTPases that comprise the Rho family, including Rho, Rac, and Cdc42, are 
key modulators of cell migration through their ability to regulate processes underlying 
migration, such as adhesion assembly, disassembly, and maturation.
1,10-12
 Rho family 
GTPases, like other small GTPases, function by cycling between a GTP-bound active 
form and a GDP-bound inactive form.
13
 This cycling is dependent on GEFs that catalyze 
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the exchange of GDP for GTP and GTPase activating proteins (GAPs), which promote 
the hydrolysis of GTP.
14-17
 Upon activation by GEFs, the Rho GTPases, in turn, activate a 
series of downstream effector proteins that regulate adhesion and actin dynamics.
12,18,19
 
While the role of the Rho GTPases in regulating cell migration has been studied, less is 
known about the function of the various GEFs and GAPs in modulating migration and its 
underlying processes.   
 Asef2 is a recently discovered GEF that has been implicated in the regulation of 
cell migration.
20-22
 This 652-amino acid protein is composed of several functional 
domains: an APC-binding region (ABR), a Src homology 3 (SH3) domain, a Dbl 
homology (DH) domain, and a pleckstrin homology (PH) domain.
20
 The DH domain 
mediates GTP exchange for Rac and Cdc42, while the PH domain is most likely involved 
in membrane localization.
20-22
 The ABR and SH3 domains work in concert to regulate 
Asef2 activity.
20
 Asef2 exists in an autoinhibited conformation that prevents nucleotide 
exchange by the DH domain; once the tumor suppressor APC binds to the tandem ABR 
and SH3 domains, Asef2 undergoes a conformational change that stimulates its GEF 
activity.
20,23,24
 While the mechanism of APC binding to Asef2 and relieving 
autoinhibition has been studied,
20
 little is currently known about other potential modes of 
Asef2 regulation. For example, post-translational modification of Asef2 is one possible 
avenue of modulating its activity and function. The addition of chemical moieties, such 
as acetyl, phosphate, or glycosyl groups, to a protein is a common mechanism for altering 
its conformation, localization, and activity.
25
 Indeed, it has previously been shown that 
phosphorylation of GEFs is necessary for proper function.
26-28
 These data point to a 
possible role for phosphorylation in regulating Asef2 activity and function.   
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Here, we describe the identification of phosphorylation sites in Asef2 using a 
liquid chromatography-mass spectrometry (LC-MS) approach consisting of high-mass 
resolution Orbitrap MS, data-dependent tandem MS (MS/MS), multiple protease and 
denaturing strategies, and bioinformatics-based peptide and protein assignments.
29
 This 
methodology yielded 94.6% sequence coverage and identified six sites of 
phosphorylation. The 5.4% of the sequence does not contain serine, threonine or tyrosine 
residues; therefore, 100% coverage of possible phosphorylatable sites was achieved. The 
majority of these sites are clustered in the N-terminus of Asef2; one site (S106) is located 
in the ABR domain, suggesting that it could regulate Asef2 activity. Indeed, we show that 
S106 phosphorylation is crucial for Asef2-promoted Rac activation, cell migration, and 
adhesion turnover, pointing to a new regulatory mechanism for Asef2 activity and 
function.      
 
4.2. Experimental Methods 
Reagents and Plasmids  
Mouse IgG agarose, FLAG M2-agarose affinity gel, FLAG peptide 
(DYKDDDDK), FLAG monoclonal antibody (clone M2), and fibronectin were obtained 
from Sigma (St. Louis, MO). Sodium vanadate was purchased from Fisher Scientific 
(Fairlawn, NJ), and calyculin A was obtained from EMD Millipore (Billerica, MA).  
Peroxovanadate was prepared as previously described.
29
 Glutathione sepharose beads 
were purchased from GE Healthcare Life Sciences (Piscataway, NJ). Phosphoserine 
polyclonal antibody (catalog number 61-8100) was obtained from Life Technologies 
(Grand Island, NY). GFP-Asef2 was generated by cloning human Asef2 (accession 
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number: NM_153023.2) into EGFP-C3 vector (Clontech, Mountain View, CA) at EcoRI 
sites as previously described.
22
 FLAG-GFP was prepared as previously described,
29
 and 
FLAG-GFP-Asef2 was generated by inserting human Asef2 into the FLAG-GFP vector 
at EcoRI sites. Asef2 serine 106 mutants were created via site-directed mutagenesis using 
the following primers: serine 106 to alanine (Asef2-S106A), forward (5’-
GGTACTGAGCCCGCTGCCTTAGTGGAT-3’) and reverse (5’-
ATCCACTAAGGCAGCGGGCTCAGTACC-3’); serine 106 to aspartic acid (Asef2-
S106D), forward (5’-GGTACTGAGCCCGATGCCTTAGTGGAT-3’) and reverse (5’-
ATCCACTAAGGCATCGGGCTCAGTACC-3’). mCherry-paxillin was a generous gift 
from Steve Hanks (Vanderbilt University, Nashville, TN).  
 
Cell Culture and Transfection 
HT1080 fibrosarcoma cells and human embryonic kidney 293 (HEK293) cells 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies, Grand 
Island, NY), which was supplemented with 10% fetal bovine serum (FBS; Thermo 
Scientific, Waltham, MA) and penicillin/streptomycin (Life Technologies, Grand Island, 
NY).  These cells were maintained in an incubator with 5% carbon dioxide (CO2) at 37 
°C.  Cells were transiently transfected with appropriate cDNAs using Lipofectamine
TM
 
2000 (Life Technologies, Grand Island, NY) according to the manufacturer’s instruc-
tions. 
 
Protein Purification 
HEK293 cells were cultured in eight 150 mm dishes (Corning, Tewksbury, MA) 
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for 24 h and then transfected with FLAG-GFP-Asef2 cDNA (12 µg per dish). After 
approximately 40 h, cells were treated with 1 mM peroxovanadate  and 50 nM calyculin 
A for 10 min and then extracted with 25 mM Tris, 137 mM NaCl, 1% NP-40, 10% 
glycerol, and 2 mM EDTA (pH 7.4) containing a phosphatase inhibitor cocktail (Sigma, 
St. Louis, MO; catalogue number P2714) for 30 min on ice. The lysate was precleared 
with mouse IgG agarose for 1 h at 4 °C with end-over-end mixing; the lysate was then 
precleared a second time by overnight incubation with IgG agarose. After preclearing, the 
lysate was incubated with FLAG-agarose for 2 h at 4 °C with end-over-end mixing, and 
the beads were washed three times (15 min each, 4 °C) with 25 mM Tris and 100 mM 
NaCl (pH 7.4). FLAG-GFP-Asef2 protein was eluted from the beads by incubation with 
0.2 mg/mL FLAG peptide suspended in 25 mM Tris and 100 mM NaCl (pH 7.4) for 30 
min at 4 °C; this elution was repeated, and the eluates were pooled. The eluate was 
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 
a 10% slab, followed by staining with Coomassie Brilliant Blue R-250 (EMD 
Millipore, Billerica, MA) to determine the protein purity. 
 To examine serine phosphorylation, HEK293 cells from a single 150 mm dish 
per condition were transfected with 8 µg of either FLAG-GFP or FLAG-GFP-Asef2 
cDNAs and were immunoprecipitated using the aforementioned protocol. The eluates 
were subjected to SDS-PAGE and transferred to nitrocellulose membranes. Membranes 
were incubated with either phosphoserine polyclonal antibody or M2 FLAG monoclonal 
antibody, followed by incubation with AlexaFluor 680 anti-rabbit IgG (Life 
Technologies, Grand Island, NY) or IRDye 800 anti-mouse IgG (Rockland 
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Immunochemicals Inc., Gilbertsville, PA). Membranes were scanned with a LI-COR
®
 
Odyssey
®
 Infrared Imaging System (LI-COR Biosciences, Lincoln, NE). 
 
Enzymatic Proteolysis 
Purified Asef2 was separated into three aliquots containing equal amounts of 
protein and was subjected to enzymatic digestion using trypsin, chymotrypsin and Glu-C 
proteases (Promega, Madison, WI), as described previously.
29
  Briefly, approximately 5 
µg of purified Asef2 was resuspended in 75 µL of 25 mM ammonium bicarbonate and 
were aliquoted into three 25 µL samples containing approximately 1.7 µg of protein.  
Reduction and alkylation of cysteine sulfhydryl groups were performed by the addition of 
1.5 µL of 45 mM dithiothreitol (DTT) and incubation for 30 min at 55 °C, followed by 
the addition of 2.5 µL of 100 mM iodoacetamide (IAM) and incubation in darkness for 
30 min at room temperature. Digestion was performed by adding 42 ng of trypsin, 
chymotrypsin, or Glu-C at a ratio of 1:40 protease:protein (w/w), followed by incubation 
at 37 °C for 16, 4, and 6 h, respectively. To quench proteolysis, 1 µL of 88% formic acid 
was added. The digested material was lyophilized and reconstituted in 25 µL of 0.1% 
formic acid for MS analysis. 
 Two additional trypsin digestions were performed at strongly denaturing 
conditions using heat and organic solvent. Both samples contained approximately 2 µg of 
purified and aliquoted protein. For denaturation by heat, the sample was reconstituted 
with 25 µL of 25 mM ammonium bicarbonate and denatured for 15 min at 90 °C. For 
denaturation by high organic solvent, the respective sample was reconstituted with 20 µL 
of acetonitrile (HPLC Grade) and 5 µL of 25 mM ammonium bicarbonate to achieve a 
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solution of 80% acetonitrile.
30,31
 Both samples were treated with DTT and IAM as 
described above to reduce and alkylate cysteine sulfhydryl groups. Digestion was 
performed by adding 52 ng (1:40 protease:protein, w/w) of trypsin (Promega, Madison, 
WI) to each sample. The high organic digestion (referred to as Trypsin
Org
) was stopped 
after 1 h of incubation at 37 °C, while the high temperature denatured digestion (referred 
to as Trypsin
Temp
) was allowed to proceed for 16 h at 37 °C. The digestions were 
quenched, dried, and reconstituted as described above.  
 
LC-MS/MS 
Initial digestions of Asef2 were loaded onto a reverse-phase capillary trap column 
using a helium-pressurized cell (pressure bomb). The trap column (360 µm OD x 150 µm 
ID) was fitted with a filter end-fitting (IDEX Health & Science, Oak Harbor, WA) and 
packed with 4 cm of C18 reverse phase material (Jupiter, 5 µm beads, 300 Å; 
Phenomenex, Torrance, CA). After sample loading, an M-520 microfilter union (IDEX 
Health & Science) was used to connect the trap column to a capillary analytical column 
(360 µm OD x 100 µm ID) equipped with a laser-pulled emitter tip and was packed with 
20 cm of C18 material (Jupiter, 3µm beads, 300Å; Phenomenex, Torrance, CA).  
Peptides were gradient-eluted at a flow rate of 500 nL/min using an Eksigent NanoLC 
Ultra HPLC, and the mobile phase solvents consisted of 0.1% formic acid, 99.9% water 
(solvent A) and 0.1% formic acid, 99.9% acetonitrile (solvent B). The gradient consisted 
of the following:  2-45% B in 40 min, 45-90% B in 10 min, 90% B for 5 min, 90-2% B in 
10 min. Subsequent trypsin digestions of Asef2 were loaded directly onto the capillary 
analytical column using the Eksigent NanoLC Ultra HPLC and autosampler, and the 
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same reverse phase gradient was performed. Upon gradient-elution, peptides were mass 
analyzed on a LTQ Orbitrap Velos mass spectrometer (Thermo Scientific, San Jose, CA) 
equipped with a nanoelectrospray ionization source. The instrument was operated using a 
data-dependent method with dynamic exclusion enabled. Full scan (m/z 300-2000) spec-
tra were acquired with the Orbitrap as the mass analyzer (resolution 60,000), and the top 
ten most abundant ions in each MS scan were selected for fragmentation in the LTQ. An 
isolation width of 2 m/z, activation time of 10 ms, and normalized collision energy of 
35% were used to generate MS/MS spectra. The MS
n 
AGC target value was set to 1X10
4
, 
and the maximum injection time was 100 ms.  
 
Bioinformatics 
For peptide identification, tandem mass spectra were converted into DTA files 
using Scansifter and searched using a custom version of Sequest (Thermo Fisher 
Scientific, San Jose, CA) on the Vanderbilt ACCRE Linux cluster against a concatenated 
forward and reversed (decoy) database containing the Homo sapiens subset of the 
UniProtKB (www.uniprot.org) protein database. The protease was identified for samples 
digested with trypsin, while non-specific protease was indicated for the chymotrypsin and 
Glu-C digests.  A maximum of 10 missed cleavages was allowed for trypsin digests, and 
zero missed cleavages were allowed for chymotrypsin and Glu-C digests. Spectra were 
searched using a 2.5 Da mass tolerance for the precursor peptide mass, and parameters 
were set to search for monoisotopic masses of the product ions.  Allowable variable 
modifications were limited to carbamidomethyl derivatization of cysteine, oxidation of 
methionine, and phosphorylation of serine, tyrosine, and threonine.  Scaffold version 
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3.3.3 (Proteome Software Inc., Portland, OR) was used to visualize and validate peptide 
and protein identifications based on MS/MS data. A threshold of 95% probability was 
required for peptide identifications, and a minimum of two identified peptides and a 
probability threshold of 99% were required for protein identifications.
32, 33
  Identifications 
made to Asef2 were based on the sequence associated with accession number 
A2VEA_HUMAN. All potential phosphopeptides with probabilities of 95% or greater 
were manually validated, and labeled MS/MS spectra from which these assignments were 
based are available in Appendix D. Additionally, several peptides not found by the 
bioinformatics were manually identified and validated.  
 
Migration Analysis and Microscopy 
HT1080 cells were transfected with 1.5 µg of GFP, GFP-Asef2, GFP-Asef2-
S106A, or GFP-Asef2-S106D cDNAs and were incubated for 24 h at 37 °C. Then, the 
cells were plated on tissue culture dishes that were coated with 5 µg/ml fibronectin 
(diluted in Dulbecco’s Phosphate Buffered Saline (DPBS, Life Technologies, Grand 
Island, NY)) and allowed to adhere for 1 h at 37 °C. Prior to imaging, the culture medium 
was replaced with SFM4MAb
TM
 medium (Hyclone, Logan, UT) supplemented with 2% 
FBS. Images were obtained every 5 min for 6 h using an inverted Olympus IX71 
microscope (Melville, NY) with a Retiga EXi CCD camera (QImaging, Surrey, BC), a 
10X objective (NA 0.3), and MetaMorph software (Molecular Devices, Sunnyvale, CA) 
connected to a Lambda 10-2 automated controller (Sutter Instruments, Novato, CA).  
GFP-expressing cells were visualized with an Endow GFP Bandpass filter cube 
(excitation HQ470/40, emission HQ525/50, Q495LP dichroic mirror) (Chroma, 
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Brattleboro, VT). MetaMorph software was used to track cell movement, and the 
migration speed was calculated by dividing the net distance traveled (µm) by the 
migration time (h). Wind-Rose plots were generated as previously described.
34
 For 
migration, adhesion turnover, and Rac activity assays, statistical analyses were performed 
using a Student’s t-test. 
 
Adhesion Turnover Assay 
HT1080 cells were co-transfected with 1.5 µg mCherry-paxillin cDNA and 1.5 µg 
of either GFP, GFP-Asef2, GFP-Asef2-S106A, or GFP-Asef2-S106D cDNAs and were 
incubated for 24 h. Cells were then plated on glass-bottom dishes coated with fibronectin 
(5 µg/mL) and were allowed to adhere for 1 h at 37 °C. Fluorescent time-lapse images 
were acquired at 15 s intervals for 20 min using the Olympus IX71 microscope setup 
described above with a PlanApo 60X OTIRM objective (NA 1.45) and Metamorph 
software.  mCherry was visualized with a TRITC/Cy3 cube (excitation HQ545/30, 
emission HQ610/75, Q570LP dichroic mirror). The t1/2 values for adhesion assembly and 
disassembly were measured as previously described.
7, 22
 
 
Rac Activity Assay 
Glutathione-S-transferase (GST)-tagged p21-activated kinase (PAK) binding 
domain (GST-PBD) was expressed and attached to glutathione sepharose beads as 
previously described.
35
 HT1080 cells were cultured on 60 mm tissue culture dishes 
coated with 5 µg/mL fibronectin and co-transfected with 2 µg FLAG-Rac1 cDNA and 4 
µg of GFP, GFP-Asef2, GFP-Asef2-S106A, or GFP-Asef2-S106D cDNAs. After 24 h, 
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cells were lysed and assayed for Rac activity as previously described.
34, 35
 Briefly, cells 
were lysed with 50 mM Tris, 1% NP-40, 10% glycerol, 100 mM NaCl, 2 mM MgCl2, and 
a protease inhibitor cocktail (lysis buffer). A small fraction of the each lysate was kept to 
determine the amount of total Rac. The remaining lysate was incubated with GST-PBD 
beads for 1 h at 4 °C with end-over-end mixing. The beads were washed three times with 
lysis buffer. Then, the bound protein was eluted from the beads with Laemmli sample 
buffer and analyzed via Western blot. The amount of active Rac pulled down was 
normalized to total Rac for each condition.   
 
4.3. Results and Discussion 
Identification of Phosphorylation Sites in Human Asef2  
Because Asef2 phosphorylation, which could be an important regulatory 
mechanism for the activity and function of this protein, had not been previously 
investigated, we utilized a MS-based approach to uncover potential phosphorylation sites 
in Asef2.
29
 To perform MS analyses, FLAG-GFP-Asef2 was expressed in HEK293 cells 
and then purified according to the immunoprecipitation protocol outlined in Figure 
4.1(a).
29
  A predominant band with a molecular mass corresponding to that of FLAG-
GFP-Asef2 was observed when the immunoprecipitated protein sample was subjected to 
SDS-PAGE followed by Coomassie Blue staining (Figure 4.1b). This band was 
confirmed to be FLAG-GFP-Asef2 via Western blot analysis (Figure 4.1c). We next 
examined the phosphorylation state of Asef2 by using a phosphoserine antibody; a dis-
tinct band was observed for the Asef2 sample compared to the control sample (FLAG-
GFP), demonstrating that Asef2 is phosphorylated on serine residues (Figure 4.1c).   
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Figure 4.1.  Purification of FLAG-GFP-Asef2. (a) Schematic showing the protocol used 
to purify FLAG-GFP-Asef2 for MS analysis. (b) SDS-PAGE gel of immunoprecipitated 
FLAG-GFP-Asef2 that was stained with Coomassie Blue. The arrow points to the band 
representing purified FLAG-GFP-Asef2 in the eluted sample. (c)  Purified FLAG-GFP 
(Control) and FLAG-GFP-Asef2 were subjected to SDS-PAGE, followed by 
immunoblotting (IB) with phosphoserine (pSer, upper panel) and FLAG (lower panel) 
antibodies. These panels show that FLAG-GFP-Asef2 is phosphorylated on serine 
residues.     
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Collectively, these results indicate that the immunoprecipitated protein sample is suitable 
for MS analysis to identify specific phosphorylated residues in Asef2. 
Multiple proteases were used to obtain complete coverage of the potential sites of 
phosphorylation in Asef2. Initially, trypsin, chymotrypsin, and Glu-C digestions were 
used, providing partial (85.6%) sequence coverage, with 93% coverage of serine, 
threonine, and tyrosine residues. However, two significant stretches of the Asef2 protein 
sequence from R492-K518 and R561-Y596 (Figure 4.2a) were not covered in the trypsin, 
chymotrypsin, or Glu-C digestions. These regions have a high abundance of aspartic acid 
and glutamic acid residues, and therefore may not provide peptides of suitable length for 
MS analysis upon digestion with Glu-C. While these amino acid sequences have multiple 
lysine and arginine residues, regions R492-K518 and R561-Y596 were found to be 
inaccessible or resistant to trypsin and chymotrypsin under standard digestion conditions.  
 In order to obtain sequence coverage of regions R492-K518 and R561-Y596 of 
Asef2, additional trypsin digestions were performed using two strongly denaturing 
approaches: heat and a high organic solvent concentration. Digestions done in mixed 
aqueous-organic solvent conditions have been demonstrated to increase peptide 
identifications from proteolysis-resistant proteins, while simultaneously allowing for 
shorter digestion times.
30,31
 Our results showed that an additional 44 residues were 
covered in regions R492-K518 and R561-Y596 with the strongly denaturing digestions.  
Of these 44 amino acids, approximately 64% were observed in the high organic solvent 
digestion (Trypsin
Org
). Combined, the two strongly denaturing digestions yielded nearly 
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Figure 4.2.  Phosphorylation sites identified in Asef2. (a) The protein sequence of Asef2 
is shown with the phosphorylation sites that were detected by MS in red. Colored shading 
represents the conserved domains in Asef2 as shown in panel B. Underlined residues 
were not detected in the MS analyses. (b) Schematic of Asef2 showing conserved 
domains and the location of the six identified phosphorylation sites (red). The domain 
numbering is based on Kawasaki et al.
21
 (c) Summary of Asef2 amino acid sequence 
coverage by MS analyses. Purified Asef2 samples were treated with multiple proteases 
(trypsin, chymotrypsin, or Glu-C) to achieve high sequence coverage. Additional trypsin 
digestions were performed with strongly denaturing conditions, which included high 
temperature (90 
o
C, Trypsin
Temp
) or a high percentage of organic solvent (80% 
acetonitrile, Trypsin
Org
), to obtain sequence coverage of regions that were resistant to 
trypsin under standard digestion conditions.      
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83% sequence coverage and accessed additional regions of Asef2 compared to the more 
conventional, aqueous-based digestions. Sequence coverage of 94.6% was achieved with 
the five different digestions (Figure 4.2c), and all of the serine, threonine, and tyrosine 
residues were found in the identified peptides.  
 The identified phosphopeptides are shown in Table 4.1, along with the type of 
enzymatic digestion used and the associated mass error. Phosphopeptide identities were 
initially revealed by SEQUEST, but each was manually validated to confirm the location 
of the phosphorylation. Four sites of phosphorylation were identified in the digestions 
using standard conditions: pS5, pS78, pS106 and pT217. Two additional sites, pS26 and 
pT617, were identified from the strongly denatured digestions. Three (pS78, pS106 and 
pT217) of the six total sites of phosphorylation were observed in multiple digests. An 
example of MS/MS data for the phosphorylated peptide, 
94
ASNVSSDGGTEPpSALVDDNGSEEDFSYEDLCQASPR
129
 is shown in Figure 4.3.  
This peptide was conserved in all three trypsin digests, and the observation of y
23
+3
 
enabled the exact site of phosphorylation (pS106) to be discerned. 
 
Serine Phosphorylation Stimulates Asef2 GEF Activity  
A majority of the confirmed phosphorylation sites in Asef2 are concentrated at the 
N-terminus (Figure 4.2b).  One residue (S106) is in the ABR domain, while four others 
(S5, S26, S78, and T217) bracket the adjacent ABR-SH3 domains. The sixth 
phosphorylation site (T617), conversely, resides in the C-terminus of Asef2 (Figure 
4.2b).  Of these six phosphorylation sites, S106 was particularly intriguing because of its 
location in the ABR domain, which is a critical region for Asef2 activation. This led us
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Table 1.  Phosphorylation sites identified within Asef 2 by MS analysis. 
 
Peptide
a Sequence 
Position 
Protease
b 
m/z (Charge)  
Mass Error 
(ppm) 
2
TSApSPEDQNAPVGC*PK
17 
5S Chymotrypsin 869.36 (+2) -1.27 
21
RRRPIpSVIGGVSLYGTNQTEELDNLLTQPASRPPMPAHQVPPYK
64 
26S Trypsin
Org 
993.52 (+5) 1.81 
22
RRPIpSVIGGVSLYGTNQTEELDNLLTQPASRPPMPAHQVPPYK
64 
26S Trypsin
Org 
962.30 (+5) 1.77 
22
RRPIpSVIGGVSLYGTNQTEELDNLLTQPASRPPMPAHQVPPYKAVSAR
69 
26S Trypsin
Org 
1059.15 (+5) 2.55 
23
RPIpSVIGGVSLYGTNQTEELDNLLTQPASRPPMPAHQVPPYK
64 
26S Trypsin
Temp 
1163.59 (+4) 0.52 
23
RPIpSVIGGVSLYGTNQTEELDNLLTQPASRPPMPAHQVPPYK
64 
26S Trypsin
Org 
1163.59 (+4) 2.49 
70
FRPFTFSQpSTPIGLDR
85 
78S Trypsin  650.32 (+3) 0.92 
70
FRPFTFSQpSTPIGLDR
85 
78S Trypsin
Temp
 650.32 (+3) 0.77 
70
FRPFTFSQpSTPIGLDR
85 
78S Trypsin
Org
 650.32 (+3) 2.00 
70
FRPFTFSQpSTPIGLDRVGR
88 
78S Trypsin
Org
 566.04 (+4) 0.53 
70
FRPFTFSQpSTPIGLDRVGRR
89 
78S Trypsin
Org
 605.06 (+4) 0.66 
94
ASNVSSDGGTEPpSALVDDNGSEEDFSYEDLC*QASPR
129 
106S Trypsin  1295.86 (+3) -0.23 
94
ASNVSSDGGTEPpSALVDDNGSEEDFSYEDLC*QASPR
129 
106S Trypsin
Temp
 1295.86 (+3) -0.39 
94
ASNVSSDGGTEPpSALVDDNGSEEDFSYEDLC*QASPR
129 
106S Trypsin
Org
 1295.86 (+3) 1.00 
205
VNQEELSENSSSpTPSEEQDEEASQSR
230 
217T Trypsin  992.73 (+3) -0.40 
205
VNQEELSENSSSpTPSEEQDEEASQSR
230 
217T Trypsin
Temp
 992.73 (+3) 0.71 
203
LRVNQEELSENSSSpTPSEEQDEEASQSR
230 
217T Trypsin
Org
 1082.46 (+3) 0.00 
210
LSENSSSpTPSEEQDEEASQSRHRHC*E
235
 217T Glu-C 774.81 (+4) -0.26 
615
HIpTMPTSVPQQQVFGLAEPK
634 
617T Trypsin
Org
 763.38 (+3) 1.18 
 
 
a
 The “p” denotes a site of phosphorylation;  an asterisk “*” denotes carboxyamidomethylation of cysteine. b The superscript “Org” denotes sample denatured by 
high percent organic solvent; the superscript “Temp” denotes sample denatured by heat. 
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Figure 4.3.  MS and MS/MS spectra for an Asef2 phosphorylated peptide. Data-targeted 
MS/MS scan of m/z 1295.86 in the Trypsin
Org
 sample, corresponding to the triply charged 
(inset) phosphopeptide 
94
ASNVSSDGTEPpSALVDDNGSEEDFSYEDLC*QASPR
129
. 
Backbone cleavages (b and y-ions) observed are marked on the sequence (top) and 
additional ions are labeled in the spectrum. Sequence positions for b8 and y6 are shown 
with dashed markers (top) due to isobaric m/z values of 718.3. “C*” denotes a 
carbamidomethyl modified cysteine.  “#” indicates ions corresponding to –H2O from b11 
(2), b31
+2
, and b34
+2
, respectively. “ ” denotes ions corresponding to –H3PO4 from b24
+2
 
and b33
+2
, respectively. 
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to hypothesize that phosphorylation of S106 is an important regulatory mechanism for 
Asef2 GEF activity. To investigate the effect of S106 phosphorylation on Asef2 activity,  
we mutated this residue to either alanine (S106A) or aspartic acid (S106D) using site-
directed mutagenesis; these substitutions represent non-phosphorylatable and 
phosphomimetic analogues, respectively.
36-38
 Then, we assessed the effect of S106 
mutation on the activation of the small GTPase Rac using a GTPase activity assay.
22, 34
 In 
this assay, the GST-tagged binding domain from the Rac effector PAK (GST-PBD) is 
used to detect the active form of Rac from lysates of GFP- and GFP-Asef2-expressing 
cells (Figure 4.4a). As expected, expression of wild-type Asef2 caused a significant in-
crease in the level of active Rac (Figure 4.4b). Quantification showed that the amount of 
active Rac was increased approximately 8-fold in GFP-Asef2-expressing cells compared 
with control cells expressing GFP (Figure 4.4c). In contrast, GFP-Asef2-S106A ex-
pression caused an approximately 80% decrease in active Rac compared to expression of 
GFP-Asef2 (Figure 4.4b, c), suggesting that phosphorylation of Asef2 at S106 promotes 
its GEF activity towards Rac. Expression of GFP-Asef2-S106D resulted in an approxi-
mately 2-fold increase in active Rac compared to expression of GFP-Asef2 (Figure 
4.4b,c). Therefore, these results point to S106 as an important phosphorylation site in 
Asef2 that mediates its ability to activate Rac. 
 
S106 Phosphorylation Regulates Cell Migration  
We have previously shown that Asef2 promotes the migration of HT1080 cells 
plated on fibronectin via active Rac.
22
  In this study, we demonstrate that phosphorylation 
of S106 is critical for Asef2-mediated activation of Rac. This led us to hypothesize that  
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Figure 4.4.  Phosphorylation of S106 stimulates Asef2 GEF activity. (a) Schematic 
depicting the protocol used to detect active Rac (Rac activity assay). (b) HT1080 cells 
were co-transfected with FLAG-Rac1 cDNA and either GFP, GFP-Asef2, GFP-Asef2-
S106A, or GFP-Asef2-S106D, and three days later active Rac was pulled down from 
lysates from these cells. The amount of total Rac is shown as a control. (c)  
Quantification of the amount of active Rac from 3-7 separate experiments is shown.  
Error bars represent s.e.m.  *, p < 0.002, **, p < 0.0001. 
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S106 phosphorylation of Asef2 plays a role in regulating cell migration. To test 
this hypothesis, we transfected HT1080 cells with GFP, GFP-Asef2, GFP-Asef2-S106A, 
or GFP-Asef2-S106D cDNAs, then plated the cells on fibronectin-coated dishes, and 
assessed cell migration using live-cell imaging. Migration data were generated by 
tracking individual cells and were used to calculate the migration speed. Figure 4.5(a) 
shows the individual tracks of GFP-, GFP-Asef2, GFP-Asef2-S106A, and GFP-Asef2-
106D-expressing cells. The migration paths of GFP-Asef2-expressing cells were 
significantly longer than those of control cells expressing GFP. Quantification showed an 
approximately 1.3-fold increase in migration speed in GFP-Asef2-expressing cells 
compared to those expressing GFP (Figure 4.5b). Intriguingly, mutation of serine 106 to 
alanine abolished this increase in migration (Figure 4.5b). The migration speed of GFP-
Asef2-S106A-expressing cells was significantly decreased compared to cells expressing 
GFP-Asef2, suggesting that S106 phosphorylation is important for Asef2-promoted cell 
migration. All of the GFP-tagged proteins were expressed at similar levels (Figure 4.5c), 
indicating that changes in migration speed were not due to differential protein expression. 
Expression of the phosphomimetic S106D mutant resulted in an increase in migration 
speed compared to that observed with GFP expression (Figure 4.5b). However, the 
migration speed of cells expressing GFP-Asef2-S106D was not significantly different 
than the migration speed of GFP-Asef2-expressing cells. This result is somewhat 
unexpected given the additional increase in Rac activity detected in the GFP-Asef2-
S106D-expressing cells (Figure 4.4c). The expression of wild-type Asef2 may be 
sufficient to maximally stimulate Asef2 signaling, at least in terms of promoting cell 
migration.  Specifically, the  high  level  of  active  Rac  resulting from  wild-type  Asef 2 
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Figure 4.5.  Phosphorylation of S106 is critical for Asef2-promoted cell migration. (a) 
HT1080 cells expressing GFP, GFP-Asef2, GFP-Asef2-S106A, or GFP-Asef2-S106D 
were plated on fibronectin-coated dishes and imaged using time-lapse microscopy. The 
migration of individual cells was tracked and analyzed. Wind-Rose plots depicting the 
migrations tracks for individual cells are shown. (b) Migration speed was quantified for 
GFP-, GFP-Asef2-, GFP-Asef2-S106A-, and GFP-Asef2-S106D-expressing cells.  (c) All 
GFP-tagged proteins were expressed to similar levels; therefore differential protein 
expression was not responsible for changes in migration speed. Error bars represent 
s.e.m. for 4-9 independent experiments (*, p < 0.02, **, p < 0.004, ***, p < 0.002).  For 
(b) and (c), “n.s.” denotes no statistically significant difference. 
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expression could be adequate to saturate downstream signaling; thus, a further increase in 
active Rac, such as that caused by GFP-Asef2-S106D expression, would not yield higher 
migration speed. Consistent with this, a previous study showed that expression of 
constitutively-active Rac did not further increase in migration speed compared to that 
observed with wild-type Rac expression.
39
  Nevertheless, these results underscore the im-
portance of S106 phosphorylation in regulating Asef2-mediated cell migration.     
 
Phosphorylation of S106 Modulates Adhesion Turnover 
Because the ability of cells to migrate efficiently is dependent on the proper 
assembly and disassembly of their adhesions (adhesion turnover), and because Asef2-Rac 
signaling plays an important role in regulating adhesion dynamics,
7,11,22
 S106 
phosphorylation may affect migration by modulating adhesion turnover.  Therefore, we 
co-expressed mCherry-paxillin, a well-characterized adhesion marker, with GFP, GFP-
Asef2, GFP-Asef2-S106A, or GFP-Asef2-S106D in HT1080 cells and analyzed adhesion 
turnover using an assay that we previously developed.
7, 22
 In this assay, mCherry-paxillin-
containing adhesions from these cells were imaged using time-lapse microscopy (Figure 
4.6a), and the change in fluorescence intensity in individual adhesions was used to 
calculate t1/2 values for adhesion assembly and disassembly. Expression of GFP-Asef2 
resulted in an approximately 50% decrease in the t1/2 values for adhesion assembly and 
disassembly (Figure 4.6b); this suggests that adhesions in GFP-Asef2-expressing cells 
turn over more quickly, resulting in faster cell migration speeds.
22
 Conversely, the t1/2 
values for  both  adhesion  assembly  and  disassembly were significantly larger  in  GFP-  
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Figure 4.6. S106 phosphorylation regulates adhesion turnover. (a) HT1080 cells were co-
transfected with mCherry-paxillin cDNA and GFP, GFP-Asef2, GFP-Asef2-S106A, or 
GFP-Asef2-S106D cDNAs and were subsequently used in adhesion turnover assays.  
Time-lapse images show adhesions that are assembling and disassembling at the leading 
edge of migrating cells (arrows). Bar=5 μm. (b) Quantification of the apparent t1/2 of 
adhesion assembly and the t1/2 of adhesion disassembly for transfected cells is shown.  
For each condition, 34-70 adhesions from 11-22 cells were analyzed. Error bars represent 
s.e.m. for 3-6 independent experiments (*, p < 0.04, **, p < 0.006, ***, p < 0.004). “n.s.” 
denotes no statistically significant difference. 
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Asef2-S106A-expressing cells compared to those cells expressing GFP-Asef2 (Figure 
4.6b).  These data are consistent with the slower cell migration speed that was observed 
in GFP-Asef2-S106A-expressing cells (Figure 4.5b), further emphasizing the importance 
of phosphorylation of this residue for efficient cell migration. Expression of the S106D 
mutant, on the other hand, resulted in t1/2 values that were comparable to those observed 
with GFP-Asef2 expression. Collectively, these results suggest that the phosphorylation 
of Asef2 at S106 promotes faster adhesion turnover, which is critical for proficient cell 
migration.   
 
4.4. Conclusions 
Asef2 is emerging as an important GEF in modulating cellular processes, such as 
migration and adhesion dynamics; however, the mechanisms that regulate the activity and 
function of Asef2 are currently not well understood. In this study, we identified six 
phosphorylation sites in Asef2 by MS analysis. We demonstrate that phosphorylation of 
one of these sites, S106, which is located in the ABR domain, is important for modulating 
Asef2 GEF activity as well as for Asef2 function in cell migration and adhesion turnover.  
Four of the other detected phosphorylation sites (S5, S26, S78, and T217) are 
congregated toward the N-terminus of Asef2. This region of the protein contains the 
ABR-SH3 module, which maintains Asef2 in an autoinhibited, inactive state.
20
  
Therefore, the location of these phosphorylation sites puts them in a potential position to 
regulate the autoinhibitory state of Asef2, even though these sites are not found within a 
known domain of the protein. The sixth phosphorylation site (T617) is located in the C-
terminus of Asef2. The C-terminus associates with the ABR-SH3 module to maintain 
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Asef2 in an autoinhibitory state.
20
 Thus, phosphorylation within this region could also 
affect Asef2 GEF activity. Furthermore, the C-terminus of Asef2 is involved in mediating 
protein-protein interactions; for example, Asef2 interacts with the actin-binding protein 
spinophilin, via this region.
40
 Phosphorylation of T617 could be involved in regulating 
this association or other protein-protein interactions. Future studies are needed to 
determine the significance of these phosphorylation sites on Asef2 activity and function.   
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CHAPTER V 
 
PERSPECTIVES ON EMERGING AND FUTURE DIRECTIONS 
 
5.1. Summary  
 The biomolecular signatures of diseases have been investigated using advanced 
IM and MS techniques and bioinformatics strategies. A workflow for the untargeted ESI-
IM-MS analysis of 64 samples of diabetic wound fluid was developed, which included 
statistically-driven prioritization of differentially expressed biomolecules, bioinformatics-
based tentative identifications, targeted UPLC-IM-MS analyses, MS/MS experiments, 
and validation of tentative identifications with standards. Cholic acid, 
lysophosphatidylcholine 20:4, and the protein S100-A8 were found to be differentially 
expressed between wound fluids from diabetic and non-diabetic animals across two time 
points after the initial wound. The utility of IM-MS for complex biological sample 
analysis was demonstrated in the identification of biomolecular signatures of disease 
representing protein, lipid and metabolite classes of biomolecular species. 
The workflow developed for the wound fluid analysis was expanded upon for the 
study of breast cancer metabolomics. Breast tissues representing disease and matched 
controls were homogenized and polar species extracted. An untargeted analysis by 
UPLC-IM-MS/MS, combined with biostatistics and bioinformatics tools, revealed an 
unexpected grouping of the samples. Although researchers were blinded to the particular 
pathologies of the tissues, grouping in the PCA lead to the hypothesis that the disease 
tissues represented both cancerous and benign breast diseases, and was later confirmed 
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upon revealing of the tissue pathologies. Key molecular features distinguishing these 
states represented species previously known to be affected by the aberrant metabolism in 
cancer, including the polypeptides thymosin β4 and thymosin β10, choline-containing 
metabolites, adenosine monophosphate, and reduced and oxidized glutathione. The 
transition from unknown molecular features to validated identifications of biomolecular 
signatures using an IM-based approach was demonstrated for the glutathione species, 
where structural separation in IM dimension was critical for resolving isobaric species 
and distinguishing multiple sources of fragmentation.  
An MS approach was used to study another biomolecular species implicated in 
cancer. Asef2 is a protein suspected to regulate the cell migration, a process central to the 
development of metastasis in cancer. Phosphorylation of Asef2 was previously 
uncharacterized, but was implicated as a possible method of regulation based on results 
for other proteins in the GEF family. Using an LC-MS/MS proteomics approach 
incorporating multiple digestion strategies and bioinformatics based peptide and protein 
identification, the phosphorylation of the protein Asef2 was mapped. While initial 
digestions with trypsin, chymotrypsin and Glu-C provided moderate sequence coverage 
(85.6%), additional trypsin digestions under strongly denaturing conditions of heat and 
high organic solvent content increases the sequence coverage of the 652 amino acid 
protein to 94.6%. Most notably, 100% of the phosphorylatable residues (serine, 
threonine, tyrosine) were covered by the combine analyses, and six sites of 
phosphorylation were identified. One particular site, serine 106, was located in a region 
of Asef2 critical for relief of autoinhibition. Mutation analysis revealed this site of 
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phosphorylation regulated adhesion turnover and cell migration, and promoted Rac 
activation.  
 
5.2. Future Directions 
5.2.1. Biomolecular Signatures of Diabetic Wound Healing 
 Many of the biomolecular signatures found to distinguish control and diabetic 
wound fluids have also been characterized from biological matrices such as blood, serum 
and plasma. As the molecular contents of wound fluid originate in some part from the 
circulatory system, a dual characterization of wound fluids and serum may provide new 
insight into the wound healing process. Relative to wound fluid, serum represent a more 
abundant and more accessible biological sample from which the state of wound healing 
may be assessed. Of particular interest would be whether these different biological 
matrices reveal the same biomolecular signatures for distinguishing diabetic versus non-
diabetic. Additional time points prior to the earliest time point used in our study would 
provide a better perspective on the rate at which diabetic and non-diabetic wound diverge 
in the wound healing process. 
 
5.2.2. Distinguishing Cancerous and Noncancerous Breast Diseases  
 From Figure 3.2(b), it is apparent that there are many more molecular species 
contributing to the differentiation of cancerous, benign and healthy tissues than those 18 
which were focused on in our analysis. While interrogation of all these features is 
feasible with a sufficient investment in time, a more targeted strategy may be to first 
investigate the features which are connected to those already identified through known 
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metabolic pathways. This is possible with use of the KEGG metabolite database and 
software such as Cytoscape and Metscape, which can be used to map known features to 
the pathways in which they participate and reveal molecules in those pathways.  
 The analysis of breast cancer metabolomics could be expanded by adding more 
samples to each of the disease subsets used here to describe their metabolic differences 
with more statistical power. Power analysis for the features identified in the current work 
indicates that a total of three biological replicates per current sample (i.e. 18 tissues: 3 
triple negative, 3 fibroadenoma, 3 pseudoangiomatous hyperplasia and 9 appropriate 
matched controls) would provide a statistical power of one for a two-tailed t-test where 
α=0.01 (calculation based on means for choline, m/z 104, for samples 3C and 4D). The 
study may also be expanded by analyzing the nonpolar extracts of the tissues, which 
would reflect the changes in species such as lipids, steroids, and fatty acids between 
cancerous and non-cancerous breast tissues.  
 
5.2.3. Characterizing the Phosphorylation of Asef2  
 A total of six sites of phosphorylation were identified in our analysis of Asef2, 
many of which clustered near the N-terminus of the protein. The site S106 was chosen for 
the initial experiments based on its location within the APC binding region (ABR; Figure 
4.2b). As discussed in section 4.1, relief of Asef2’s autoinhibition occurs through tandem 
binding of the ABR and SH3 domains by APC. One of the five unexplored 
phosphorylation sites, T217, lies just beyond the SH3 domain. Given the significance of 
the ABR and SH3 domains, mutation analyses similar to those described in Chapter IV 
could be performed for T217 to determine if this phosphorylation impacts the 
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autoinhibition of Asef2 in a manner comparable to S106. In addition, dual mutation 
experiments for both S106 and pT217 simultaneous may provide further insight into the 
role of phosphorylation in regulating the activity of Asef2. Another promising site is 
T617, located within the C-terminus of Asef2. As described in Chapter IV, the C-
terminus is involved in maintaining the autoinhibitory state of Asef2 by associating with 
the ABR-SH3 domains. Thus, T617 presents a third potential avenue for modulating the 
activity and autoinhibition of Asef2. 
 
5.3. Conclusions  
 Mapping the phosphorylation of the protein Asef2 with an MS-based proteomics 
strategy was a substantial undertaking in terms of the data generated and interpreted. The 
development of robust bioinformatics contributed substantially to the wide-spread 
acceptance of MS-based proteomics as the standard approach for identifying proteins. 
Given the enormity of such datasets, manual interpretation would require an extensive 
investment of time. IM-MS approaches face a similar challenge for the identification of 
biomolecular signatures of diseases from complex samples. The development of 
bioinformatics and biostatistics platforms utilizing the data in the IM dimension would 
vastly expand the utility and approachability of IM for large-scale analyses of highly 
complex samples. As discussed in Chapters II and III, peak picking and data alignment in 
the IM dimension is typically not supported by the most widely used bioinformatics 
platforms. This often necessitates incorporation of chromatographic separations, for 
which most bioinformatics packages were developed, effectively excluding the IM 
dimension and reducing the dimensionality of the dataset in order to perform peak 
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picking and data alignment. In this case, the information in the IM dimension is not being 
utilized to the maximum but used as supplementary information in support of results 
from the LC-MS-based bioinformatics.  
Despite the current challenges described above, the works described in this 
dissertation strongly demonstrate the merits of incorporating IM separations into the 
traditional strategies used for untargeted analyses of complex biological samples. 
Chapters II and III demonstrated the advantages of incorporating ion mobility into 
workflows for characterizing complex biological samples. In the analysis of wound 
fluids, the improvement in S/N gained by extracting signals away from overlapping 
chemical noise in the IM dimension was demonstrated. Additionally, the structural 
information provided by IM separation enabled hypothesis driven identification of 
unknown molecular species based on their locations within conformation space or the 
proximity between species in conformation space. The flexibility of extracting 
information from multidimensional UPLC-IM-MS/MS analysis was demonstrated in the 
context of the breast cancer metabolomics study. The separation in the IM dimension of 
nearly isobaric species and different sources of fragmentation from data-independent 
acquisition of MS/MS spectra aided in the identification of a significantly differentially 
expressed metabolite. Further, the additional information in the form of a drift time 
provided a third piece of evidence on which experimental unknowns and standards could 
be compared in the validation of tentative identifications. Thus, the incorporation of IM 
into contemporary MS techniques greatly benefits the field of biologically driven studies 
targeting the biomolecular signatures of diseases. 
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APPENDIX B 
 
SUPPORTING INFORMATION FOR CHAPTER II 
 
B.1. Model Parameters for PLS-DA Score Plots and OPLS-DA S-Plots 
The following model parameters (Tables A.1-A.3) correspond with the PLS-DA 
score plots and OPLS-DA S-plots found in the main text of Chapter II as Figure 2.3. The 
values were reported directly from the Extended Statistic software, and represent the 
variability extracted from the data by each principal component. Values of R2Y and Q2 
for principal components beyond component 1 (Comp. 1) represent cumulative totals of 
the variability accounted for by addition of each consecutive principal component. 
Therefore, the variability extracted by one particular component can be determined by 
subtracting the value of R2Y or Q2 corresponding to the previous component. 
Components for the OPLS-DA analyses are labeled “Princ.” and “Orthog.” to indicate the 
principal component which extracts the variability due to the group differences, and the 
orthogonal components which extract all other variability from the dataset, respectively. 
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Table B.1.  Day 2 Control vs. Diabetic PLS-DA and OPLS-DA Model Parameters. 
 
PLS-DA Model Parameters 
Component No. R2Y(cum) Q2(cum) 
Comp. 1 0.69 0.61 
Comp. 2 0.83 0.71 
Comp. 3 0.90 0.79 
Comp. 4 0.96 0.83 
Comp. 5 0.98 0.89 
Comp. 6 0.99 0.93 
OPLS-DA Model Parameters 
Component No. R2Y(cum) Q2(cum) 
Comp. 1 (Princ.) 0.90 0.61 
Comp. 2 (Orthog.) 0.90 0.72 
Comp. 3 (Orthog.) 0.90 0.82 
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Table B.2.  Day 5 Control vs. Diabetic PLS-DA and OPLS-DA Model Parameters. 
 
PLS-DA Model Parameters 
Component No. R2Y(cum) Q2(cum) 
Comp. 1 0.33 0.26 
Comp. 2 0.66 0.48 
Comp. 3 0.86 0.61 
Comp. 4 0.92 0.72 
Comp. 5 0.97 0.82 
Comp. 6 0.98 0.87 
OPLS-DA Model Parameters 
Component No. R2Y(cum) Q2(cum) 
Comp. 1 (Princ.) 0.86 0.26 
Comp. 2 (Orthog.) 0.86 0.46 
Comp. 3 (Orthog.) 0.86 0.66 
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Table B.3.  Day 5 Control vs. Day 2 Diabetic PLS-DA and OPLS-DA Model Parameters. 
 
PLS-DA:  Day 5 Control vs. Day 2 Diabetic 
Component No. R2Y(cum) Q2(cum) 
Comp. 1 0.31 0.22 
Comp. 2 0.63 0.50 
Comp. 3 0.92 0.68 
OPLS-DA:  Day 5 Control vs. Day 2 Diabetic 
Component No. R2Y(cum) Q2(cum) 
Comp. 1 (Princ.) 0.92 0.22 
Comp. 2 (Orthog.) 0.92 0.47 
Comp. 3 (Orthog.) 0.92 0.70 
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B.2. Box-and-Whisker Plots for Biomolecular Signatures 
 
 
Figure B.1. Box-and-whisker plots prepared from the mobility-extracted integrated m/z 
peak areas for the species found to be statistically significant. (a) The S100-A8 was 
observed with a 5-fold increase in the diabetic day 2 group relative to the control (p = 
9.56 x10
-5
). No significance was found between the day 5 control and diabetic groups. (b) 
Lysophosphatidylcholine (20:4) (m/z 544.4) was generally more abundant in the control 
groups relative to the diabetic groups at both time points. A 4.3-fold increase was 
observed in control day 2 wound fluids relative to diabetic day 2 wound fluids (p = 
3.66x10
-11
), and a 2.7-fold increase was observed in control day 5 wound fluids relative 
to diabetic day 5 wound fluids (p = 8.37x10
-6
). (c) The cholic acid species [-3H2O] (m/z 
355.3) was generally more abundant in the diabetic wound fluids relative to control 
wound fluids at both time points. A 2.6-fold increase (p = 2.5x10
-8
) was observed in the 
diabetic day 2 group relative to its control, and a 1.5-fold increase (p = 1.8x10
-4
) was 
observed in the diabetic day 5 wound fluids relative to their controls. (d) The cholic acid 
[-2H2O] species (m/z 373.3) was generally more abundant in the diabetic wound fluids 
relative to control wound fluids at both time points. An 8.8-fold increase (p = 2.3x10
-10
) 
was observed in the diabetic day 2 group relative to its control, and a 1.7-fold increase (p 
= 1.1x10
-3
) was observed in the diabetic day 5 wound fluids relative to their controls. 
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B.3. Demonstration of IM-MS for Separating Interfering Signals  
 
Figure B.2. Demonstration of IM-MS for separation of chemical noise from signals. (a) 
The area outlined with blue lines corresponds to extracting a defined region of m/z space 
across all drift times. The corresponding mass spectrum is presented in (b), and 
represents a typical mass spectrum without mobility separation. Individual isotopic 
clusters are not baseline resolved due to high background chemical noise in (b). The area 
outlined with red lines corresponds to extracting the signals contained in the defined 
region of IM. The combination of the blue lines and the red lines defines a region of drift 
time-m/z space, yielding the extracted mass spectrum (c). The combination of the blue 
lines and the green lines defines the region of drift time-m/z space containing the 
multiply-charged species, shown in (d). Structural separation of the background chemical 
noise in (c) from the full mass spectrum in (b) yields (d), in which the isotopic 
distribution of the multiply-charged species is baseline resolved. 
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Figure B.3. Demonstration of IM-MS for resolving overlapping isotopic distributions of 
nearly-isobaric species. (a) The area outlined with blue lines corresponds to extracting a 
defined region of m/z space across all drift times. The corresponding mass spectrum is 
presented in (b), and represents a typical mass spectrum without mobility separation. 
While the monoisotopic peak of m/z 544.4 is resolved, the second isotopic peak m/z 545.5 
is not baseline resolved. The area outlined with red lines corresponds to extracting the 
signals contained in the defined region of IM space. The combination of the blue lines 
and the red defines a region of drift time-m/z space, yielding the mass spectrum in (c). 
Likewise, the combination of the blue lines and the green lines defines the region of drift 
time-m/z space containing the multiply-charged species, shown in (d). Structural 
separation of these two species yield baseline resolve mass spectra for both, clearly 
showing a singly-charged species at m/z 544.4 in (c) and a 6
+
 species at m/z 544.9. 
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APPENDIX C 
 
SUPPORTING INFORMATION FOR CHAPTER III 
 
C.1. Tissue Weights 
 
 
 
 
 
Table C.1.  Weights of Tissues used for Polar Metabolite Extraction 
Sample  Name Tissue Weight (mg, wet) 
1C 44.93 
2D 50.57 
3C 40.69 
4D 48.99 
5C 52.09 
6D 48.80 
Average 47.68 
Standard Deviation ± 3.81 
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C.2. Method for Data Processing with XCMS 
 The R package can be downloaded from http://www.r-project.org/. After 
installing R, XCMS may be downloaded using the following code in an active R session: 
source("http://bioconductor.org/biocLite.R") 
biocLite("xcms", dep=T) 
 
Additional details may be found on the XCMS Bioconductor website (http://www.bio 
conductor.org/packages/release/bioc/html/xcms.html). Prior to processing data with 
XCMS, .raw files must be converted to .mzXML using ProteoWizard (http://proteo 
wizard.sourceforge.net/) MSConvert and the “sortByScanTime” function. 
 
C.2.1. XCMS Method 
xset <-xcmsSet() 
xset 
xset <-group(xset) 
xset2 <-retcor (xset, method=”obiwarp”, 
plottype=”deviation”) 
 xset2 <-group(xset2, bw=10) 
 xset3 <-fillPeaks(xset2) 
 xset3  
reporttab <-diffreport(xset3, “Group_1”, “Group_2”, 
“File_Name”, [Number of EICs, boxplots, to 
generate]) 
 
 The aligned data in the diffreport was normalized such that all intensities within a 
sample summed to 10,000. The data was then transposed such that the sample and file 
names were in a column instead of a row, and this dataset was imported into Umetrics 
Extended Statistics for statistical analysis. 
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C.3. Principal Components Analysis with QC Samples 
 
 
 
 
 
Figure C.1. Principal component analysis score plot for breast cancer tissue dataset 
including quality control (QC) samples for diagnostic purposes. QC samples group 
together well, indicating good reproducibility throughout the queue. QC samples cluster 
near the center of the PCA indicating they are representative of all samples. 
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C.4. Goodness of Fit for PCA (Figure 3.2(a)) 
 
 
 
 
 
 
 
 
 
 
 
Figure C.2. Goodness of fit for PCA analysis of breast tissue extracts. Model 
parameters R2X (light grey) and Q2 (dark grey) describe the cumulative variability 
extracted by including each consecutive principal component (PC1-6). For example, 
including PC1 and PC2 extracts approximately 70% (R2X) of the variability in the 
dataset. 
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C.5. Data Used to Prepare Figure 3.2(c) and Table 3.1 
 Data from XCMS peak aligned output. All comparisons are made between 
matched disease and control pairs. Fold-changes were calculated by dividing the larger of 
the two tissues (control or diabetic) by the smaller to obtain numbers ≥1. The student’s t-
test with two-tails, equal variance, and α=0.05 was used to calculate p-values. 
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Table C.2. Normalized abundances, fold-changes and p-values for Feature #1. 
Feature 1 
m/z 258.11, 1.53 min 
 Norm. Int. Average Standard Dev. 
Fold-
change 
p-value 
1C_01 
1C_02 
1C_03 
20.62 
21.23 
21.51 
21.12 0.37 
8.1 6.5E-7 
2D_01 
2D_02 
2D_03 
3.01 
2.44 
2.34 
2.60 0.30 
3C_01 
3C_02 
3C_03 
57.87 
57.65 
62.03 
59.18 2.02 
3.7 1.4E-6 
4D_01 
4D_02 
4D_03 
222.92 
219.03 
212.03 
217.99 4.51 
5C_01 
5C_02 
5C_03 
10.41 
10.13 
9.26 
9.93 0.49 
6.0 3.0E-5
 
6D_01 
6D_02 
6D_03 
58.93 
56.65 
64.57 
60.05 3.33 
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Table C.3. Normalized abundances, fold-changes and p-values for Feature #2. 
Feature 2 
m/z 348.07, 2.36 min 
 Norm. Int. Average 
Standard 
Dev. 
Fold-change p-value 
1C_01 
1C_02 
1C_03 
6.64 
6.86 
6.80 
6.77 0.09 
5.7 3.2E-06 
2D_01 
2D_02 
2D_03 
1.01 
1.46 
1.11 
1.19 0.19 
3C_01 
3C_02 
3C_03 
44.55 
43.20 
49.76 
45.84 2.82 
3.2 7.5E-06 
4D_01 
4D_02 
4D_03 
152.84 
145.58 
143.86 
147.42 3.89 
5C_01 
5C_02 
5C_03 
1.40 
1.43 
0.91 
1.25 0.24 
10.5 1.1E-06 
6D_01 
6D_02 
6D_03 
13.42 
12.81 
13.25 
13.16 0.26 
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Table C.4. Normalized abundances, fold-changes and p-values for Feature #3. 
Feature 3 
m/z 136.06, 2.36 min 
 Norm. Int. Average Standard Dev. Fold-change p-value 
1C_01 
1C_02 
1C_03 
10.41 
9.18 
9.50 
9.70 0.52 
3.9 5.3E-05 
2D_01 
2D_02 
2D_03 
2.44 
2.26 
2.74 
2.48 0.20 
3C_01 
3C_02 
3C_03 
46.06 
47.64 
51.60 
48.43 2.33 
2.4 7.3E-06 
4D_01 
4D_02 
4D_03 
116.81 
113.81 
111.86 
114.16 2.04 
5C_01 
5C_02 
5C_03 
2.71 
2.47 
1.93 
2.37 0.33 
5.2 4.4E-06 
6D_01 
6D_02 
6D_03 
12.69 
12.09 
12.29 
12.36 0.25 
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Table C.5. Normalized abundances, fold-changes and p-values for Feature #4. 
Feature 4 
m/z 308.09, 2.45 min 
 Norm. Int. Average 
Standard 
Dev. 
Fold-
change 
p-value 
1C_01 
1C_02 
1C_03 
6.01 
4.26 
4.33 
4.86 0.81 
7.8 1.8E-03 
2D_01 
2D_02 
2D_03 
0.65 
0.60 
0.62 
0.62 0.02 
3C_01 
3C_02 
3C_03 
35.38 
37.38 
38.53 
37.10 1.30 
4.8 1.3E-05 
4D_01 
4D_02 
4D_03 
186.32 
176.02 
167.92 
176.75 7.53 
5C_01 
5C_02 
5C_03 
8.66 
9.94 
8.77 
9.12 0.58 
4.6 9.9E-06 
6D_01 
6D_02 
6D_03 
42.75 
43.53 
39.88 
42.05 1.57 
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Table C.6. Normalized abundances, fold-changes and p-values for Feature #5. 
Feature 5 
m/z 613.01, 3.79 min 
 
Norm. 
Int. 
Average Standard Dev. 
Fold-
change 
p-value 
1C_01 
1C_02 
1C_03 
27.39 
27.43 
30.04 
28.29 1.24 
20.1 6.8E-06 
2D_01 
2D_02 
2D_03 
1.36 
1.45 
1.42 
1.41 0.04 
3C_01 
3C_02 
3C_03 
5.66 
5.44 
5.74 
5.61 0.12 
15.6 1.5E-05 
4D_01 
4D_02 
4D_03 
94.05 
85.30 
83.34 
87.57 4.66 
5C_01 
5C_02 
5C_03 
17.34 
15.74 
17.13 
16.74 0.71 
1.0 6.4E-01 
6D_01 
6D_02 
6D_03 
16.07 
16.33 
16.96 
16.45 0.37 
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Table C.7. Normalized abundances, fold-changes and p-values for Feature #6. 
Feature 6 
m/z 104.17, 1.49 min 
 Norm. Int. Average 
Standard 
Dev. 
Fold-change 
p-
value 
1C_01 
1C_02 
1C_03 
21.28 
21.19 
20.87 
21.11 0.18 
1.3 
2.0E-
03 2D_01 
2D_02 
2D_03 
27.71 
28.45 
25.63 
27.26 1.20 
3C_01 
3C_02 
3C_03 
34.93 
35.69 
37.96 
36.19 1.29 
2.3 
2.3E-
05 4D_01 
4D_02 
4D_03 
84.99 
80.70 
78.97 
81.55 2.53 
5C_01 
5C_02 
5C_03 
23.26 
24.85 
25.21 
24.44 0.85 
1.4 
1.4E-
04 6D_01 
6D_02 
6D_03 
34.34 
33.57 
34.72 
34.21 0.48 
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Table C.8. Normalized abundances, fold-changes and p-values for Feature #7. 
Feature 7 
m/z 705.95, 4.64 min 
 Norm. Int. Average 
Standard 
Dev. 
Fold-change p-value 
1C_01 
1C_02 
1C_03 
37.77 
31.75 
37.44 
35.65 2.76 
7.4 1.0E-04 
2D_01 
2D_02 
2D_03 
4.54 
4.44 
5.55 
4.84 0.50 
3C_01 
3C_02 
3C_03 
12.85 
8.88 
4.30 
8.67 3.49 
22.1 7.3E-07 
4D_01 
4D_02 
4D_03 
187.43 
193.29 
195.32 
192.01 3.35 
5C_01 
5C_02 
5C_03 
38.26 
31.97 
33.03 
34.42 2.75 
2.3 3.0E-05 
6D_01 
6D_02 
6D_03 
79.72 
81.37 
78.20 
79.76 1.29 
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Table C.9. Normalized abundances, fold-changes and p-values for Feature #8. 
Feature 8 
m/z 823.32, 4.64 min 
 Norm. Int. Average Standard Dev. 
Fold-
change 
p-value 
1C_01 
1C_02 
1C_03 
30.43 
29.31 
29.73 
29.82 0.46 
6.8 9.7E-07 
2D_01 
2D_02 
2D_03 
4.53 
3.66 
5.00 
4.40 0.55 
3C_01 
3C_02 
3C_03 
7.15 
7.03 
3.08 
5.75 1.89 
29.8 2.9E-07 
4D_01 
4D_02 
4D_03 
175.74 
170.48 
168.89 
171.70 2.93 
5C_01 
5C_02 
5C_03 
30.50 
27.13 
26.41 
28.01 1.78 
2.5 1.7E-05 
6D_01 
6D_02 
6D_03 
69.81 
70.48 
66.87 
69.05 1.57 
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Table C.10. Normalized abundances, fold-changes and p-values for Feature #9. 
Feature 9 
m/z 827.82, 4.58 min 
 
Norm. 
Int. 
Average Standard Dev. 
Fold-
change 
p-value 
1C_01 
1C_02 
1C_03 
159.75 
145.99 
166.89 
157.54 8.67 
11.8 2.3E-05 
2D_01 
2D_02 
2D_03 
12.75 
10.76 
16.60 
13.37 2.43 
3C_01 
3C_02 
3C_03 
38.04 
31.69 
7.06 
25.60 13.36 
10.4 1.5E-05 
4D_01 
4D_02 
4D_03 
268.45 
263.04 
266.60 
266.03 2.25 
5C_01 
5C_02 
5C_03 
130.72 
115.75 
123.75 
123.40 6.12 
2.0 1.7E-05 
6D_01 
6D_02 
6D_03 
250.24 
241.32 
244.45 
245.34 3.69 
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Table C.11. Normalized abundances, fold-changes and p-values for Feature #10. 
Feature 10 
m/z 152.11, 2.30 min 
 
Norm. 
Int. 
Average 
Standard 
Dev. 
Fold-change p-value 
1C_01 
1C_02 
1C_03 
12.37 
10.01 
10.51 
10.96 1.01 
4.4 3.4E-04 
2D_01 
2D_02 
2D_03 
2.08 
2.67 
2.72 
2.49 0.29 
3C_01 
3C_02 
3C_03 
4.54 
5.05 
5.16 
4.92 0.27 
17.1 4.9E-06 
4D_01 
4D_02 
4D_03 
88.62 
81.48 
81.53 
83.88 3.35 
5C_01 
5C_02 
5C_03 
18.37 
19.25 
18.70 
18.77 0.36 
3.6 3.9E-07 
6D_01 
6D_02 
6D_03 
65.54 
68.03 
66.62 
66.73 1.02 
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Table C.12. Normalized abundances, fold-changes and p-values for Feature #11. 
Feature 11 
m/z 184.11, 1.53 min 
 
Norm. 
Int. 
Average 
Standard 
Dev. 
Fold-change p-value 
1C_01 
1C_02 
1C_03 
6.14 
5.74 
5.59 
5.82 0.23 
3.5 6.2E-05 
2D_01 
2D_02 
2D_03 
1.98 
1.58 
1.39 
1.65 0.25 
3C_01 
3C_02 
3C_03 
18.82 
20.35 
20.93 
20.03 0.89 
3.7 3.3E-06 
4D_01 
4D_02 
4D_03 
76.97 
75.48 
72.35 
74.93 1.93 
5C_01 
5C_02 
5C_03 
5.75 
6.87 
5.63 
6.08 0.56 
15.8 1.3E-07 
6D_01 
6D_02 
6D_03 
98.02 
95.57 
94.59 
96.06 1.44 
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Table C.13. Normalized abundances, fold-changes and p-values for Feature #12. 
Feature 12 
m/z 137.10, 3.94 min 
 Norm. Int. Average 
Standard 
Dev. 
Fold-change p-value 
1C_01 
1C_02 
1C_03 
160.13 
130.10 
155.52 
148.58 13.20 
1.3 3.3E-02 
2D_01 
2D_02 
2D_03 
206.12 
181.94 
178.94 
189.00 12.16 
3C_01 
3C_02 
3C_03 
99.71 
106.99 
111.38 
106.03 4.81 
2.0 2.2E-04 
4D_01 
4D_02 
4D_03 
218.17 
208.63 
193.64 
206.81 10.10 
5C_01 
5C_02 
5C_03 
148.78 
139.75 
128.65 
139.06 8.24 
1.5 3.1E-04 
6D_01 
6D_02 
6D_03 
206.67 
212.36 
210.33 
209.79 2.36 
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Table C.14. Normalized abundances, fold-changes and p-values for Feature #13. 
Feature 13 
m/z 246.19, 4.99 min 
 
Norm. Int. Average 
Standard 
Dev. 
Fold-change p-value 
1C_01 
1C_02 
1C_03 
3.69 
3.26 
3.91 
3.62 0.27 
1.9 6.9E-04 
2D_01 
2D_02 
2D_03 
6.63 
7.34 
6.43 
6.80 0.39 
3C_01 
3C_02 
3C_03 
5.64 
3.97 
5.54 
5.05 0.76 
1.1 4.2E-01 
4D_01 
4D_02 
4D_03 
4.67 
4.29 
4.70 
4.55 0.19 
5C_01 
5C_02 
5C_03 
3.18 
3.32 
2.79 
3.10 0.22 
67.8 4.6E-09 
6D_01 
6D_02 
6D_03 
209.56 
208.15 
211.83 
209.85 1.52 
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Table C.15. Normalized abundances, fold-changes and p-values for Feature #14. 
Feature 14 
m/z 137.10, 2.68 min 
 
Norm. 
Int. 
Average 
Standard 
Dev. 
Fold-
change 
p-value 
1C_01 
1C_02 
1C_03 
72.95 
81.97 
78.58 
77.83 3.72 
3.3 1.8E-05 
2D_01 
2D_02 
2D_03 
254.93 
268.00 
243.99 
255.64 9.81 
3C_01 
3C_02 
3C_03 
71.24 
73.19 
83.20 
75.87 5.24 
3.5 1.3E-06 
4D_01 
4D_02 
4D_03 
265.46 
268.27 
261.99 
265.24 2.57 
5C_01 
5C_02 
5C_03 
114.19 
119.30 
115.82 
116.44 2.13 
2.6 5.3E-06 
6D_01 
6D_02 
6D_03 
308.29 
293.77 
290.96 
297.68 7.59 
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Table C.16. Normalized abundances, fold-changes and p-values for Feature #15. 
Feature 15 
m/z 152.11, 3.93 min 
 Norm. Int. Average 
Standard 
Dev. 
Fold-change p-value 
1C_01 
1C_02 
1C_03 
34.02 
26.69 
33.96 
31.56 3.44 
2.1 
4.66E-
04 2D_01 
2D_02 
2D_03 
70.91 
65.79 
63.11 
66.60 3.24 
3C_01 
3C_02 
3C_03 
7.31 
7.11 
8.41 
7.61 0.57 
5.7 
4.31E-
05 4D_01 
4D_02 
4D_03 
46.82 
42.24 
40.82 
43.29 2.56 
5C_01 
5C_02 
5C_03 
41.50 
39.91 
36.89 
39.44 1.91 
1.7 
1.77E-
04 6D_01 
6D_02 
6D_03 
65.51 
70.43 
65.94 
67.29 2.22 
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Table C.17. Normalized abundances, fold-changes and p-values for Feature #16. 
Feature 16 
m/z 203.09, 1.48 min 
 
Norm. 
Int. 
Average 
Standard 
Dev. 
Fold-change p-value 
1C_01 
1C_02 
1C_03 
87.57 
79.66 
87.08 
84.77 3.62 
1.0 3.1E-01 
2D_01 
2D_02 
2D_03 
84.01 
81.81 
76.83 
80.88 3.01 
3C_01 
3C_02 
3C_03 
71.68 
71.84 
75.53 
73.02 1.78 
7.3 9.8E-07 
4D_01 
4D_02 
4D_03 
10.02 
9.67 
10.22 
9.97 0.23 
5C_01 
5C_02 
5C_03 
39.69 
41.82 
38.84 
40.12 1.25 
3.5 7.7E-06 
6D_01 
6D_02 
6D_03 
12.17 
10.88 
11.12 
11.39 0.56 
 
 
 
 
 
 204 
 
 
 
 
 
 
Table C.18. Normalized abundances, fold-changes and p-values for Feature #17. 
Feature 17 
m/z 437.13, 9.31 min 
 Norm. Int. Average 
Standard 
Dev. 
Fold-change p-value 
1C_01 
1C_02 
1C_03 
119.37 
111.26 
105.22 
111.95 5.80 
1.1 7.1E-02 
2D_01 
2D_02 
2D_03 
96.68 
105.65 
94.86 
99.06 4.72 
3C_01 
3C_02 
3C_03 
125.05 
113.68 
120.62 
119.78 4.68 
3.2 5.3E-05 
4D_01 
4D_02 
4D_03 
43.04 
32.73 
35.18 
36.98 4.40 
5C_01 
5C_02 
5C_03 
99.13 
81.75 
76.93 
85.94 9.54 
1.9 5.1E-03 
6D_01 
6D_02 
6D_03 
50.84 
44.27 
43.61 
46.24 3.26 
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Table C.19. Normalized abundances, fold-changes and p-values for Feature #18. 
Feature 18 
m/z 387.15 
 
Norm. 
Int. 
Average 
Standard 
Dev. 
Fold-
change 
p-value 
1C_01 
1C_02 
1C_03 
86.43 
87.11 
85.69 
86.41 0.58 
1.0 7.2E-01 
2D_01 
2D_02 
2D_03 
82.64 
93.62 
86.69 
87.65 4.54 
3C_01 
3C_02 
3C_03 
120.37 
129.84 
142.42 
130.88 9.03 
7.0 6.6E-05 
4D_01 
4D_02 
4D_03 
16.64 
18.53 
20.67 
18.62 1.65 
5C_01 
5C_02 
5C_03 
62.81 
59.46 
59.89 
60.72 1.49 
2.1 8.5E-06 
6D_01 
6D_02 
6D_03 
29.30 
30.03 
29.50 
29.61 0.31 
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C.6. Expression of Thymosins β4 and β10 by Peak Areas for 8+ Species 
 The region containing thymosins β4 and β10 was mobility-extracted from the IM-
MS spectra of each sample (18 total) using a defined selection rule similar to that shown 
in Figure 3.1. Total abundances of the 6+ charge states of thymosins β4 and β10 were 
determined by summing the peak areas in the regions of the mobility-extracted mass 
spectrum centered about the isotopic distribution for the 8+ species, m/z 827.5-829.5 and 
m/z 823.0-825.0, respectively. All comparisons are made between matched disease and 
control pairs. Fold-changes were calculated by dividing the larger of the two tissues 
(control or diabetic) by the smaller to obtain numbers ≥1. The student’s t-test with two-
tails, equal variance, and α=0.05 was used to calculate p-values. 
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Table C.20. Abundances of Thymosin β4 (6+) from IM-Extracted MS Peak Areas. 
 
Norm. 
Int. 
Average 
Standard 
Dev. 
Fold-
change 
p-value 
1C_01 
1C_02 
1C_03 
206039 
208877 
198867 
204594 4212 
3.0 4.5E-05 
2D_01 
2D_02 
2D_03 
60145 
61216 
80429 
67263 9320 
3C_01 
3C_02 
3C_03 
60755 
47597 
16387 
41580 18606 
38.1 7.0E-07 
4D_01 
4D_02 
4D_03 
1631322 
1544283 
1579135 
1584913 35768 
5C_01 
5C_02 
5C_03 
346773 
308806 
283154 
312911 26134 
3.8 3.5E-06 
6D_01 
6D_02 
6D_03 
1217249 
1184695 
1163585 
1188510 22074 
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Table C.21. Abundances of Thymosin β10 (6+) from IM-Extracted MS Peak Areas. 
 
Norm. 
Int. 
Average 
Standard 
Dev. 
Fold-
change 
p-value 
1C_01 
1C_02 
1C_03 
45840 
48722 
42673 
45745 2470 
1.3 3.6E-03 
2D_01 
2D_02 
2D_03 
34868 
35239 
34954 
35020 159 
3C_01 
3C_02 
3C_03 
16016 
15619 
8612 
13416 3401 
76.0 1.4E-06 
4D_01 
4D_02 
4D_03 
1062637 
1000684 
993786 
1019036 30959 
5C_01 
5C_02 
5C_03 
96636 
77735 
65772 
80048 12706 
4.8 8.2E-06 
6D_01 
6D_02 
6D_03 
389273 
389153 
373514 
383980 7401 
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Figure C.3. Expression of thymosins β4 and β10 across the breast tissue samples. 
Relative abundances were calculated from the peaks areas of the isotopic distribution for 
the 6+ charge state of thymosins β4 and β10. 
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B.7. MS/MS Spectra for Features in Table 3.1 
 
 
 
 
 
Figure C.4. Mobility- and chromatography-extracted (2.62 ms; 1.51 min) DIA MS/MS 
spectrum of Feature #1, glycerophosphocholine (m/z 258.13).  
 
 
 
 
 
 
 
 
 
 
 
m/z
60 80 100 120 140 160 180 200 220 240 260 280 300 320 340
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_258 39 (2.622) Cm (31:47) 1: TOF MS ES+ 
3.91e4104.1140
86.1002
258.1181
221.0305
125.0071
184.0813
166.0699
237.0005
296.0778
280.1075
259.1227
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Figure C.5. Mobility- and chromatography-extracted (3.11 ms; 2.33 min) DIA MS/MS 
spectrum of Feature #2, adenosine monophosphate (m/z 348.09).  
 
 
 
 
 
 
 
 
 
m/z
60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_348 46 (3.105) Cm (22:66) 1: TOF MS ES+ 
4.73e4136.0703
348.0859
137.0709 349.0891
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Figure C.6. Mobility- and chromatography-extracted (1.52 ms; 2.33) DIA MS/MS 
spectrum of Feature #3, adenine/fragment of adenosine monophosphate (m/z 136.07). 
The region m/z 50-125 is shown at 5X magnification for clarity. 
 
 
 
 
 
 
m/z
50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_136 23 (1.518) Cm (10:37) 1: TOF MS ES+ 
9.04e3x5 136.0703
119.0382
110.0398
92.0279
84.0854
67.0322
109.0567
96.0137
117.0022
135.0378
120.0460
129.0841
137.0709
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Figure C.7. Mobility- and chromatography-extracted (3.04 ms; 2.45 min) DIA MS/MS 
spectrum of Feature #4, glutathione (m/z 308.10).  
 
 
 
 
 
 
 
 
 
 
 
m/z
60 80 100 120 140 160 180 200 220 240 260 280 300 320 340
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_308_02 45 (3.036) Cm (41:48) 1: TOF MS ES+ 
1.44e4179.0543
162.0301
76.0243
130.0537
116.021484.0493 144.0154
308.1044
233.0691
215.0572
180.0611
291.0777
245.0712
290.0947
309.1097
310.1013
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Figure C.8. Mobility- and chromatography-extracted (5.66 ms; 3.76 min) DIA MS/MS 
spectrum of Feature #5, oxidized glutathione (m/z 613.19).  
 
 
 
 
 
 
m/z
100 150 200 250 300 350 400 450 500 550 600 650
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_613 83 (5.658) Cm (73:98) 1: TOF MS ES+ 
3.01e4613.1851
484.1395
355.0895
538.1561
614.1916
615.1880
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Figure C.9. Mobility- and chromatography-extracted (4.76 ms; 4.56 min) DIA MS/MS 
spectrum of Feature #7-9, thymosins β4 and β10 (m/z 705.94, 823.44, 827.76). 
 
 
 
 
 
 
m/z
615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_thymosins 705 709 70 (4.761) Cm (58:92) 1: TOF MS ES+ 
1.08e4694.9617
677.5328
655.7753
655.5740
635.3527
635.1545
619.3450
638.7598
638.9696
652.5798
677.3850
661.3809
661.5831
677.2372
661.7854
676.3848
661.9764
676.2485
675.8963
662.1675
694.8235679.2395
679.3876
689.9611
689.8234
681.1080
695.1115
695.2497
695.3994
695.5377
695.6875
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Figure C.10. Mobility- and chromatography-extracted (4.76 ms; 4.56 min) DIA MS/MS 
spectrum of Features #7- , thymosins β4 and β10 (m/z 705.94, 823.44, 827.76). 
 
 
 
 
 
 
m/z
750 760 770 780 790 800 810 820 830 840 850 860 870 880 890 900 910 920
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_thymosins 705 709 70 (4.761) Cm (58:92) 1: TOF MS ES+ 
2.34e4759.0113
758.8067
758.6022
755.6091
759.2039
790.2823
790.1104
778.1710
759.4086
770.9369
790.4542
790.6139
810.6260
790.7859
810.4518
792.6174
807.6188
810.9494
915.4954811.1235
823.6382
873.2212830.9511
869.4814
914.9932
873.7118
915.9845
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Table C.21. Backbone cleavages observed for Thymosin β4 and β10 
 
Thymosin β4 Fragmentation  Thymosin β10 Fragmentation 
m/z charge fragment  m/z charge fragment 
619.1161 8+ MH-H2O
+8
  635.1545 5+ y27-NH3
+5
 
635.3738 5+ b27-H2O
+5
  638.5611 5+ y27
+5
 
655.9865 5+ a28
+5
  660.7968 5+ y28-NH3
+5
 
661.5927 5+ b28
+5
  677.2372 7+ b41+H2O
+7
 
676.5419 7+ b41
+7
  689.6857 7+ y42
+7
 
679.2603 7+ b41+H2O
+7
     
694.9823 7+ b42
+7
     
745.4326 4+ b25
+4
     
773.9556 4+ b26
+4
     
792.1327 6+ b41+H2O
+6
     
810.8069 6+ b42
+6
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Figure C.11. Mobility- and chromatography-extracted (1.59 ms; 2.26 min) DIA MS/MS 
spectrum of Feature #10 (m/z 152.06). Fragmentation pattern and mass accuracy suggest 
the following molecules as potential identifications: 2-hydroxyadenine (C5H5N5O; 
cLogP: 0.56); 8-hydroxyadenine (C5H5N5O; cLogP: 0.48); and guanine (C5H5N5O; 
cLogP: -1.16). Also observed at 3.93 min in chromatogram, suggesting this particular 
species is guanine due to CLogP values. 
 
 
 
 
m/z
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_152_2min 24 (1.587) Cm (14:39) 1: TOF MS ES+ 
1.01e4152.0620
135.0378
110.0398
136.0703
186.1199
153.0657
160.1394
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Figure C.11. Mobility- and chromatography-extracted (1.93 ms; 1.51 min) DIA MS/MS 
spectrum of Feature #11, phosphocholine (m/z 184.08).  
 
 
 
 
 
m/z
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_184 29 (1.932) Cm (19:41) 1: TOF MS ES+ 
1.01e4184.0813
162.1191
125.0071
86.1002
70.066660.0833
71.0758
98.9901108.9655 152.9090
138.9801
175.1244 186.9253
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Figure C.12. Mobility- and chromatography-extracted (1.52 ms; 3.93 min) DIA MS/MS 
spectrum of Feature #12 (m/z 137.05). Fragmentation pattern and mass accuracy suggest 
the following molecules as potential identifications: hypoxanthine (C5H4N4O; CLogP: 
0.49); allopurinol (C5H4N4O; CLogP: -0.74). Also observed at 2.67 min in 
chromatogram, suggesting this particular species is hypoxanthine due to CLogP values. 
Signals at m/z 137, 119, 110 and 94 correspond to Feature #12, while m/z 135 and 110 
correspond to feature #15 (m/z 152). 
 
 
 
 
m/z
50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_RT 3-9_137 23 (1.518) Cm (11:42) 1: TOF MS ES+ 
3.98e4137.0504
110.0398
135.0378
119.0429
138.0546
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Figure C.13. Mobility- and chromatography-extracted (2.76 ms; 5.01 min) DIA MS/MS 
spectrum of Feature #13 (m/z 246.18). Fragmentation pattern and mass accuracy suggest 
the following molecules as potential identifications: 2-methylbutyroylcarnitine 
(C12H23NO4); pivaloylcarnitine (C12H23NO4). 
 
 
 
 
 
m/z
60 80 100 120 140 160 180 200 220 240 260 280 300
%
0
100
2013_09_28_6T AQ_01_dt_MSMS_246 41 (2.760) Cm (31:55) 1: TOF MS ES+ 
3.05e4246.1804
85.0334
187.1046
247.1821
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Figure C.14. Mobility- and chromatography-extracted (1.52 ms; 2.67 min) DIA MS/MS 
spectrum of Feature #14 (m/z 137.05). Fragmentation pattern and mass accuracy suggest 
the following molecules as potential identifications: hypoxanthine (C5H4N4O; CLogP: 
0.49); allopurinol (C5H4N4O; CLogP: -0.74). Also observed at 3.93 min in 
chromatogram, suggesting this particular species is allopurinol due to CLogP values. 
 
 
 
 
m/z
50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_RT 2-67_137 23 (1.518) Cm (13:41) 1: TOF MS ES+ 
5.68e4137.0504
119.0429110.0398
138.0546
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Figure C.15. Mobility- and chromatography-extracted (1.52 ms; 3.93 min) DIA MS/MS 
spectrum of Feature #15 (m/z 152.06). Fragmentation pattern and mass accuracy suggest 
the following molecules as potential identifications: 2-hydroxyadenine (C5H5N5O; 
cLogP: 0.56); 8-hydroxyadenine (C5H5N5O; cLogP: 0.48); and guanine (C5H5N5O; 
cLogP: -1.16). Also observed at 2.67 min in chromatogram, suggesting this particular 
species is hydroxyadenine due to CLogP values. Signals at m/z 137, 119, 110 and 94 
correspond to Feature #12, while m/z 135 and 110 correspond to feature #15. 
 
 
 
 
 
 
 
 
m/z
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200
%
0
100
2013_09_28_4T AQ_01_dt_MSMS_152_4min 23 (1.518) Cm (11:39) 1: TOF MS ES+ 
3.98e4137.0504
110.0398 119.0429
152.0620
138.0546
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Figure C.16. DIA MS/MS spectrum of Feature #16, a sodiated monosaccharide (m/z 
203.05) at 1.5 min.  
 
 
 
 
 
 
 
 
 
 
 
m/z
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210
%
0
100
2013_09_28_2T AQ_01 74 (1.410) Cm (74:81) 2: TOF MS ES+ 
3.36e3203.0633
191.0874
112.8994
96.9277
80.9544
70.0703
62.9856
82.9515
90.9791
98.9249
164.9402
114.8995
150.0218
120.0077
135.9836
134.0244 142.9531
164.0382
162.1191
186.9194
169.9942
175.1302
180.9121
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Figure C.17. DIA MS/MS spectrum of Feature #17 (m/z 437.19) at 9.31 min.  
 
 
 
 
 
 
 
 
 
 
 
 
m/z
60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440
%
0
100
2013_09_28_3N AQ_01 494 (9.269) Cm (493:495) 2: TOF MS ES+ 
8.31e3437.2163
119.0906
279.1068
201.0638
415.2298
367.1682
438.2125
 226 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C.18. Mobility- and chromatography-extracted (4.21 ms; 9.14 min) DIA MS/MS 
spectrum of Feature #18, phosphocholine (m/z 387.22).  
 
 
 
 
 
 
 
 
 
 
 
m/z
100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420
%
0
100
2013_09_28_3N AQ_03_dt_MSMS_387 62 (4.209) Cm (51:72) 1: TOF MS ES+ 
6.20e3331.1485
175.0261
275.0781
231.0925
387.2150
332.1509
409.1985
410.2066
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C.8. MS/MS Spectra for Standards 
 
 
 
 
 
Figure C.19. MS/MS spectrum for 2. 6 µg/ml standard of adenosine 5’-
monosphosphate with 0 V collision energy. The area from m/z 100-150 is shown at 10X 
magnification for clarity. 
 
 
 
 
 
 
 
 
 
 
10 ul/min 2.86 ug/ml
m/z
100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400
%
0
100
2014_01_30_AMP_2-9_UG-ML_MSMS_0_CE 77 (1.331) Cm (2:116) TOF MSMS 348.10ES+ 
2.38e5x10 348.0881
136.0712
349.0914
350.2514
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Figure C.20. MS/MS spectrum for 2.86 µg/ml standard of adenosine 5’-
monosphosphate (m/z 348.09) with 15 V collision energy.  
 
 
 
 
 
 
 
 
 
 
 
10 ul/min 2.86 ug/ml
m/z
100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400
%
0
100
2014_01_30_AMP_2-9_UG-ML_MSMS_15_CE 50 (0.870) Cm (2:116) TOF MSMS 348.10ES+ 
1.79e5348.0881
136.0712
349.0914
350.2514
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Figure C.21. Mobility-extracted (2.98 ms) MS/MS spectrum for 2.12 µg/ml standard of 
reduced glutathione (m/z 308.11) with 15 V collision energy.  
 
 
 
 
 
 
 
 
 
 
10 ul/min 
m/z
60 80 100 120 140 160 180 200 220 240 260 280 300 320 340
%
0
100
2014_01_30_GSH_2UG-ML_MSMS_15_CE_dt_01 44 (2.978) Cm (24:74) TOF MSMS 0.00ES+ 
1.33e5308.1050
179.0567
162.0319
233.0671
309.1104
310.1020
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Figure C.22. Mobility-extracted (5.61 ms) MS/MS spectrum for 1.1 µg/ml standard of 
oxidized glutathione (m/z 613.18) with 25 V collision energy.  
 
 
 
 
 
 
 
 
 
 
10 ul/min 25 CE
m/z
100 150 200 250 300 350 400 450 500 550 600 650
%
0
100
2014_01_30_GSSG_1UG-ML_MSMS_25_CE_dt_01 82 (5.609) Cm (49:123) TOF MSMS 0.00ES+ 
8.51e4613.1776
484.1379
355.0837
485.1382
595.1699
486.1298
614.1840
615.1805
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Figure C.23. Mobility-extracted (2.15 ms) MS/MS spectrum for 3.6 µg/ml standard of 
α-D-glucose (m/z 203.07) with 20 V collision energy. The region m/z 50-190 is shown at 
10X magnification for clarity. 
 
 
 
 
 
10 ul/min 
m/z
50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250
%
0
100
2014_01_30_GLUCOSE_3-6_UG-ML_MSMS_20_CE_dt_01 32 (2.147) Cm (22:50) TOF MSMS 0.00ES+ 
1.14e4x10 203.0667
84.9650
81.0763
67.0573
98.9816
147.1264
121.1067
109.1073
135.0895
161.1433
187.1551175.1613
188.1306
203.1539
203.1912
204.0702
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APPENDIX D 
 
SUPPORTING INFORMATION FOR CHAPTER IV 
 
D.1. Supplementary Information for Mass Spectrometry Data Acquisition According 
to MIAPE-MS Format 
1. General Features 
 1.1. Global Descriptors 
i. Dates on which data was acquired, 01_24_12 and 08_13_12, may 
be found in the file names in the following format: 
“sh_2514_JF_012412_” and “sh_27 6_KH_0 1312_” 
ii. The samples were processed and analyzed by the Vanderbilt 
Proteomic Core 
 Contact Info: Kristie L. Rose, Ph.D. -  Co-Associate Director 
  Email: kristie.rose@vanderbilt.edu 
  Phone: (615) 343-1568 
 Contact Info: Salisha Hill, M.S. – Sr. Research Specialist 
  Email: salisha.hill@vanderbilt.edu 
  Phone: (615) 343-2739 
iii. Instrument Manufacturer and Model 
 LTQ-Orbitrap: Thermo Scientific LTQ Orbitrap Velos 
iv. Customizations: none 
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2. Ion sources 
2.1. nanoElectrospray ionization (2 kV source voltage, 100 µA source current, 
0V skimmer offset) 
  Fed by Eksigent NanoLC Ultra HPLC 
  Laser-pulled emitter tip, fused silica (360 µm OD x 100 µm ID) 
3.. Post-source component 
 3.1. Mass Analyzer: MS, Orbitrap, MS/MS, Ion Trap 
 3.2. Ion trap final MS stage achieved: MS2 
  MS/MS: CID, Argon, HCD Collision cell 
4. Spectrum and peak list generation and annotation 
4.1. Data acquisition: 
Thermo Xcalibur 2.1.0.1139 
 Switching criteria: Top ten most intense peaks in MS scan subject to 
MS/MS by CID in the LTQ 
  Min. signal required: 500 
 Isolation width: 2.0 
 Normalized collision energy: 35% 
 Default charge state: 4 
Activation time: 10 ms 
4.2. Analysis Software:  
MS/MS File Converter:  ScanSifter Desktop, Vanderbilt University 
Medical Center, conversion of .raw MS/MS spectra to DTA files 
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Database Searching: Thermo Fisher Scientific SEQUEST version 27.12 
(Custom Version on Vanderbilt ACCRE Linux Cluster, concatenated 
forward and reverse (decoy) database containing Homo sapiens subset of 
the UniProt KB protein database, 173736 protein sequences for forward 
and reverse databases) 
 
Parameters for Sequest: 
Protease: specified for typsin digestions, non-specific for Chymotrypsin 
and Glu-C. 
Max. missed cleavages: 10 for trypsin, 0 for chymotrypsin and Glu-C. 
Peptide mass tolerance: 2.5 Da, monoisotopic 
Variable modifications: carbamidomethyl derivatization of cysteine, 
oxidation of methionine, phosphorylation of serine, threonine, and 
tyrosine. 
Validation/Visualization: Proteome Software Scaffold 3.3.3 
Peptide probability threshold: 95% 
Protein probability threshold: 99%, 2 identified peptides required 
Algorith: Protein Prophet, Nesvizhskii et al., Anal. Chem. 2003. 
4.3. Resulting data 
FDR Statistics for database searches: 
Trypsin, Chymotrypsin and Glu-C: 10% Protein FDR, 0.5% 
Peptide FDR 
Trypsin
Heat
 and Trypsin
Org
: 0.5% Protein FDR, 4.5% Peptide FDR 
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Identifications to Asef2 based on sequence associated with accession 
number A2VEA_HUMAN in custom database described in 
Section 4.2. 
195 Peptides assigned to Asef2, 99% probability for protein identification 
  Sequence coverage: 617/652 amino acids, 94.6% 
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D2. Summary of Database Search Results for Phosphopeptides Identified for Asef2  
 
 
 Table D.1. Sequences, Mass Errors, and Sequest Scores (Xcorr and ΔCn) for Identified Phosphopeptides
Phopsphopeptide Sequence Obs. z Theor. ΔAMU ΔPPM Mod. XCorr ΔCn Start Stop 
TRYPSIN 
          
(R)ASNVSSDGGTEPsALVDDNGSEEDFSYEDLcQASPR(Y) 1295.8563 3 1295.8566 -0.0003 -0.23 P (+80), C (+57) 4.9310 0.1234 94 129 
(R)VNQEELSENSSStPSEEQDEEASQSR(H) 992.7332 3 992.7336 -0.0004 -0.40 P (+80) 5.5673 0.1236 205 230 
(R)FRPFTFSQsTPIGLDR(V) 650.3160 3 650.3154 0.0006 0.92 P (+80) 4.0599 0.3762 70 85 
  
          
CHYMOTRYPSIN 
          
(M)TSAsPEDQNAPVGcPK(G) 869.3600 2 869.3611 -0.0011 -1.27 P (+80), C (+57) 3.5373 0.1373 2 17 
  
          
GLU-C 
          
(E)LSENSSStPSEEQDEEASQSRHRHcE(N) 774.8111 4 774.8113 -0.0002 -0.26 P(+80), C(+57) 4.1883 0.0768 210 235 
  
          
TRYPSIN ORG 
          
(R)ASNVSSDGGTEPsALVDDNGSEEDFSYEDLcQASPR(Y) 1295.8579 3 1295.8566 0.0013 1.00 P (+80), C (+57) 3.8711 0.3045 94 129 
(R)FRPFTFSQsTPIGLDR(V) 650.3167 3 650.3154 0.0013 2.00 P (+80) 4.4995 0.4199 70 85 
(R)FRPFTFSQsTPIGLDRVGR(R) 566.0364 4 566.0361 0.0003 0.53 P (+80) 3.4340 0.1742 70 88 
(R)FRPFTFSQsTPIGLDRVGRR(R) 605.0618 4 605.0614 0.0004 0.66 P (+80) 3.0850 0.1938 70 89 
(R)HItMPTSVPQQQVFGLAEPK(R) 763.3772 3 763.3763 0.0009 1.18 P (+80) 3.0999 0.1475 615 634 
(R)LRVNQEELSENSSStPSEEQDEEASQSR(H) 1082.4620 3 1082.4620 0.0000 0.00 P (+80) 5.3512 0.3239 203 230 
(R)RPIsVIGGVSLYGTNQTEELDNLLTQPASRPPMPAHQVPPYK(A) 1163.5928 4 1163.5899 0.0029 2.49 P (+80) 5.0000 0.3509 23 64 
(R)RRPIsVIGGVSLYGTNQTEELDNLLTQPASRPPMPAHQVPPYK(A) 962.2953 5 962.2936 0.0017 1.77 P (+80) 2.9387 0.2696 22 64 
(R)RRPIsVIGGVSLYGTNQTEELDNLLTQPASRPPMPAHQVPPYKAVSAR(F) 1059.1515 5 1059.1488 0.0027 2.55 P (+80) 4.8367 0.2227 22 69 
(R)RRRPIsVIGGVSLYGTNQTEELDNLLTQPASRPPMPAHQVPPYK(A) 993.5156 5 993.5138 0.0018 1.81 P (+80) 4.2402 0.1231 21 64 
  
          
TRYPSIN TEMP 
          
(R)ASNVSSDGGTEPsALVDDNGSEEDFSYEDLcQASPR(Y) 1295.8561 3 1295.8566 -0.0005 -0.39 P (+80), C (+57) 4.6717 0.1855 94 129 
(R)FRPFTFSQsTPIGLDR(V) 650.3159 3 650.3154 0.0005 0.77 P (+80) 4.9663 0.3846 70 85 
(R)RPIsVIGGVSLYGTNQTEELDNLLTQPASRPPMPAHQVPPYK(A) 1163.5905 4 1163.5899 0.0006 0.52 P (+80) 4.9410 0.3356 23 64 
(R)VNQEELSENSSStPSEEQDEEASQSR(H) 992.7343 3 992.7336 0.0007 0.71 P (+80) 5.3548 0.0555 205 230 
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D.2. Annotated DDA MS/MS Spectra for Identified Phosphopeptides 
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